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ABSTRACT 
The effect of guanethidine (1.20 mg/kg, i.p.) or reserpine (0.2 
mg/kg, i.p.) has been compared on various indices of pituitary-adrenal 
stimulation in rats subjected to chronic forced restraint for 24 days. 
This was accomplished by analyzing the serum corticosterone, the adrenal 
ascorbic acid (AAA) and various organ weights such as the adrenals, brain 
and heart. Peripheral and central norepinephrine (NE) was also measured. 
Chronically stressed, control rats or those treated with guanethidine 
demonstrated both behavioral and neurochemical adaptation. Initial exci-
tation associated with restraint was related to changes in NE in the brain 
and heart. As the experiment progressed, the stressed, guanethidine-
treated animals showed changes in peripheral NE that were similar to those 
of the stressed, vehicle-treated animals; whereas, the non-stressed guan-
ethidine-treated animals showed a progressive decline in peripheral NE 
over the 24 day study. This change in the peripheral NE in the stressed, 
guanethidine-treated animals was attributed to increased production of 
NE, perhaps by the adrenals, since low doses of guanethidine do not 
affect adrenal catecholamines. 
Reserpine-treated, stressed animals showed 40% mortality over the 
24 day period, thus indicating non-adaptation. This increased mortality 
was not due to starvation or decreased water intake. It is suggested 
that non-adaptation in these animals may be due to a chemical sympa-
thectomy, and the animals were unable to respond to severe · changes · in the 
environment. 
Changes in behavior, in the different groups of animals, were cor-
related with changes in brain NE. Evidence is also presented indicating 
that reserpine and guanethidine do not deplete heart NE by the same 
mechanism(s). 
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I. INTRODUCTION 
The life of an animal depends upon its ability to adapt to changes 
in both internal and external environment; for example, one of Claude 
Bernard's classical experiments demonstrated that adaption to cold 
exposure involved heat production from two main sources: muscular 
activity and chemical processes other than those concerned with mus-
cular activity. Research in this field has shown· that adaptation to 
changes in environment or to a stimulus (stressor) involves an inter-
play between the central nervous system (CNS), the autonomic nervous 
system (ANS) and the endocrine system. In many species, including man, 
every type of stress activates the anterior pituitary-adrenocortical 
system (Tepperman, 1962). A discharge of sympathin, thought to be a 
mixture of epinephrine (E) and norepinephrine (NE), from adrenergic 
nerve endings, has also been shown to occur during systemic stress. In-
asmuch as adaptation involves nervous activity, numerous studies have 
been carried out to determine the effects of various drugs on the central 
and peripheral nervous systems. 
The major function of NE in the body is as the dominant transmitter 
released from sympathetic adrenergic neurons of mammals (von Euler, 1956). 
In view of the presence of both NE and dopamine in brain neurons having 
the same characteristics as sympathetic adrenergic neurons, it is prob-
able that NE also serves as the transmitter in the CNS (Hillarp et al., 
1966a). Maynert and Klingman (1961) discussed the possibility that brain 
NE functions as part of the sympathetic nervous system and that its 
release is accompanied by arousal or excitement. Trendelenburg (1963) 
reported that the nerve terminals of adrenergic fibers have functions 
l 
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other than just those concerned with the synthesis and release of NE. 
The NE stores are important sites of action for various drugs, and the 
ability of the stores to take up various sympathomimetic agents has been 
the subject of much important physiological and pharmacological research. 
Leblanc and Nadeau (1961) and Leduc (1961) showed that exposure of 
an animal to cold produced a significant and immediate increase in uri-
nary excretion of NE. These observations drew attention to the important 
role of both the adrenergic nervous system and the adrenal glands in cold 
adaptation and survival. Others have shown that catecholamine (CA)-
depleting drugs, such as reserpine, prevented the normal physiological 
responses to cold, leading to poor adaptation and death (Zilberstein, 
1960; Taylor, 1961); a close relationship between cold resistance and 
urinary excretion of NE was obtained in such treated animals (Johnson, 
1963). Previous work in this laboratory (Rosecrans and DeFeo, 1965) 
showed first, that reserpinized animals subjected to chronic restraint 
stress (CRS) had a 50% greater mortality than did similarly treated rats 
which were not stressed, and second, that the reserpinized animals sub-
jected to stress showed a decreased food and water intake. The question 
therefore arose whether this increased mortality might be due either to 
depletion of the central and/or peripheral NE or to starvation. Since 
non-adaptation may be associated with interference with some physiological 
mechanism(s), the question was further refined to include a study of the 
relationship between the apparent exhaustion of NE with non-adaptation 
(Rosecrans, 1963). 
These reports and others indicated the importance of NE in the 
survival of rats subjected to stress. However, it is difficult from 
studies such as these to determine whether the decreased resistance was 
3 
due mainly to a peripheral or central action of reserpine, since this 
drug has important depleting effects on both brain CA and indolamines 
(Sheppard and Zirrnnerman, 1960a), on peripheral CA (Orlans et~., 1960), 
and produces marked sedation. 
In the present study guanethidine was selected to evaluate the 
importance of the peripheral liberation of CA. Guanethidine is a potent 
sympatholytic drug, which blocks nervous transmission in the noradrenergic 
postgangl i onic fibers (Maxwell et al., 1960a) and depletes various periph-
eral organs of their CA content without affecting amine stores in the 
brain (Kuntzman et al., 1962). This drug does not cross the blood-brain 
barrier to any appreciable extent (Kuntzman et al., 1962). Further, 
guanethidine, contrary to reserpine, does not impair the resistance of 
rats exposed to very low temperatures (Pouliot and Leblanc, 1963). 
An additional purpose of the present investigation was to evaluate 
more precisely the importance of peripheral secretion and action of NE 
vs the central secretion and action of NE in the defense against stress 
and the involvement in adaptation. 
In summary, this work was designed to test the following hypotheses: 
1. Increased mortality of reserpine-treated rats subjected to 
chronic restraint may be due to : 
a. depletion of central NE, 
b . depletion of peripheral NE, 
c. depletion of both central and peripheral NE, 
d. starvation. 
2. Non-adaptation of rats subjected to chronic restraint is due at 
least in part to exhaustion of central and/or peripheral NE. 
II. LITERATURE SURVEY 
A) STRESS 
1. Introduction 
The term "stress" is undoubtedly one of the most impressive terms 
in the lexicon of science; but like many words, it means different 
things to different people. The term probably originated in the field 
of engineering; and to the engineer it means an external force directed 
at some physical object, with the result of "strain" and temporary or 
permanent alteration in the structure of the object. The word has also 
been borrowed for use in literature and conversation to indicate a 
special force or emphasis exerted on some word or idea in speaking or 
writing. 
The concept of stress was first introduced into the life sciences 
by Hans Selye in 1936 and elaborated in successive papers, leading to 
a full theoretical statement in book form in 1950. Today, many writers 
in physiology and psychology have adapted the engineering convention; 
stress being the external agent or stimulus and strain being the result-
ant. This usage is probably appealing because of the ease with which 
it seems to fit into the concept of homeostasis. 
From the homeostatic point of view, a stress is some stimulus 
condition that results in the disruption of equilibrium in a system 
and produces changes in that system against which mechanisms of equili-
brium are activated. One example of such mechanisms at the physiological 
level is Selye's adaptation syndrome, which is an elaborate series of 
neural-hormonal reactions against the effects of noxious agents on the 
tissue system. However, Selye (1956) has been instrumental in 
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stimulating a reversal of the engineering convention for the language 
of stress. He refers to the "noxious" stimulating condition which pro-
duces stress reactions as the "stressor"; and the reaction is called 
the stress. Sometimes Selye uses the term "stress" to refer to the 
initial impact of the stressor on the tissue, sometimes to the adap-
tive mechanisms whose function it is to restore homeostasis, and 
sometimes to the wear and tear, damage, or disease consequences of pro-
longed homeostatic processes. There are at least three meanings here 
to the term "stress", even though the word always refers to the state 
or reaction of the animal's tissue systems to the stressor or noxious 
stimulus. 
It makes little difference, however, if the external force is 
called a stress or stressor, or whether the effect on the animal is 
called stress or strain. It is important that we are consistent in 
our terminology, that the definition of terms is clear, and that the 
connotations of terms come as close as possible to the analogy intended 
by theory . For example, "strai n" is a poor analogy to adaptive or 
homeostatic mechanisms, but "adaptive syndrome" is more suitable. 
2. History 
It would be impossible to do justice to Selye's concept of stress 
in the few short paragraphs to follow. His own work on this subject 
has extended over four decades and has resulted i.n over a thousand pub-
lications. Selye (1936) found antecedents for his work in the concept 
of Hippocrates, that disease is not only suffering but also toil; that 
is , the fight of the body to restore itself to normal. Claude Bernard's 
(1859) description, that one of the most characteristic features of all 
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living beings is their ability to "maintain the constancy of their 
internal milieu", despite changes in the surroundings, was an acknow-
ledged base for Selye (1950) and also for Cannon (1932) in the develop-
ment of his concept of homeostasis. 
Cannon suggested that the ANS is the initiator of adaptive 
mechanisms. He proposed that under environmental changes, ANS 
stimulation, especially plasma adrenalin, could initiate cellular pre-
paredness and permit adaptation. His main experimental approach was 
total or partial sympathectomy where homeostatic responses were ob-
served under normal and stress conditions. 
Selye, dissatisfied with Cannon's theory, did a series of experi-
ments demonstrating that any animal presented with a noxious stressor 
would respond in a very characteristic manner elicited by adrenalcorti-
cal hyperfunction due to stimulation of the anterior pituitary. 
The theories of Cannon and Selye do not necessarily conflict but 
together tend to present the overall picture of the concept of stress. 
While the classical observations of Cannon clearly pointed to the 
adrenal medulla as an important reactor in response to disturbing 
factors, Selye studied the adrenal cortex and placed more emphasis on 
the pituitary-adrenocortical system. However, both of these systems 
are operating in stress conditions, and the type of reaction depends 
on the nature of the stressing factors. 
There is little doubt of the central position of the pituitary-
adrenal axis in adaptation; however, ANS activity is also important. 
George Sayers (1950) compared these relationships. He stated that the 
adrenal-cortical hormones play a generally supportive role rather than 
an initiating role in bodily processes; whereas the adrenal medulla 
7 
initiates cellular and metabolic changes in response to an emergency. 
Also, the adrenal cortex plays a passive role and makes it possible for 
various regulatory systems to expend the additional effort necessary 
for homeostatic adjustment. 
3. General Adaptation Syndrome 
Selye pointed out that, although different disease syndromes have 
unique properties and symptoms, they have many features in corrnnon, and 
it is these common features that constitute stress . Disease is not just 
suffering, but a fight to maintain the homeostatic balance of our tissues, 
despite damage. Se lye's definition of stress is as follows: "Stress 
is a state manifested by a specific syndrome, which consists of all the 
non-specifically induced changes within a biological system." Thus 
stress has its own characteristic form and composition but no particular 
cause. It may be described more simply as the rate of wear and tear in 
the body. It is increased during nervous tension, physical injury, 
infection, muscular exertion or any other strenuous activity, and is 
connected with a nonspecific defense mechanism which increases resist-
ance to stressor agents. An important part of this defense mechanism 
is the increased secretion by the hypophysis of adrenocorticotrophic 
hormone (ACTH), which in turn stimulates the adrenal cortex to produce 
corticoids (gluco- and mineralocorticoids). 
Selye postulated that organisms subjected to alarming stimuli will 
respond in a given manner, which he termed the "stress syndrome" or 
"general adaptation syndrome" (GAS). The GAS evolves in three stages: 
the initial stage, or the "alarm reaction" (AR) during which defensive 
forces are mobilized; a secondary stage, the 11 stage of resistance", 
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which reflects full adaptation to the stressor; and, finally, the "stage 
of exhaustion" which follows when the stressor is severe and applied for 
a prolonged period. 
The AR is associated with the discharge of ACTH, cortical steroids 
(CS), and CA, plus various other physiological changes such as autonomic 
excitability, heart rate, muscle tone, blood content changes and gastro-
intestinal ulceration. During the second stage, there is an adaptation 
to the stressor which results in a diminished reaction and thus increased 
resistance. Depending on the nature and intensity of the stressor and 
the condition of the organism at the time of exposure, the period of 
resistance may be short or prolonged. Finally, when the animal can no 
longer adapt to or compensate for the prolonged overexposure to the stress-
or, it will pass into the exhaustive stage and death ensues. 
Berry and Buckley (1966) reviewed the physiological responses to 
stress as suggested by Selye (1955). The responses are as follows: 
the stressor acts on the body or some part of it directly by way of the 
pituitary and adrenals. An immediate discharge of ACTH stimulates the 
release of corticoids from the adrenal cortex. If the stress is ex-
tremely severe, the adrenal cortex shows morphological changes char-
acteristic of hyperactivity. Simultaneously, the animal's corticoid 
requirement markedly increases, and there is an increase in the blood 
concentration and urinary excretion of corticoids and their metabolites. 
There is a general stimulation of the sympathetic division of the ANS; 
and the splanchnics induce the adrenal medulla to discharge E and NE, 
thus increasing the discharge of NE at various peripheral receptor sites 
and causing the cardiovascular responses of vasoconstriction and hyper-
tension. Other physiological changes include alterations in water and 
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electrolyte metabolism, gluconeogenesis and increased blood sugar levels, 
alteration in both red and white blood cell counts, and · increased renin 
production by the kidney. 
Selye (1950) reported that alm~; aU the changes caused by systemic 
stressors follow a characteristic triphasic course, in which the direct-
ion of the deviation from the normal is the same in the AR (stage one) 
and the stage of exhaustion (stage three) but is reversed in the stage 
of resistance (stage two). For example, the adrenals lose lipids in 
stages one and three, but store lipids in stage two; the thymus dis-
charges thymocytes in stages one and three, but stores them in stage 
two; there are hypoglycemia and hypochloremia in stages one and three, 
but hyperglycemia and hyperchl.oremia in stage two. This explains many 
of the apparently contradictory findings reported in the literature con-
cerning the effects of exposure to systemic stressor agents. Hence, the 
changes produced by stressors in the various targets cannot be discussed 
without consideration of the time-relations as stated above. There are 
also organ weight changes which characterize each particular stage of 
the stress syndrome. In general, there is adrenalcortical enlargement 
and hyperactivity; there is atrophy of the thymus, the spleen and lymph 
nodes and of other lymphatic structures in the body during the AR. 
Gonadal weight is also decreased during this stage. In the latter 
stages of the syndrome these changes will persist or return to the 
normal. 
Throughout the stress syndrome, numerous biochemical patterns 
change, an indication of specific homeostatic adjustments. Changes in 
adrenal weight provide some information on endogenous ACTH secretion; 
however, adrenal weight alone does not reflect rapid modifications in 
ACTH secretion. Other changes that are attributed to the release of 
ACTH are : a fall in adrenal ascorbic acid (AAA); a rise in plasma 
corticosterone; an increase in livertrypt~~~ pyrrolase (TP) activ-
ity; and an excessive mobilization of free fatty acids (FFA) from 
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body fat depots (Westermann, 1962). Increases of adrenocorticosteroid 
output and decreases in adrenal cholesterol (Fortier et~. , 1950) and 
ascorbic acid (Sayers and Sayers, 1947) have been reported as good in-
dexes of adrenocortical hyperact i vity. Within the past decade numerous 
analytical methods have been developed for the direct measurement of 
ACTH (Lipscomb and Nelson, 1962; Munson and Toepel, 1958) and for the 
direct analyses of plasma and adrenal corticosteroids (Guillemin ~ ~!·• 
1958; Zenker and Bernstein, 1958) . These methods have greatly enhanced 
recent investigations concerning the pituitary-adrenal axis. 
4. Pituitary-Adrenal Axis and Stress 
Selye (1950) reported that , before a stressor will elicit a normal 
GAS response, it must first reach the centers of the two coordinat ing 
systems responsible for set t ing this defense reaction into motion . 
These are the hypothalamus, as a center of the ANS, and the anterior 
pituitary , as the chief coordinator of the endocrine glands . Smith 
(1927), one of the first researchers in this area to study the relation-
ship between adrenocortical act i vity and the pituitary gland, demonstrated 
a rapid adrenal cortical atrophy due to hypophysectomy. Selye (1936) 
reported that a number of "nocuous" treatments, which varied greatly in 
their nature and specific effects, possessed a common property : the 
ability to produce hypertrophy of the adrenals and involution of the 
thymus in the intact rat . Following hypophysec tomy, however, although 
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the specific effects were again produced, the nonspecific effects on 
the adrenals and thymus failed to appear. Since that time, it has been 
demonstrated that, every type of stressor activates the anterior pitui-
tary-adrenocortical system. 
Selye (1950) reported that, upon exposure to numerous types of 
stress, the anterior pituitary responds with an increased production of 
ACTH, thus causing a release of the adrenal cortical hormones. He also 
reported that there is some evidence to indicate that certain stressors 
may affect the anterior pituitary by way of the hypothalamic center. 
Selye's discovery initiated a great deal of research in the many aspects 
of endocrinology of the anterior pituitary-adrenocortical axis. One of 
the most important aspects, which is still being investigated, is the 
CNS control of the anterior pituitary function . Because the activation 
of the anterior pituitary-adrenocortical axis occurs in response to 
practically all experimental procedures in intact animals, it has been 
extremely difficult to analyze the mechanism of activation . This pro-
blem became more complex after it was demonstrated that the secretion 
of ACTH from the anterior pituitary is increased by neurohumors from 
hypothalamic areas (DeGroot and Harris, 1950) . This development was 
preceded by a large number of publications assigning the role of 
"activator" of anterior pituitary to many substances occuring in the 
body. However, the work of Guillemin (1958; 1959b), Saffran (1959a; 
1959b) and others, demonstrated that the hypothalamus exerts its effect 
on the pituitary via a hormonal substance, which when brought to the 
anterior pituitary through the hypophyseal portal vessels, stimulated 
the secretion of ACTH . This polypeptide, which is probably related to 
vasopressin, has been named the corticotrophin releasing factor (CRF). 
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Another physiological possibility involved in the anterior 
pituitary regulation is that the CNS exerts some chronic inhibitory 
influence over the hypothalamic mechanisms which st i mulate ACTH re-
lease (Porter, 1954; Egdahl, 1961). The basic role played by stress in 
the act i vation of the pituitary-adrenal axis has been reviewed by numer-
ous investigators, such as Fortier (1962) and Reichlin (1963) . The 
mechanism of ac tivation of ACTH is di scussed in detail by Hilf (1965). 
A more detailed di s cussion on the synthes i s and control of ACTH secre-
tion in normal and stress conditions is given by Ganong (1963) and 
Mangil i ~~ al. (1966) . 
Ganong (1 963) concluded that there is an increase in ACTH 
secret ion to meet emergency situations . The ACTH is carried along the 
pathways that funnel through the median eminence . He states that there 
is a basal level of ACTH secretion that is independent of these pathways 
but not necessarily independent of neural control. He further states 
that the hypot halamus and the pituit ary function as a unit in the re-
sponse to stress and that the ACTH secretion rate in stressed animals 
is determined by the balance struck between the hypothalamic 11 drive11 
and the degree to which circulating corticoid levels inhibit ACTH se-
cretion. Corticoids inhibit ACTH secretion by an effect on its syn-
thesis and probably by an additional acute blocking effect . Similar 
conclusions were reported by Chowers et al . (1 967) . They stated that 
corticosteroids act directly on the hypothalamus to decrease CRF re-
lease and content and to influence storage and release of ACTH. Their 
findings support the view that, under certain conditions, corticosteroids 
exert an inhib itory effect on the hypothalamus as well as on the anterior 
pituitary . Mangili et al . (1966) discuss data clearly indicating that 
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the CNS plays an essential role in the control of the pituitary-adrenal 
axis, both in basal conditions and during stress-induced activation. 
They discussed the fact that it is not yet clear whether the same nervous 
pathways which control ACTH secretion through the steroid feedback mech-
anism are also involved in the activation of the pituitary during stress. 
They cited evidence to indicate a certain degree of independence between 
these two systems and supported the hypothesis that two seperate mech-
anisms are involved in the control of the pituitary-adrenal axis . This 
does not mean, however, that the two mechanisms are operating independ-
ently. There is ample evidence to prove the contrary, that is, that the 
final adjustment. of the secretory activity of the pituitary results from 
a close interplay between the activating impulses (stress) which reach 
the pituitary and the feedback effect of the steroids . 
5 . Cathecholamines and Stress 
E is discharged from the adrenal medulla during various types of 
systemic stress. A discharge of NE from adrenergic nerve-endings also 
accompanies systemic stress. The presence of some NE-like entity is 
thought to participate in the adrenergic response to stress . This dis-
charge of its adrenergic hormones by the adrenal medulla during the GAS 
appears to be mainly, if not entirely, a result of splanchnic stimulation 
(Selye, 1950) . 
Stressing factors involving the CA-producing systems may either in-
duce a reaction from the adrenal medulla , chiefly provoking an increased 
release of E, or activating the NE-producing nerves, or both. The E-
release is the most common response t o a variety of stressing factors, 
particularly those which involve a certain degree of emotional discomfort. 
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From this point of view, the E-secretory response is in a sense unspeci-
fic . Activation of the NE system appears to result from more specific 
stimuli, which bring blood pressure and temperature homeostasis into 
action (von Euler, 1964). 
When NE is considered, the concern is not with the adrenal medulla 
but rather with the ANS and, more spec ifically, with its sympathetic 
branch . NE is a chemical transmitter of the postganglionic sympathetic 
nerves (von Euler, 1951) . Very little NE comes from the adrenals in man, 
as revealed by the slight effect of total adrenalectomy (von Euler , 1955). 
The stimulus for adrenomedullary discharge travels via preganglionic 
sympathetic pathways from the hypothalamic nuclei which are in close 
anatomical relation t o the autonomic "centers" (Folkow and von Euler, 
1954) . Ordinarily, sympathetic activation accompanies adrenomedullary 
discharge . 
Leduc (1961) reported a constant and considerable increase in the 
NE excretion in rats exposed to cold . There was also an increase in E 
secretion . However, if the NE release in these rats was prevented by 
pharmacologic agents, the animals died : an indication of the importance 
of this react i on as a homeostatic mechanism in the metabolic sector . 
Other investigators have reported the import ance of NE in cold adapta-
tion (LeBlanc and Pouliot, 1964; LeBlanc et al . , 1967). 
Gutman and Weil -Malherbe (1967) studied the subcel.lular distribution 
of NE in the heart and spleen in rats after exposure to cold. Exposure 
to -15° for 90 minutes induced release of NE from the coarse, particu-
late, and soluble fraction of heart musc le . Chang and Su (1967) exposed 
rats to cold for two hours to study the effect of increased sympathetic 
activities on the subcellular distribution of NE in the heart. Cold 
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exposure caused a 30% decrease of total NE content in both auricles and 
ventricles of normal or adrenalectomized rats. They suggested that the 
NE in the particulate fraction is the functional part of the amine avail-
able for release by nerve impulses . Ingenito (1968) reported an increase 
in brain NE following 30 days of cold exposure . He suggested that this 
increase is derived from a source similar to that involved in the in-
creases in pe~ipheral CA on prolonged exposure to cold. 
Hsieh and Carlsson (1957 ) showed that in cold~ adapted rats the 
calorigenic effect of NE was potentiated and exceeded that of E. This 
calorigenic effect of NE in cold-adapted rats is considered to be depend-
ent on an increased oxidation of lipids (Hanmon et al . , 1963). Brodie 
~ al. (1966) showed that the emergency mobilization of FFA from fat 
depots is under the precise and direct control of NE rel.eased from the 
sympathetic nerves and that E from the adrenal medulla is not needed for 
this function. They suggested that moderate exerci se may be fueled by 
an increased release of FFA through the action of NE. 
Ganong and Lorenzen (1967) reported that most stressful stimuli 
and drugs which increase ACTH secretion also decrease brain NE . Con-
versely, the monoamine oxi dase inhibitors (MAOI) increase NE content, 
and some of these drugs decrease ACTH secretion . Levi and Maynert 
(1964), however, claimed that the stress-induced decrease in brain NE 
is the result of a decline in NE that is outside the nerve endings, 
pointing out that changes in NE content do not always accompany changes 
in ACTH secretion. They also reported that stressful stimuli cause in-
creased ACTH secretion, and that adrenal.ectomy has the same effect on 
ACTH secretion . One might expect that brain NE would be decreased by 
adrenalectomy; however, adrenalectomy had no effect on brain NE. 
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In conclusion, stress and exposure to cold are mainly associated 
with an increase in the NE excretion, ·indicat i ng the importance of this 
hormone in circulatory and temperature controlling homeostatic mechanisms. 
Mental stress involving exhilaratory or aggressive reactions is also 
associated with an increase in the NE excretion. The types of emotional 
stress characterized by apprehension, anxiety, pain, or general dis -
comfort are regularly acc.ompanied by an increase in the E excretion 
(von Euler, 1964). 
B) CATECHOLAMINES 
1. Catecholamine Metabolism 
Research on the physiology and pharmacology of the CA during the 
past few years has introduced into the literature many excellent reports 
concerning the syntheses and metabolism of the CA in the brain and heart 
and also the role of these amines as neurochemic al transducers. Review 
articles (Axelrod, 1963; 1965; Kopin, 1964; Glowinski and Baldessarini, 
1966); two excellent symposia (Kr ayer, 1959; Achenson, 1966); and t wo 
texts (von Euler, 1956; Wurtman, 1966) are available f or information on 
·; 
;.· other aspects of CA function . 
\\. 
1 
' The CA have been recognized as hormones , and it is now known that 
NE plays a dual role : it is the immediate precursor of E; and it is 
also considered by many investigators to be the neurotransmitter sub-
stance at adrenergic nerve endings. The steps in the formation of the 
CA; E, and NE from phenylalanine were first proposed by Blaschko in 
1939. This pathway was estab lished by Gurin and Delluva (1947) who 
administered radioactive phenyl alanine to rats and isolated radioactive 
E from the adrenal gland . Udenfriend and Wyngaarden (1956) demonstrated 
that, in addit ion to radioactive phenylalanine, radioactive tyrosine 
and dopa also form radioactive E in the adrenal medulla. It is now 
accepted that this pathway represents the actual biosynthetic trans-
formations. Sympathetic nerve preparations are also capable of con-
verting radioactive tyrosine or dopa to radioactive E (Goodall and 
Kirshner, 1958). 
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Some CA are synthesized in the brain (Udenfriend and Zal.tzman-
Ninenberg, 1963) and in chromaffin tissue such as the adrenal medulla, 
but most of it is synthesized in the sympathetic nervous system 
(von Euler, 1956). The starting material. is the amino acid L-phenyl-
alanine, which is converted by a hydrolase enzyme to L-tyrosine (Gurin 
and Delluva, 1947). L-tyrosine can also be taken up by the blood and 
is converted by L-tyrosine hydroxylase to L-dopa. This hydroxylation 
is the rate-limiting step (Levett et al., 1.964; Udenfriend et al., 
1966; Neff and Costa, 1.966; Spector et ~·, 196 7) . Another step is 
the conversion of L-dopa .to L-dopamine via the enzyme dopa decarbo-
xylase (Holtz, 1.939; Lovenberg, 1962) . Dopamine is then converted to 
L-NE by the enzyme dopamine-beta-oxidase (Levin et~., 1960). The 
properties of this enzyme were reviewed by Schoot and Creveling (1965). 
NE is then converted to E by the enzyme, phenylethanolamine-N-methyl 
transferase (Axelrod, 1962). This enzyme is highly localized in the 
adrenal medulla. The biosynthesis of E in the adrenal medulla appears 
to be regulated by the pituitary-adrenocortical system (Wurtman and 
Axelrod, 1965). 
Blaschko and Welch (1953) showed that E is stored in chromaffin 
tissue and that NE is stored in both chromaf fin tissue and in certain 
neurons, including the sympathetic nerves. The storage complex contains 
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adenosine triphosphate (ATP) and a protein in vesicles or granules 
(Hillarp and Nelson, 1954 ) . The neural storage mechanisms can store 
not only locally synthesized by also circulat i ng CA (Axelrod et al., 
1959c), as well as structurally related substances (Crout and Shore, 
1964); these mechanisms can also restore a portion of the CA released 
from their granules (Mendlowitz ~al . , 1964). 
The uptake of circulating E and NE by various tissues was studied 
in animals after the int. ravenous administrat ion of physio l ogical 
amounts of tr itium-labeled compounds (Axelrod e t al., 1959c; Whitby 
et al. , 1961). Within two minutes , heart, spleen, lung , and adrenal 
gland took up the largest amounts of the c i rculating amines, while 
muscle and brain took up the least . The large amount of circulating 
CA taken up by the heart suggests that these amines discharged from 
the adrenal medulla int o the blood stream could serve to stock the 
myocardial stores. Kopin and Gordon (1963b) observed that 20% of the 
CA stores in the heart are derived from t he circulating NE. Only 
negligible qµantities of the circulating CA were taken up by the brain 
(Weil-Malherbe et al., 1959; 196la) , a resul t o f the presence of a 
blood-brain barrier toward these amines. The hypothalamus took up 
small _ amounts of CA, whi le the pi tu i tary gland and the pineal gland 
contained larger concentrations of radioactive CA, probably because 
the blood-brain barrier is not in the immedi at e area of these struc-
tures. The large amounts of CA that are present endogenously in the 
brain are presumably synthesized from pr ecursors that are capable of 
crossing the blood-brain barr i er . Glowinski and Iversen (1966) show 
that t.here are also differences i n NE turnover rates in specific areas 
of the brain . The rapid uptake and binding of CA occurs mainly in the 
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sympathetic nervous system (Hertting and Axelrod, 1961) and is a major 
means of CA inactivation (Kopin et ~·, 1962). The amount of labeled 
CA taken up into a tissue is related to the fraction of the cardiac 
output which perfuses the organ and the density of sympathetic nervous 
tissue in the organ. The heart, which has a rich sympathetic nerve 
supply and which receives a relatively large proportion of the cardiac 
output, takes up a large proportion of the administered CA. Other 
organs which have a rich sympathet ic nerve supply also bind NE (Kopin, 
1966). NE is not only taken up by tissues from the circulation but it 
is also retained for long periods of time (Whitby et al., 1961). Evi-
dence that bound NE is present in more than one pool has been derived 
both from pharmacologic and from biochemical sources . After the admin-
istration of labeled NE, there is a multiphasic decrease in the radio-
active NE remaining in the heart ~ both in vivo (Axelrod et al., 196la) 
and in vitro (Kopin et al ., 1962), indicating that there is more than 
one compartment for storage of the amine. Trendelenburg (196lb) sug-
gested a division of tissue NE stores into a "bound" and an "available" 
store. The binding protects NE from enzymatic attack (Whitby et al., 
1961). 
As the CA are released for alpha or beta stimulation (Ahlquist, 
1948), they are quickly degraded by enzymes, chiefly monoamine oxidase 
(MAO) (Blaschko et al. , 193 '7; Zeller et al. , 1955) and catechol-0-
methyl transferase (COMI') (Axelrod, 1957). The physiological activity 
of the deaminated or the 0- methylated metabolites is only a fraction 
of that of the parent compound , indicating that both types of trans-
formation are inactivating. After the administration of NE or E, the 
main urinary metabolites are vanillyl-mandelic acid (VMA) (Armstrong 
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et al., 1957), normetanephrine (NM), metanephrine (M) (Axelrod, 1957) 
and 3-methoxy-4-hydroxyphenylglycol (MHPG) (Axelrod et al ., 1959a). 
The following minor metabolit es have also been identified: 3,4-dihydro-
xymandelic acid (Kershaw et al ., 1958); 3,4-dihydroxyphenylglycol 
(Kopin and Axelrod, 1960); N- acetylnormetanephrine (Smith and Wortis, 
1962); N-methyladrenaline and N-methylmetanephrine (Axelrod, 1960) . 
Some of these metabolites are conjugated in the liver to form 
sulfates and glucuronides; and most of them, as well as E and NE, can 
be detec t ed in the urine and blood under c ertain circumstances (Manger 
et al . , 1959; Armstrong and McMillan, 1957; Sjoerdsma et al . , 1959) . 
MAO is a nonspecific enzyme; it deaminates alkyl and aromatic 
amines that have an amine group attached to the terminal carbon atoms 
(Blaschko et al . , 1937). This enzyme has been found in all mammalian 
tissues, highly localized in the mitochondria (Bl aschko et al ., 1957). 
MAO is inhibited by hydrazine derivatives in vitro and in vivo (Zeller 
and Barsky , 1952). Relatively large quant ities of MAO are present in 
sympathetic nerves (Snyder et al . , 1965). Tyramine, dopamine and sero-
tonin are much better substrates for MAO than NE and E (Kopin, 1964). 
When MAO activity is markedly inhibited in the intact animal, there is 
a rise in the tissue levels of several monoamines, i ncluding NE and 
serotonin (Shore et al ., 1957). MAO inhibition also depresses the 
spontaneous release of stored radioactive NE from sympathetic nerve 
endings (Axelrod et al ., 196la) as well as the release of amine follow-
ing the administrat ion of reserpine (Shore et al ., 1957) . 
COMT has been partially purif i ed and its properties studied 
(Axelrod and Tomchick, 1958) . It catalyzes the transfer of the methyl 
group of S-adenosylmethionine to the 3-hydroxy group of catechols. The 
enzyme is relatively nonspecific and 0-methylates a wide variety of 
endogenous catechols such as E, NE, dopamine, dopa, 3,4-dihydroxy-
phenylacetic acid and 3,4-dihydroxymandelic acid as well as many 
foreign catechols. It does not 0-methylate monophenols. COMT is 
widely distributed in all organ tissues including sympathetic and 
parasympathetic nerves, glands, blood vessels and all areas of the 
brain; but it is concentrated chiefly in the liver and kidney 
(Axelrod and Tomchick , 1958) 0 The enzyme is localized in the cyto-
plasm, in contrast to MAO which is found in the mitochondria. COMT 
is inhibited by pyrogallol (Axel.rod and Laroche , 1959b), catechols 
(Carlsson et al., 1962) and tropolones (Belleau and Burba , 1961). 
When given to intact animals, COMT inhibitors prolong the action of 
administered CA or CA discharged from nerves. 
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In conclusion then , a hypothetical picture of the metabolism and 
storage of CA, as shown by Bertler (1961) is as f ollows : 
1.. tyrosine is the precursor of dopa; 
2. dopa is decarboxylated in the cytoplasm by dopa decarboxylase; 
3. the dopamine formed is immediately transferred to granules, 
which probably are of the same type as the E and NE containing particles. 
In these granules dopamine can be stored unchanged as in the caudate 
nucleus; 
4. dopamine can also be transformed t o NE; 
5. the amines are liberated from their storage sites by nerve 
impulses and then reach their receptors in relatively high concentra-
tions; 
6. outside the granules a continuous inactivation of the CA is 
going on by means of MAO and COMT; 
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7. most of the circulating NE is metabolized by 0-methylation; 
the remainder is taken up and bound in dense core vesicle in sym-
pathetic nerves; 
8. when NE is released, it is metabolized by MAO within the 
nerve or by COMT outside the nerve; 
9. a large amount of the CA is inactivated by being bound again 
or by diffusing into the circulation. 
2. Norepinephrine and the Concept of Neurochemi.cal Transducer 
Background information on the role of NE as a neurotransmitter is 
included in papers by Brodie and Bevane (1963) and Maynert and Kuriyama 
(1964). The sympathet i c or adrenergic nervous system is recognized as 
one of the fine regulatory mechanisms in animals. It is involved in 
regulation of blood pressure , carbohydrate and fat metabolism, tempera-
ture, eye movement, and many other functions both central and peripheral. 
The concept that the sympathetic nerves secrete a physiologically active 
compound was first proposed by Elliott (1905). He described the action 
of E on smooth muscle organs and on the heart muscle and suggested that 
sympathetic nerves release a pressor substance which could then act on 
an effector organ. Many years later, the cl assic experiments of Loewi 
(1921) and of Cannon and Uridil (1921) revealed that a chemical sub-
stance secreted by the sympathetic nerves is the actual regulatory 
agent. Loewi provided experimental evidence that stimulation of sym-
pathetic nerves result ed in the release of an adrenalin-like substance. 
These workers established the concept of neurotransmission. The identi-
fication of the sympathetic neurotransmitter as NE was established by 
von Euler in 1949. Once the neurotransmitter was identified, it became 
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obvious that its formation involved several intermediates and tissue 
enzymes. The demonstration by Goodall and Kirshner (1958) of the 
formation of NE from tyrosine in homogenates of sympathetic nerve 
tissue provided final evidence that the nerve trunk and terminals 
can manufacture their own neurotransmitter from the dietary precursor, 
tyramine. 
Brodie and Beaven (1963) described a theoretic al model of the 
biophysical units at nerve endings that are responsible for the forma-
tion, storage, inactivation and physiological release of NE and other 
biogenic amines. These units have been termed "neurochemical trans-
ducers", since they translate elctrical impulses into a quantity of 
free hormone; the free amine, in turn, acts on a target organ to pro-
duce mechanical or chemical energy or on an adjacent neuron to produce 
more electrical impulses. The theoretical model of the neurochemical 
transducer is based on kinetic data which describe the movement of H3-NE 
within compartments in sympathetic nerve endings after the amine is 
taken up in tracer amounts. Mathematical analysis of the kinetic data 
has shown that endogenous NE is localized in an open two-compartment 
system and that the content of stored amine is in a dynamic balance 
between rates of synthesis and disappearance (Montanari et~., 1963). 
One compartment is a mobile or readily available pool from which NE is 
released by nerve impulses. The amine f ormed in this pool is main-
tained at a high concentration by a transport mechanism or pump which 
resists its free outward diffusion. This mob ile NE pool is in chemical 
equilibrium with a larger pool of NE in the second compartment, held 
in granules, presumably as a complex . The NE in granules is considered 
to act as a reserve pool of amine . Hence, if NE is released by a 
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primary action on the mobile pool, some of the amine in the reserve 
pool will also be mobilized in order to maintain chemical equilibrium. 
According to the neurochemical transducer model, MAO controls the 
amount of NE in the nerve endings so that at the s t eady-state level 
the amine does not freely diffuse onto receptor sites. In the absence 
of sympathetic tone, NE can leave the storage compartments by simple 
diffusion through the lipoid membrane onto MAO. After nerve stimulation 
the amine is r eleased directly onto the receptor sites and reaches the 
blood stream as the free base. 
The possibility that the sympathetic nerves may be involved in the 
selective uptake and retention of CA has been previously discussed. 
Circulating NE and E are selectively taken up and retained by sym-
pathetic nerves. This uptake and binding serves as an important mech-
anism for the rapid inactivation of these hormones . The action of the 
transmitter released at the adrenergic terminals may also be terminated 
by localized enzymat ic destruction and by escape into the circulation. 
A number of inves tigator s have reported that dur i ng sympathetic 
nerve stimulation endogenous NE is released int o the circulation 
(von Euler, 1956; Rosell et al., 1963; Boull.i.n , 1966b). The fate of 
this transmitter substanc e depends upon the fract i on of the cardiac 
output to the tissue and the density o f the sympathetic innervation 
(Kopin et al., 1965). Leduc (1 961) postulated the expectation that 
steady state levels of the transmitter within adrenergic nerves could 
be maintained by a mechani sm of local synthesis , c upled in some way 
to the state of nervous act ivity and hence t.o the rate of secretion of 
NE. 
There is acceleration of CA biosyntheses due to increased nervous 
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activity in the adrenal medulla (Bygdeman and von Euler, 1958; 
Bygdeman et al., 1960). The rate-limiting step f or the biosynthesis 
of NE in heart tissue (Levitt et al., 1965) and in salivary glands 
(Musacchio and Weise, 1965) has been shown to be the conversion of 
tyrosine to dopa. Roth et al. (1966) using an isolated hypogastric 
nerve-vas deferens preparation, also reported a 3-fold increase in 
the amount of NE synthesized from exogenous tyrosine. They concluded 
that the isolated vas def erens preparation is capable of synthesizing 
NE from exogenous tyrosine and that local NE synthesis is in some way 
regulated by nervous activity and is not a steady state phenomenon 
independent of impulse traffic. Austin et al. (196'7) confirmed these 
re$ults, showing that on electrical stimulation of the nerve an in-
creased synthesis and release of NE and dopamine was observed. They 
postulated that nerve stimulation increased production of some step 
in the pathway subsequent to tyrosine hydroxylase. Sedvall and Kopin 
(1967), using the rat submaxillary gland preparation, suggested an 
impulse-induced acceleration of NE synthesis in the adrenergic neurons 
and an apparently stimulated synthesis at or before the tyrosine hydro-
xylation step. They concluded that the rate of NE synthesis might be 
controlled by tyrosine transport, product inhibition, endogenous in-
hibitors or cofactors of tyrosine hydroxylase. 
Kopin (1967) stated that the events that occur following the 
arrival of the sympathetic nerve impulse at the nerve terminals and 
that lead to release of NE are essentially unknown. Acetylcholine 
can induce the release of NE from sympathetic nerves; however, the 
importance of acetylchol.ine as an obligatory intermediary in release 
of the adrenergic transmitter is not established. There is evidence 
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that , at least at some sites in some species, acetylcholine may play 
a facilitory role in the release of NE from sympathetic nerve endings. 
C) GUANETHIDINE 
1. History and Pharmacology 
Guanethidine, (2-(octahydro-1-azocinyl)-ethyl)-guanidlne -sulfate is 
a potent antihype+t~nsi've agent which is purely a synthet:ic •c1:>mpou_nl1_. ·. 
Its synthesis was first described in 1959 by Maxwell, Mull and Plummer. 
Maxwell et al. (1959; 1960a; 1960b) have comprehensively investigated 
the pharmacology of guanethidine. Guanethidine elicits a biphasic 
response : an initial sympathomimetic effect (hypertension and con-
traction of the nictitating membrane in the cat), followed by the 
failure of postganglionic nerve stimulation. Guanethidine also po-
tentiates the response of effector systems to NE , and after a single 
dose the potentiation may be observed for up to five days. Maxwell 
et ~· suggested that the initial sympathomimetic responses were due 
to direct adrenergic effects and that the later sympatholytic actions 
were due to a reserpine- like depletion of CA stores. 
Page and Dustan (1959) gave five to 15 mg/kg i.v., of guanethidine 
to normotensive dogs and cats. They found an initial transient fall 
in the arterial pressure, followed by a prominent rise and tachycardia 
that persisted from 30 minutes t o two hours. The increase in pressure 
was associated with vaso- constriction and increase in cardiac output; 
its degree and duration were directly related to the dose. The pressor 
response was accompanied by some sympathomimetic effects, such as pilo-
erection-and contraction of the nictitating membrane, probably the 
result either of the release of the endogenous stores of NE or of a 
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more direct syrnpathomimetic action of the compound. The initial 
syrnpathomimetic action was followed by a prolonged period of sympa-
thetic paralysis, accompanied by a decrease of arterial pressure (which 
was more prominent in experimentally produced hypertensive animals than 
in normal), bradycardia, decrease of pulse pressure and relaxation of 
the nictitating membrane. These effects persisted to some degree for 
four to ten days . Page et ~l· (1961) tentatively concluded that guan-
ethidine caused a decrease in blood pressure by initially interfering 
with the release of NE at the myoneural junction. The pressor response 
was associated with the initial depletion of endogenous amine stores, 
especially in the heart and blood vessels. The chronic hypotensive 
effect was due to the depletion of peripheral stores of NE. 
Mccubbin et al. (1961) reported similar effects in anesthetised 
dogs. They showed that during the sustained pressor response, i.v. NE 
responses were augmented in dogs with the vagus nerve severed. No 
signs of augmentation were observed in dogs with the nerve intact. 
They concluded that the increase in pressure suggests the release of 
bound endogenous CA stores . 
Cass and Spriggs (1 961) suggested that guanethidine has a dual 
mechanism in exerting its syrnpatholytic actions. They proposed that 
the syrnpatholytic action is secondary to its primary bretylium-like 
action. (Bretylium is a unique compound among the syrnpatholytic drugs, 
since it is a quaternary ammonium compound that acts at nerve terminals 
to prevent the physiological release of the adrenergic transmitter and 
neither releases apprec i able amounts of NE in vivo nor antagonizes the 
effects of administered CA (Boura and Green, 1959)). Their conclusion 
was based on the finding that guanethidi ne blocks the effects of 
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sympathetic stimulation in rats long before it produces an appreciable 
decline in the anount of NE in sympathetic nerve endings. This mech-
anism of action of guanethidine was reinforced by the findings · ~f _Hertting 
et~· (1962). Bein (1960), however, has expressed doubt that guan-
ethidine action includes a mechanism similar to that suggested . ~or 
bretylium. 
2. Effects on Catecholamines 
Sheppard and Zirmnerman (1959; 1960b) showed in rats that guanethi-
dine reduced the CA concentration of the spleen and heart, and in dogs 
it lowered the CA concentration of the heart and arteries. Cass et al. 
(1960) reported that guanethidine depleted the NE in the heart of 
rabbits and cats . They suggested that the compound produced its chem-
ical sympathectomy through depletion of NE at the peripheral nerve 
endings . Cass and Spriggs (1961) observed that a single dose of guan-
ethidine in rats produced a considerable and longlasting depletion of 
the CA. Other workers have reported depletion of CA in peripheral 
tissue with guanethidine (Butterfield and Richardson, 1961; Stone and 
Beyer, 1962; Sanan and Vogt, 1962; Kuntzman et~·, 1962) . 
Hertting et al. (196lb) showed in male cats that guanethidine 
markedly decreased the uptake of H3-NE in the heart and spleen, but 
not in the adrenals, and only moderately decreased it in the liver. 
These workers suggested that guanethidine appeared to act by prevent-
ing entry and/or binding of H3-NE in the tissues. Dengler et ~· 
(1961) demonstrated that guanethidine inhibited the uptake of iso-
topic NE by cat tissue and depleted the peripheral tissues of NE but 
not of serotonin . They suggested that the depletion of the NE stores 
in cells may depend on inhibition of the uptake mechanism. Bisson and 
Muschell (1962) suggested that guanethidine abolishes the ability of 
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the tissue to bind CA. 
Lindmar and Muschell (1961) used isolated rabbit hearts perfused 
with Tyrode's solution to study the effect on the NE output. Tyramine 
and 1,1-dimethyl-4-phenylpiperazinium iodide (DPP) increased the out-
put of NE. Guanethidine decreased the NE release by tyramine and the 
NE release induced by DPP was also blocked. Similar results were also 
reported by Kroneberg and Schumann (1962). They showed that inhibition 
of the tyramine response was due to a direct action of guanethidine and 
not to a depletion of CA stores. However, guanethidine has also been 
shown to ppt~ntiate the response to NE and to inhibit the pressor 
response to tyramine (Bhagat and Shideman, 1963a). Bhagat (1963a) 
showed that guanethidine had no effect on the depleting action of 
tyramine in the rat heart. 
Kuntzman et al. (1962) reported that guanethidine produces a 
longlasting depletion of heart NE; however, it does not lower the 
amine in the brain, presumably owing to the low rate of penetration 
across the blood-brain barrier. The investigators concluded that guan-
ethidine releases NE from sympathetic nerve endings by an action which 
seems to differ from that of reserpine. Evidence is also given for 
the view that guanethidine acts oppositely to bretylium and activates 
the process involved in the normal release of NE by nerve impulses. 
Day and Rand (1963) showed that guanethidine acts on stores of NE 
at sympathetic nerve endings. Abercrombie and Davies (1963) discussed 
the nature of the action of guanethidine and concluded that it blocks 
the effect of postganglionic sympathetic nerve stimulation by inter-
fering with the syntheses of transmitter and that it also has a direct 
sympathetic effect. Davanzo et al. (1964) showed that guanethidine 
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decreased the effectiveness of sympathetic nerve stimulation by 
causing a depletion of CA stores in peripheral nerves. They concluded 
that this depletion occurs by a mechanism different from that of the 
ganglionic and adrenergic blocking agents. 
Chang ~ al . (1964) reported that guanethidine does not release 
NE by a simple one-to- one displacement . Guanethidine must first be 
taken up before appreciable amounts of CA are released . Initially, 
the drug shares occupancy of the nerve endings with the endogenous 
amine, then, after entering the sympathetic neurons, it releases NE, 
perhaps by enhancing the permeability of the terminal membranes . At 
first, guanethidine releases at a rapid rate the more available pool 
of NE; in fact, large doses of guanethidine can elicit a pronounced 
sympathomimetic effect . Guanethidine also remains localized in adre-
nergic neurons for a considerable time and causes a steady loss of CA 
after the period of rapid release . 
The action of guanethidine in blocking adrenergic function is not 
a direct result of NE loss; in fact, the amine levels are not yet 
reduced when sympathetic blockade is complete and are still low when 
it is terminated . However, the intensity of the adrenergic blockade 
ultimately produced by single doses of the drug is directly proportional 
to the initial rate of NE depletion and is closely related to the amount 
of guanethidine taken up by NE storage depots. These results suggest 
that the drug increases the porosity of the nerve membrane, thereby 
releasing NE and making nerve terminals unresponsive to incoming stim-
uli (Brodie et al., 1965). 
Shore and Giachetti (1966) presented evidence that guanethidine 
at l0-4M inhibited both a membrane amine pump and an intracellular 
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amine-concentrating mechanism. At a low concentration of guanethidine 
-6 ) (5 X 10 M the intracellular mechanism is preferentially inhibited. 
The action of guanethidine on the membrane pump is readily removed by 
washing . They concluded, that at clinical doses, guanethidine acts 
only on the intracellular mechanism, thus leading to depletion of NE. 
Lundborg and Stitzel (1967) showed that guanethidine inhibits 
both the transport of amines through the nerve cell membrane and an 
uptake mechanism present in amine-storage granules. They suggested 
that the membrane pump-inhibiting ability possessed by guanethidine 
may account for the sympathomimetic activity and exogenous amine po-
tentiation which often accompanies guanethidine administration . 
Fielden and Green (1967) did a study on the NE-depleting and 
sympathetic-blocking action of guanethidine. They concluded that 
the sympathetic-blocking action of guanethidine is distinct from its 
NE-depleting action. The early action of guanethidine may be due, 
then, to adrenergic neuronal blockade, and in light of the Burns and 
Rand (1962) hypothesis, the drug may act by preventing the release of 
acetylcholine and its ability to release, in turn , NE. 
Guanethidine, like alpha-methyl NE, metaraminal, and octopamine, 
is taken up and retained by adrenergic neurons; it causes the release 
of NE and is itself released by reserpine (Chang~ al., 1964; 1965; 
Brodie et~· , 1965). Boullin et al . (1966) reported that the term 
"false transmitter" has been applied to substances that replace NE in 
sympathetic nerve endings and that on nerve stimulation are themselves 
released onto adrenergic receptors to evoke sympathetic responses. 
Guanethidine is also taken up by adrenergic neurons, displaces the 
transmitter, and is discharged by nerve stimulation; but it fails to 
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exert a sympathomimetic action of its own. 
Boullin (1966a; 1966c) showed that calcium is also involved in the 
storage and release of guanethidine, but not in guanethidine uptake. 
Boullin (1968) showed that the removal of calcium ions causes release 
of guanethidine primarily from nonspecific cellular binding sites and 
not from the intra-neuronal stores. He suggested that the action of 
guanethidine is to destroy the intra-neuronal store, and that its action 
may be particularly evident under calcium-free conditions. 
Dixit et al. (1961) showed that guanethidine can also produce 
neuromuscular blockade, possibly by preventing acetylcholine release. 
Costa et al. (1962a) suggested that guanethidine might actually mimic 
the action of acetylcholine in adrenergic fibers, thus leading to a 
prolonged release of NE. Agarwal et ~· (1965) found that chronic 
administration of guanethidine increased the acetylcholine content of 
brain, intestines and heart of albino rats. Rand and Wilson (1967) 
proposed receptors for adrenergic neuron-blocking activity allied to 
the acetylcholine receptors at other sites, and that interaction by 
guanethidine with these receptors interferes with cholinergic trans-
mission at the neuromuscular junction and the ganglionic synapse. 
However, Chang et al. (1967b) in studies on the neuromuscular-blocking 
action of guanethidine, reported that its main effect appeared to be 
on muscle fibers. Contractile responses to direct muscle stimulation 
were reduced, and the form of muscle action potentials were changed. 
There is also conflicting evidence for the effect of guanethidine 
on brain CA. Pfeifer et al. (1962; 1967) reported that guanethidine 
produced some effect on the CNS and decreased the NE in the brain. 
Dagirmanjian (1963) showed that single injections of guanethidine did 
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not lower the hypothalamic NE in the cat, but daily injections over 
a period of seven days consistently produced a decrease in the hypo-
thalamic NE. Attempts to lower the hypothalamic NE in rats after 
single injections or daily injections of guanethidine were unsuccess-
ful. Sanan and Vogt (1962) observed a fall in NE of the hypothalamus 
in cats after guanethidine and suggested that the effect was due to a 
reflex stimulation of the sympathetic centers, rather than to a direct 
effect on the hypothalamus. Studies on the disposition of guanethidine 
in the body show that the drug does not readily cross the blood-brain 
barrier . This seems to explain the lack of effect on brain amines, 
since intracisternal injections of the drug can lead to depletion of 
brain NE (Kuntzman et~., 1962). 
Cass et ~· (1960) reported that guanethidine did not affect the 
CA in brain and adrenal glands. Stone and Beyer (1962) reported simi-
lar results. Kuntzman et al. (1962) reported the resistance of the CA 
in the rat adrenal medulla to depletion by guanethidine. (See page 48.) 
Athos et al. (1962) demonstrated that direct perfusion of the isolated 
denervated adrenal gland in situ in the dog with guanethidine had no 
effect on the CA secretion. Intravenous dose in intact dogs caused no 
adrenal medullary stimulation; in fact, the adrenal secretion rate was 
markedly lowered. Garrett et al. (1965) did studies on isolated bovine 
adrenal glands but reported that both E and NE were released in varying 
proportions. 
Superstine and Sulman (1966) found that guanethidine also influenced 
the output of pituitary hormones. Guanethidine suppressed the secretion 
of follicle-stimulating hormone, luteinizing hormone and somatotropin, 
while it stimulated the secretion of the luteotropic, adrenocortico-
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tropic and antidiuretic hormones. Although the altered hormone 
secretion did not bear directly on the mode of action of guanethidine, 
the suggestion was made that the hypothalamus might be intermediary in 
the drug's useful physiological effects. 
3. Miscellaneous 
Kuntzman et al. (1962) reported that after the administration of 
guanethidine, 35 mg/kg, i . v . , to ~ats, about half of the drug disappears 
from the animal in the first hour. After two hours, the rate of dis -
appearance is sharply reduced and the level in the body declines 
exponentially with a half-life of about seven hours. At this time the 
drug is highly localized in various tissues; however, brain and plasma 
levels were barely measurable . 
According to Chang et al. (1964), guanethidine is localized in rat 
tissues by two kinds of binding sites : nonspecific sites, present in 
all tissues and analogous to those which reversibly bind most drugs 
with tissue components; and specific sites; present mainly in tissues 
containing NE in high concentration . They found guanethidine taken up 
into heart slices by two processes, only one of which is readily sat-
urated and which is inhibited by anaerobic conditions and by amphetamine. 
In accord with this view are the results of Schanker and Morrison 
(1965), who administered guanethidine to rats (3 . 5 - 28 mg/kg, i.v . ) 
and found that it became localized in a number of tissues. After two 
hours, the tissue/plasma concentration ratios were about 20 for heart, 
10-12 for lung and intestines, 5-6 for skeletal muscle, spleen and kid-
ney and 2 for liver . The general pattern of distribution changed with 
time. Localization was greatest in liver and kidneys in the beginning, 
but later became greatest in heart and skeletal muscle. 
Furst (1968) reported that after the injection of guanethidine 
sulfate (20 mg/kg, i.p.) the drug was rapidly and extensively meta-
bolized. Approximately 70% of the drug was eliminated in the urine with-
in 24 hours, mainly as a polar metabolite. Schanker and Morrison (1965) 
reported similar results, citing rapid metabolism and excretion in 
urine during the first hour after administration. 
4 . Sumnary 
Kopin (1968) briefly summarized the effect of guanethidine in the 
following manner : Guanethidine depletes NE stores in tissues (Sheppard 
and Zimmerman, 1959; Cass et al . , 1960), is bound to some extent in the 
same particulate fraction as NE (Chang et al., 1965), and can be re-
leased by sympathetic nerve stimulation (Boullin et al., 1966). Although 
this guanidine derivative may displace NE and have a role as a false 
transmitter (Boullin et al . , 1966), it interferes with sympathetic 
neuronal function prior to any decrease in CA stores (Cass and Spriggs, 
1961) . Guanethidine may, therefore, diminish release of NE by inter-
fering with the process of transmitter release rather than by replacing 
the transmitter . 
D) RESERPINE 
1. History and Pharmacology 
Rauwolfia preparations employed clinically are obtained primarily 
from the root of Rauwolfia serpentina (Benth), a climbing shrub of the 
Apocynaceae family. Although preparations of the Rauwolfia alkaloids 
have been used for centuries i n India, their widespread use in Western 
medicine began only after the isolation of reserpine in 1952 (Mueller 
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et~.). The principal pharmacological actions of reserpine are: 
1. mild CNS depression and blockade of conditioned avoidance behavior, 
2. hypotension, 3. hypothermia, and 4. marked peripheral ANS effects 
consisting of an increase in parasympathetic and a decrease in sympa-
thetic activity (DiPalma, 1965; Goodman and Gilman, 1965). 
Plummer ~ al. (1954) reported that reserpine inhibited the hypo-
thalamus, initiating sympatholytic or parasympathomimetic responses. 
Weiskrantz (1957), in studying the behav~oral pattern of reserpine, 
observed that it appeared to inhibit sensory input to the brain. 
Jacobson (1959), studied reserpine under psychic stress and found that 
it produced nonspecific effects. Domino (1962) concluded that reserp-
ine either stimulates or depresses most areas of the brain, except 
the limbic system. 
Holzhauer and Vogt (1956) found that reserpine depleted NE from 
its normal brain stores and concluded that reserpine acts as a sympa-
tholytic agent. Brodie and Shore (1957) theorized that reserpine 
produces its tranquilization effect by releasing serotonin from its 
normally bound form . 
Carlsson et al . (1957) demonstrated that dopa, a precursor of NE, 
restored the normal activity of reserpinized animals . Carlsson et al . 
(1958) demonstrated that reserpine also depleted dopamine, a precursor 
to NE and it is now believed that this latter compound has an action 
of its own. Carlsson theorized that reserpine produced its effects by 
depriving central synapses of accessible NE and dopamine. 
Brodie et al. (1961) and Burns and Shore (1961) presented evidence 
that reserpine produces its effect through serotonin depletion. They 
showed that reserpine causes equal depletion of NE and serotonin from 
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their normal bound states in the brain. They observed that serotonin 
produced sedative effects similar to those of reserpine; that alpha-
methyl-m-tyrosine (alpha MMT), which depletes the brain of its NE, had 
no sedative effect; and that cold stress four hours prior to the admin-
istration of reserpine prevented its sedative effects and also inhibited 
the depletion of serotonin induced by reserpine, but not that of NE. 
Revizin ~ al. (1961) demonstrated a correlation between CNS depression 
and lowered serotonin; however, they could demonstrate no relationship 
between NE depletion and evoked potentials. 
Giarman and Schanberg (1959), working with serotonin, and Weil-
Malherbe et al . (196lb), working with NE, found that in brain fractions 
from reserpinized animals there was an increase in the free/bound ratio 
of the concentration of both amines, an indication that reserpine has 
the ability to increase the "free" form of NE and serotonin. It is 
assumed that it is this "free" form of the amine that is accessible 
to central synaptic sites. 
2. Effect on Catecholamines 
In spite of the numerous attempts to explain the sometimes dramatic 
effect of reserpine, its mode of action is still largely unknown. The 
ability of reserpine to deplete tissue stores of their CA is well estab-
lised and has been reviewed by Shore (1963) and Costa et al. (1966). 
Reserpine has been found to cause a depletion of the CA of various tis-
sues and the extent of this depletion is found to be both species 
(Collengham and Mann, 1958) and tissue dependent (Carlsson et al., 1958). 
Very small, single doses of reserpine deplete the heart 0£ NE (Brodie 
et al . , 1957), while somewhat higher doses are necessary to affect brain 
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NE (Brodie et al., 1957; Holzhauer and Vogt, 1956) and dopamine 
(Carlsson et al., 1958). The depletion of CA from the adrenal medulla 
is relatively resistant to reserpine and still higher doses are re-
quired (Carlsson et al., 1957); this depletion in the adrenal medulla 
appears to be dependent, in part, on an intact nerve supply to the 
gland (Holzhauer and Vogt, 1956; Mirkin, 1961). Other investigators 
confirmed the ability of reserpine to deplete the CA in peripheral 
tissues other than the heart and adrenal medulla, these include: 
arterial tissue (Burn and Rand, 1957); sympathetic ganglia (Muscholl 
and Vogt, 1958); and fat (Paasonen and Pletscher, 1960). 
Carlsson et al. (1957), Paasonen and Krayer (1958), and Bhagat 
and Shideman (1964) all reported that a minimum of two weeks time was 
required for the complete dissipation of the effects of reserpine upon 
cardiac CA depletion. In arriving at an explanation for this delayed 
reversibility of the effect of reserpine on CA stores, different work-
ers have ruled out such possibilities as: 1. prolonged retention of 
reserpine at the site of action (Shore and Olin, 1958); 2. inhibition 
of CA biosynthesis (Paulson and Hess, 1963); or 3. slower turnover of 
amines in the heart (Bhagat, 1963b). However, there is now some accept-
ance of a possible reason for this long-lasting effect on CA stores as 
being related to an effect on a storage mechanism. Pretreatment of 
animals with reserpine impairs the uptake of adrenalmedullary granules 
of newly formed CA after dopa administration, or of administered NE 
and Eby various tissues (Schaepdryver, 1959). 
Axelrod ~ al. (196lb) and Hertting et al. (196la) showed that in 
reserpinized tissues exogenous NE and E do not accumulate when the 
tissues are exposed to NE and E. Dengler et al. (1961) found that the 
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presence of reserpine in the incubation medium prevented t~e accumulation 
of NE in tissue slices. This ability of reserpine to inhibit the tissue 
uptake of CA has been widely accepted and theories have been elaborated 
in an attempt to explain the action of reserpine on amine storage on 
this basis (Brodie and Beaven, 1963). However, studies by Kopin et al. 
(1962) and Lindmar and Muschall (1964) present evidence that casts 
doubt upon this interpretation . Lindmar and Muschall measured the up-
take of NE in the perfused rat heart. An analysis of the NE content 
of the heart at the end of the perfusion revealed that in normal animals 
the NE taken up from the medium could be accounted for almost entirely 
as unchanged NE which accumulated in the tissue. In reserpinized hearts 
the amount of NE taken up from the perfusing medium was the same as in 
normal hearts, but in this case the accumulated material did not appear 
as unchanged NE in the heart . These results suggest that the uptake 
of NE is normal in reserpinized hearts but that the accumulated NE can-
not be retained within the tissue and is rapidly lost by metabolism. 
It follows then, that in reserpinized animals the tissues are able to 
accumulate exogenous CA, but they are no longer able to retain the CA 
thus accumulated. Kopin et al . showed that in the reserpinized rat 
heart the initial rate of accumulation of H3-NE did not differ from 
that in normal hearts. They also reported that the kinetics of release 
of NE from the isolated reserpinized heart suggest that this drug effects 
the firmly bound reserve pool, but not the readily available pool. 
Kopin and Gordon (1962; 1963a) showed that the NE released from rat 
tissues by reserpine left the tissues largely in the form of MAO meta-
bolites. Kopin et al. (1962) and Axelrod ~ ~· (1962) showed that 
reserpinized rat hearts were unable to retain accumulated H3-NE. These 
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results also indicate that the NE accumulated in reserpinized hearts 
did not leave the tissue as unchanged NE but was rapidly degraded by 
MAO to acid and alcohol metabolites which then left the tissue . 
Bhagat (1964b) also suggested that the main action of reserpine might 
be its interference with the storage mechanism and not with the uptake 
of CA. There appeared to be little change in the initial :rate of up-
take of CA after reserpine; but the tissue was unable to store it, so 
that which was taken up was rapidly lost through destruction by MAO . 
This suggestion could explain the CA-depleting effect of reserpine . 
Tissue whose ability to respond to nerve stimulation or to tyramine 
has been reduced by reserpine, can have that responsiveness temporarily 
restored by an infusion of NE (Burn and Rand, 1958; 1960; Rosell and 
Sedvall, 1961), further evidence in support of the view that CA up-
take is normal in reserpinized tissues . 
~\ 
The conclusion that reserpine does not affect CA uptake thus :' 
appears to be a reasonable one . How reserpine affects the intracell-
ular storage of CA remains obscure, though reports that reserpine 
affects the uptake and storage of NE in isolated NE storage particles 
(von Euler and Lishajko, 1963; von Euler ~ al., 1964) suggest that 
this may be the site of action of res.erpine. Dahlstrom et al. (1965) 
concluded that the primary action of reserpine in producing a long-
lasting block of storage function is not to block the mechanism for 
amine uptake (reabsorption) localized in the cell membrane of the 
entire adrenergic neuron, but to block the storage mechanism in the 
amine granules. They also concluded that the cell membrane is not the 
primary site of action of reserpine . 
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3. Effects on the Pituitary-Adrenal Axis 
A survey of the literature concerning the action of reserpine on 
the pituitary-adrehocol:_d.cal system reveals a conflicting picture. 
Several workers have shown . that reserpine reduces the reactivity of 
the pituitary7.adrenocortical system, probably by depressing the re-
sponse of the hypothalamic regions that control the secretion of ACTH. 
This view was based on experiments which demonstrated that reserpine 
pretreatrrent of rats and monkeys prevented the decline in AAA or the 
rise in plasma corticosteroids ordinarily evoked by ether, histamine, 
surgical trauma, cold exposure, or emotional stress (Wells et~. , 
1956; Mahfouz and Ezz, 1958). Investigation of this possible mech-
anism was complicated by the fact that reserpine stimulates ACTH 
secretion. This has been shown in the rat (Khanzan et ~·, 1961; 
Maickel et al., 1961; Saffran and Vogt, • 1960'~ "'Wells ~ al., 1956), 
in the dog (Egdahl et al . , 1956) and in the monkey (Harwood and 
Mason, 1957). The dose levels found to stimulate ACTH secretion in 
the rat were 1 mg / kg, i.v . or 2.5 mg/kg, i . p.; changes in AAA, blood 
corticosterone or both were used as indicators of an increase in ACTH 
secretion . 
The endocrine aspects of reserpine were first noted by Gaunt 
et al. (1954) in normal animals; changes in organ weight data indi-
cated that reserpine caused mild stimulation of the adrenal cortex . 
Egdahl et al . (1956) showed that single injections of large doses of 
reserpine in dogs caused maximal ACTH release as judged by corticoid 
secretion rates. Work done in the monkey by Haward and Mason (1957) 
was in agreement with these findings . However, Mason and Brady (1956) 
found that reserpine, given for one week in monkeys, completely 
suppressed the expected rise in plasma corticosteroids usually 
associated with anxiety states. 
Wells ~ ~· (1956) resorted to repeated daily injections of 
reserpine, counting on ''adaptatio~' to the drug, to eliminate the 
stimulating effect on ACTH secretion. In contrast to the marked 
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decrease in AAA seen four hours after the first injection, the values 
were at the control level 24 hours after the last injection. These 
observations were confirmed by Kitay et al . (1959) and Maickel ~ ~· 
(1961). Wells~~· (1956) concluded that reserpine in a single 
initial injection caused marked ACTH release; however, after continued 
injections the pituitary became refractory to subsequent ACTH-releasing 
stimuli, and the workers concluded that reserpine in some way inhibited 
the secretion of the hypothalamic secretory factor for ACTH. 
Guillemin (1957) attempted to determine whether any of the pro-
posed neuro-humoral agents (5-HT, NE, etc.) were identical to CRF. 
He did not agree with previous findings regarding the ability of tran-
quilizers to inhibit acute stressors . Guillemin used a psychological 
stressor (forced restraint) in his study. He observed that, while 
reserpinized rats did not resist being restrained, the animals still 
displayed adrenocortical hyperfunction as indicated by the depletion 
of AAA. He also found that reserpine itself is a potent stressor, 
even though the animals were preinjected with the drug seven days prior 
to the restraint. 
Mahfouz and Ezz (1958) used very small doses of reserpine, 8 ug/kg, 
i . m., before imposition of stress . They reported that the decrease in 
AAA seen in controls after exposure to heat, exposure to cold, or blood-
letting under ether anesthetic did not occur in rats injected with 
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reserpine. Furthermore, reserpine was not able to inhibit the usual 
depletion of AAA by various doses of ACTH, but did inhibit the stressors 
mentioned above. Therefore, these workers concluded that reserpine 
inhibited the pituitary-adrenal axis by inhibiting some central regula-
tory mechanism, possibly the hypothalamus. 
Kitay et al. (1959), in confirming the experimental data of previous 
investigators in this field, added a new dimension which led to diff-
erent interpretation. They observed that when reserpine was given for 
a three-day period, the adrenal hypertrophy implied a continuous, high 
rate of ACTH secretion rather than a refractoriness after an initial 
stimulation. The essential new fact was that during this period, pitu-
itary ACTH remained low, about one-third of normal. A presumably"non-
specific'' stressor, E, had similar effects; after either reserpine or 
E had been administered over a period of three days, the stress of 
ether anesthesia failed to cause ~ depletion of AAA. They suggested 
that the refractoriness of the ACTH response to stressful stimuli 
after previous administration of a depressant drug might be due to 
the reduction of pituitary ACTH provoked by the drug. The fact that 
E had no effects similar to reserpine provided additional support for 
this hypothesis. These observations were confirmed by Brodie et al. 
(1961) and Maickel et al. (1961). They further showed that exposure 
of rats to cold also reduced pituitary ACTH content and that this was 
followed by a period during which imposition of a second stressful 
experience (reserpine or additional cold) failed to stimulate increased 
ACTH secretion 
In a series of papers, Maickel et~· (1961), Westerman et~· 
(1962) and Westerman (1965), by using the decrease in AAA, elevation 
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of plasma corticosterone and FFA, increase in the activity of TP and 
tyrosine transaminase in the liver, and increase in adrenal weight as 
indices, studied the action of reserpine and cold exposure (4°) on the 
anterior pituitary-adrenocortical system in rats. Their results indi-
cated that reserpine depleted brain serotonin and NE, produced sedation, 
and induced a sustained stimulation of the anterior pituitary-adreno-
cortical system. Cold exposure had similar effects on the pituitary; 
however, no data on brain amines were given . Demonstration that these 
effects of reserpine were not seen in hypophysectomized or adrenal-
ectomized rats while the drug still depleted brain amines indicated 
that the increased activity of the adrenal cortex was induced by a 
hypersecretion of ACTH. These investigators contended that the long 
duration of the pituitary activation was not evoked by reserpine ~ 
~· which disappeared from the body within a few hours (Hess ~ ~· , 
1958), but by the amine-depleting action of the drug. In these 
studies, it was shown that reserpine (5.0 mg/kg, i.v.) or a prolonged 
exposure to cold (4° for 20 hours) lowered the ACTH content of the 
pituitary to such an extent that the animals were unable to respond to 
an additional stressful stimulus or to another dose of reserpine by 
increasing plasma corticosterone. 
Eechaute et al. (i962) failed to confirm these observations. 
~ ~
They found that after pretreatment with a single dose of reserpine or 
after a series of four daily injections, reserpine did not block the 
adrenocortical response to stress of acute cold exposure. Montonari 
and Stockham (1962) presented similar results in different types of 
experiments. However, no pituitary ACTH or brain amine levels were 
reported in either of these studies. 
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Since CA injected in very low doses will stimulate ACTH secretion 
(Harris, 1955), the possibility was considered that the reserpine-
induced release of CA from the adrenal medulla and sympathetic nerve 
endings might mediate ACTH hypersecretion. However, Maickel ~ ~· 
(1961) reported that administration of reserpine to adrenodemedullated 
rats induced the same degree of pituitary activation as in the intact 
rat. 
Syrosingopine, a carbethoxy analogue of reserpine, in small doses , 
released only peripheral NE (Orlans ~al., 1960), ~·£·• from the 
heart, but did not stimulate the pituitary adrenal system. Only large 
doses which also depleted brain amines and produced sedation caused a 
sustained pituitary-adrenal stimulation . Therefore, it was suggested 
that the action of reserpine on the pituitary might be related to the 
depletion of brain amines. 
Costa et al.(1962b) showed that administration of R0-4-1284, a 
benzoquinolizine derivative having reserpine-like action, produced 
marked sedation, a depletion of brain amines, and an elevation of the 
plasma corticosterone . This compound, in contrast to reserpine , was 
very short-acting . After about eight hours the animals were no longer 
sedated, and the brain amines returned to normal. A corresponding 
short-lasting elevation of plasma corticosterone indicated a correla-
tion between brain amines and ACTH hypersecretion. Whether the 
reserpine-induced activation of the pituitary was more closely related 
to changes in the brain CA or to the depletion of brain serotonin was 
studied by using alpha-MMT, which in rats produced a long-lasting deple-
tion of brain NE without significant changes in brain serotonin (Hess 
~ al., 1961). There was no stimulation of the pituitary-adrenocortical 
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system in these rats, as indicated by unchanged TP activity. However, 
administration of reserpine caused a marked sedation and increased 
plasma corticosterone similar to those in the animals not pretreated 
with alpha-MMT. Westerman~ ~.(1962) also concluded that discharge 
of ACTH was related to serotonin depletion. 
Giuliani et ~· (1966) presented evidence to show that reserpine 
is able to enhance synthesis and release of ACTH even after both of 
these processes have been largely suppressed by the administration of 
potent adrenocortical steroids . They suggested that the main effect 
of reserpine on the pituitary-adrenal axis was that of enhancing rather 
than depressing ACTH secretion, and that this effect was achieved by 
the suppression of the midbrain inhibitory action. The reserpine-
induced block of stress reactions was thought to be a result of the 
feedback effect of the enhanced blood levels of adrenal steroids. 
4. Miscellaneous 
Reserpine has been shown to leave tissues rapidly after injection, 
so that at the time of maximal NE depletion , little or no reserpine 
can be detected in tissues (Hess et al., 1956). However, experiments 
with tritiated reserpine have revealed that the drug persists in 
tissues in very low concentrations for at least 48 hours after injection 
(Plummer et al . , 1957). 
5. Summary 
Bloom and Giarman (1958) concluded that reserpine, which reduces 
amine storage by acting on the storage particles, releases amines 
earliest from unidentified structural elements present in the super-
natant fraction, and does so with increased catabolism by MAO. Recovery 
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from reserpine-induced behavioral and autonomic symptoms correlates 
with recovery of the accumulation process but not with the slower 
recovery of endogenous amine levels. Reserpine does not appear to 
affect either the synthetic enzymes (Glowinski and Baldessarini, 
1966; Glowinski et al., 1966) or uptake of amines into the neuronal 
cytoplasm (Glowinski and Baldessarini, 1966; Dahlstrom et al., 1965; 
Carlsson et~., 1965; 1966; Malmfors, 1965). Overall synthesis could 
be impaired by accelerated catabolism of unbound dopamine before the 
latter is converted to NE. 
E. POINTS OF SIMILARITY AND DIFFERENCES REGARDING 
GUANETHIDINE AND RESERPINE EFFECTS ON CATECHOLAMINES 
Guanethidine and reserpine have several properties in conunon, but 
there is much evidence to suggest that their mechanisms of action are 
different. In the first place, the chemical structures of the two 
compounds are entirely different . Guanethidine is a derivative of 
guanidine and an extremely strong base with low lipid solubility; in 
contrast, reserpine is a polycyclic, weakly basic structure having a 
high lipid solubility . It seems unlikely, therefore, that the two 
compounds release NE by the same mechanism. 
The biphasic response to guanethidine (Maxwell et al., 1959; 
1960a; 1960b) and its potentiation of the response of effector systems 
to NE (Boura and Green, 1962) are similar to those following reserpine 
administration and this similarity is extended since the pressor action 
of tyramine is reduced after guanethidine administration (Bhagat and 
Shideman, 1963b). Sheppard and Zinunerman (1960b) showed that guan-
ethidine partially depleted the CA of rat heart and spleen, an action 
not entirely analogous to that exhibited by reserpine, because it did 
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not deplete the CA of the brain or adrenal medulla (Cass~ al., 1960). 
The effects of guanethidine on biogenic amines differ from those 
of reserpine in a number of respects: guanethidine depletes heart NE 
more slowly than does reserpine; guanethidine does not lower the sero-
tonin content of platelets or intestines; and large doses of guanethi-
dine produce a brief sympathomimetic effect which precedes the adrenergic 
neuronal-blocking action and appears to depend on the availability of 
stored NE (Bein, 1960; Burn, 1961) . 
Kuntzman et al. (1962) showed that over a four-hour period guan-
ethidine (35 mg/kg) lowered heart NE to about ten percent of normal. 
The NE remained low for 24 hours and, during the next 24 hours, gradu-
ally started to rise. Coincident with the rise in NE, the guanethidine 
had virtually disappeared from the body. These effects are in contra~t 
. 
to those of reserpine which produces a depletion of heart NE that per-
sists long after the drug is no longer detectable (Hess et al., 1956). 
Kuntzman et al . also reported that in doses of 150 mg/kg (i.p . ) 
guanethidine did not reduce the content of CA in the adrenal medulla. 
However, doses of 400 mg/kg, or 80 times those which reduce the content 
of heart NE by 50%, did lower the content of medullary amines by about 
50%. Similarly, doses of reserpine necessary to reduce medullary 
amines by one-half were about 80 times those which caused a 50% decline 
in heart NE. Kuntzman et al. further showed that heart NE was lowered 
by 50% one hour after giving reserpine in doses large enough to deplete 
heart NE completely. In contrast, the rate of release by guanethidine 
was slower : about 50% in two hours . As expected, guanethidine did 
not lower the content of brain NE since it does not enter the brain in 
appreciable amounts. 
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Kuntzman et ~· stated that although the action of guanethidine 
in reducing heart NE is readily reversible, that of reserpine is 
relatively nonreversible; however, they emphasized that this does not 
necessarily mean that the two drugs affect NE storage by different 
mechanisms. The drugs could act on the same storage process, with 
reserpine having a high affinity for the storage sites. However, 
guanethidine and reserpine appear to release NE by different mech-
anisms, since bretylium counteracts guanethidine but not reserpine in 
releasing NE. They concluded that guanethidine releases NE from sym-
pathetic nerve endings by an action which seems to differ from that 
of reserpine; guanethidine may release NE by activating the normal 
process of physiological release . 
Harrison et al . (1963) showed that in three hours guanethidine 
produced an initial loss of some 24% of the CA of the dog heart, while 
reserpine produced a 65% loss in four hours . These findings suggest 
a different mechanism of NE depletion in the period innnediately after 
administration of the drugs. Also, the amine-depleting action of 
guanethidine was accompanied by a sympathomimetic response which was 
not seen with reserpine. Apparently guanethidine releases CA on to 
the receptor sites, but the CA released by reserpine do not gain access 
to the receptor (Kuntzman et al., 1962; Bhagat, 1964a). 
Reserpine releases NE onto MAO by inhibiting nonreversibly an 
active transport mechanism or pump that maintains the amine in a 
mobile pool at nerve endings (Spector et al., 1960). In contrast, 
guanethidine has been postulated to release NE onto receptor sites 
(Kuntzman et al., 1962) . Kopin and Gordon (1963a) claimed that CA 
released by guanethidine are inactivated by MAO and COMT. Nash et al. 
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(1964) has shown that NE is released onto the receptor site and is 
subsequently 0-methylated. Their results showed that reserpine releases 
NE almost entirely in the form of deaminated products whereas guan-
ethidine releases the amine as the free base . 
Gaffney et al. (1963) suggested that guanethidine's interference 
with adrenergic transmission is independent of changes in the level of 
stored adrenergic-transmitter . The reserpine-induced blockade of adren-
ergic transmission may ultimately be dependent upon the depletion of 
adrenergic transmitter, but almost complete depletion of stored adren-
ergic transmitter must occur before reserpine-induced adrenergic block-
ade occurs. 
Chang et al. (1964) stated that guanethidine is localized in rat 
tissue by two kinds of binding sites. (See page 34). Reserpine was 
shown to release considerable amounts of guanethidine from tissues con-
taining high levels of NE; however, reserpine released little or no 
guanethidine from tissues having only small amounts of CA. It was also 
inferred that reserpine had completely blocked the uptake of guanethidine 
into adrenergic neurons, since amphetamine produced no additional inhi-
bition of guanethidine uptake . 
Muskus (1964) presented evidence of different sites of action of 
guanethidine and reserpine. His results were discussed on the basis 
of a two-compartment theory of the NE stores . He indicated that guan-
ethidine differs from reserpine in its site of action, because guan-
ethidine appears to act more strongly than reserpine on the small 
compartment of tyramine-sensitive NE. This was true for both the 
depleting and the releasing action of guanethidine. 
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Lundborg and Stitzel (196?) suggested ·that the membrane pump-
inhibiting ability possessed by guanethidine, but not reserpine may 
account for the sympathomimetic activity and exogenous amine potent-
iation which often accompanies guanethidine but not reserpine 
administration. 
Burns and Rand (1958; 1960) postulated that reserpine impairs 
adrenergic function by its action in depleting the stores of the trans-
mitter, NE. Guanethidine was also found to deplete CA from peripheral 
organs (Sheppard and Zirrnnerman, 1959), and it was suggested by Cass 
et al. (1960) that the loss of adrenergic function might be attributed 
to the loss of transmitter substance from the nerve endings . However, 
it was later shown that the ini tial blocking action of guanethidine 
was not related to depletion of the NE stores (Cass and Spriggs, 1961; 
Gaffney et~., 1963). Chang et al. (1967a) concluded that the adren-
ergic neuron blocking effect of guanethidine is consequent on the rapid 
depletion of the particulate NE which is available for release by 
nerve impulse . 
III. METHODS AND MATERIAL 
A) ANIMALS AND ANIMAL HOUSING 
Male, albino rats of the Sprague-Dawley strain , weighting between 
75-lOOg, obtained from Charles River 1 , were used throughout the investi-
gation. All animals were kept at room temperature in uncrowded community 
cages (51 x 56 x 38 cm) 2 for two to three weeks after arrival in the 
laboratory . Purina3 rat chow and tap water were provided ad libitum. 
At a period beginning two weeks prior to their use, the rats were trans-
ferred to suspended metabolism cages2 , two per cage, where they were 
kept throughout the study. The metabolism cages were placed in an air-
conditioned animal room where the temperature was maintained at 21.1 
0 
+ 0 . 5 . Following the transfer, each animal was given 20g of Purina 
rat chow daily at about 2 : 30 p . m. , and tap water was provided ad 
libitum. 
The animal room was illuminated artifically for a twelve hour 
period beginning at 6 : 00 a . m. In an effort to minimize any effect of 
movement into and out of the animal room, only authorized personnel 
were allowed admittance . When not undergoing restraint , the experi-
mental animals were housed in the same room as the control animals. 
Control rats were not restrained, but were kept in the suspended meta-
bolism cages without food and water during the restraint period. 
1. Charles River Breeding Farms, North Wilmington, Massachusetts. 
2. Wahmann Manufacturing Co . , Baltimore, Maryland. 
3. Ralston Purina Co . , St . Louis, Missouri. 
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B) RESTRAINT STRESSOR PROCEDURE 
Because innnobilization has been shown to produce considerable 
stress due to the increased neuromuscular exertion involved (Selye, 
1946), a restraint stressor procedure was used. Rats were removed 
from the animal room, about one hour after vehicle or drug injection, 
and transferred to a second room where they were restrained. The 
illumination conditions and temperature in this room were identical 
to those in the animal room. The animals were placed on restraining 
boards, similar to the ones used by Renaud (1959). 
Each board was designed to restrain four rats simultaneously by 
securing their paws to each of four vertical metal posts. Strips of 
adhesive tape, two cm wide to allow circulation, were wrapped cuff-
wise about the paws of the restrained animals, and size one safety-
pins were then pinned to the tape. The tape and pins were left on 
the animals throughout the entire period of the experimentation. The 
rats were restrained in a supine position simply by slipping the 
closed safety-pins over the metal posts. With this method, a rat 
could be innnobilized in a few seconds. The restrained animals were 
held in this position for five hours. 
The studies of Renaud (1959), reconnnended that the incisors of 
rats restrained in such a position be cut to prevent them from biting 
their paws. This probiem was solved by innnobilizing the head by 
placing it between two metal posts. 
C) EXPERIMENTAL DESIGN 
1. General Consideration and Daily Protocol 
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Drugs. 
2 
A2448) and 
Aqueous solutions of guanethidine sulfate1 (Ismelin™; 
1 TM 2 
reserpine phosphate (Serpasil ; 65-293) were prepared 
daily and administered intraperitoneally (i.p.). The doses were cal-
culated in terms of the free base content of both drugs. 
To permit the animals to adapt to the injection procedure, all 
rats were weighed to the nearest gram and injected i.p. with the drug 
vehicle, glass distilled water (1.0 ml/kg) every other day for 14 days 
prior to the experiments. The animals were kept undisturbed for 24 
hours prior to their use. Experiments were begun on the 15th day. 
From 7:00 to 9:00 a.m. daily the animals were weighed and injected by 
the same person with the vehicle or with the appropriate drug. Ani-
mals weighed between 150-215g at the beginning of the experimental 
period. Water and food consumption were measured and the water jars 
refilled during this period. 
2. Dose-Response Studies 
The purpose of this study was to determine that dose of reserpine 
effecting a 50% depletion of brain NE and that dose of guanethidine 
effecting a 50% peripheral depletion of NE as measured in the heart. 
One hundred and twenty rats were divided into twelve groups of 
ten animals each. Housing and daily preparatory protocol were as de-
scribed above. Each day for six days all rats in each group were 
injected i.p. with one of the following d~ses (mg/kg): reserpine, 
1. Both drugs graciously supplied by Mr. Jack Cooper, Ciba 
Pharmaceutical Products, Inc., Summit, N.J. 
2. Lot number. 
' ··r. 
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0 (vehicle), 0.05, 0.1, 0.25, 1.0, and 2.5; guanethidine, O (vehicle), 
0.5, 1.0, 2.5, 5.0, and 10.0. Approximately eight hours after the 
last injection the animals were removed from the animal room and with-
in one minute were sacrificed by decapitation (manual guillotin) 1 . The 
brain was removed from the skull, rinsed with saline at o0 and blotted; 
the heart was removed from the body cavity, cut in half, rinsed with 
cold saline and blotted. These operations were accomplished in less 
than a minute after decapitation . Each organ was irrnnediately placed 
into a separate aluminum mesh basket and irrnnersed into liquid nitrogen 
contained in a wide-mouthed, vacuum-insulated jar. When the nitrogen 
stopped boiling, the tissue was removed, wrapped individually in 
aluminum foil, coded and stored in a freezer at -40° until assay. 
3. Chronic Restraint Studies 
The dose of reserpine and of guanethidine established in the 
dose-response studies were used throughout this phase of experiment-
ation. The animal handling, the injection and the feeding were as 
described above. A total of 300 animals were used in this portion of 
the study, according to the following procedure : Individual experi-
ments of 1, 3, 6, 12, and 24 days duration were conducted on animals 
that were randomly divided for each experiment into six experimental 
groups of ten rats each. The daily protocols for the various groups 
were as follows: 
1. Vehicle control. These animals received 1 ml/kg, i.p., of the drug 
vehicle daily. 
1. Harvard Apparatus Co., Inc,, Dover, Massachusetts. 
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2. Guanethidine control. These animals received 1.20 mg/kg, i.p., of 
guanethidine daily. 
3. Reserpine control. These animals received 0.2 mg/kg, i.p., of 
reserpine daily. 
4. Vehicle restrained. These animals received 1 ml/kg, i.p., of the 
drug vehicle and were subjected to restraint daily. 
5. Guanethidine restrained. These animals received 1.20 mg/kg, i.p., 
of guanethidine and were subjected to restraint daily. 
6. Reserpine restrained. These animals received o.2 mg/kg., i.p., of 
reserpine and were subjected to restraint daily. 
Restrained animals were subjected daily to the immobilization pro-
cedure described above. At the te:l!'lnination of the above experiments, 
the restrained animals were sacrificed by decapitation within one minute 
of their removal from the stressing room. Control animals were decapi-
tated within one minute of their removal from the animal room. 
After decapitation, blood was collected from the trunk of each ani-
mal into twelve ml centrifuge tubes and allowed to stand until a clot 
formed. The samples were then centrifuged1 for ten minutes at 2000 rpm. 
The serum was separated by decantation into four ml Kimax2 test tubes 
0 that were then stoppered, coded, and stored for assay at -40 . The 
adrenal glands were removed from the body cavity, freed of fatty tissue, 
blotted and immediately frozen in liquid nitrogen; this procedure took 
less than one minute. The frozen adrenals were then placed in four ml 
Kimax2 test tubes, stoppered, coded and stored at -40° until assay. 
Brain and heart were removed and stored as described above. 
1. International Clinical Centrifuge, Model Cl 21890M, International 
Equipment Co., Needham Heights, Massachusetts. 
2. Owens-Illinois Glass Co., Toledo 1, Ohio. 
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4. Blood Pressure Studies 
The object of this portion of the study was to determine whether 
the dose of reserpine and of guanethidine used in the chronic restraint 
studies had any effect on blood pressure. Fifteen animals were divided 
into three groups of five animals each . Daily drug doses (i.p.) were 
as follows: group one, vehicle, 1 ml/kg; group two, reserpine, 
0.2 mg/kg; group three, guanethidine, 1 . 20 mg/kg. Daily protocols, in-
jecting and feeding procedures were as described above; however, there 
was a slight variation in the housing : in each group, one animal was 
individually housed. This modification proved to have no effect on the 
blood pressure recording. In order to permit the animals to adapt to 
the handling, the container, the tail cuff and the recording apparatus, 
blood pressures were determined on four separate days prior to drug 
treatment. During the actual determination, the animals were removed 
from the animal room, and blood pressure was determined daily from 
about 11:00 a.m. - 1 : 00 p.m. for twelve days and then every other day 
until day 24 . 
The tail cuff method for indirect systolic blood pressure 
determination was used . The animals were placed in an incubator box 
0 
at 40 for 15 - 20 minutes to cause peripheral vasodilation to f acili-
tate the determination of blood pressure. After incubation each rat 
was allowed to enter a clear plastic container (23 x 7 x 5 cm). The 
internal length of the container was regulated with a movable piston so 
that the animal is snugly but not uncomfortably restrained . The rear 
door at the open end of the chamber was then placed in position, leav-
ing only the rat's tail protruding . The rat generally becomes calm 
after a few minutes in the container . 
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1 An inflatable, blood pressure cuff , connected to a Physiograph 
2 . 
manometer system was slipped on the rat's tail as far proximally as 
possible. The manometer system was connected to a hand bulb for manual 
cuff inflation. The end of the tail distal to the cuff was passed 
through a small plastic holder , so designed that when a screw clamp 
was tightened, the tail came into contact with a Beckman microphone 
transducer . 3 3 The transducer lead was connected to a Beckman Infraton 
signal divider set for maximum pulse . The Infraton output lead was 
4 
connected to the di rect current input of an HP oscilloscope (Model 130B) 
set at a sweep time of 20 msec/cm. 
This system converts pressure pulses in the rat's tail to peaks 
on the oscilio?cope screen. Squeezing the rubber bulb of the manual 
manometer system increases pressure in the system, causes the cuff to 
be inflated with the consequence that the peaks on the oscilloscope 
screen disappear as tail circulation distal to the cuff is cut off. 
By allowing the air in the cuff to escape slowly, pressure in the mono-
meter system is reduced and tail circulation is restored as indicated 
by the reappearance of peaks on the screen. Because it is assumed that 
for distal circulation to be restored the pressure in the tail arteries 
must be slightly greater than the pressure in the manometer system, the 
pressure, as read on the manometer dial, at which pulsation first appears 
on the screen is a measure of systolic blood pressure of the animal. 
Diastolic pressures cannot be observed with this technique . The recorded 
1. Harvard Instruments, Cambridge, Massachusetts . 
2 . E. and M. Instruments, Houston, Texas . 
3. Beckman Co., Palo Alto, Cal i forni a . 
4. Hewlett-Packard Co . , Palo Alto, California . 
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blood pressure of a rat on a given day is reported as the average of at 
least three successive determinations. Once the animal was quiet, 
successive determinations fell into a range not exceeding a few mm Hg. 
D) ANALYTICAL METHODS 
1. Estimation of Brain and Heart Norepinephrine 
The extraction procedure here is a modification of the method 
described by Shore and Olin (1958), and the quantities were reduced to 
one-third. This rapid and simple procedure for the chemical estimation 
of NE in animal brain and heart tissue involves an extraction with 
n-butanol from salt-saturated, acidified homogenate. The amine is 
unstable at alkaline pH. Reduction of the polarity of the butanol by 
the addition of n-heptane and extraction with dilute acid (O.OlN HCl) 
returns the NE to the aqueous-acid phase. An oxident is then added to 
the aqueous-acid solution to form the aminochrome, which on the addi-
tion of alkaline ascorbic acid, yields the trihydroxyindole. The oxi-
dation products of NE in alkaline solution shift the fluorescence 
emission to the visible region (520 mu) . The solutions were then 
assayed for the development of fluorescence by a modification of the 
method described by Maynert and Klingman (1962). 
Solvents and Reagents : 
Ascorbic acid (reagent grade, Matheson, Coleman and Bell) 
Acetic acid, glacial (reagent grade, Baker and Adamson) 
n-Butanol (reagent grade, Baker and Adamson) 
Ethylenediamine (reagent grade, Eastman Organic Chemicals) 
Hydrochloric acid (reagent grade, Baker and Adamson) 
n-Heptane (reagent grade, Matheson, Coleman and Bell) 
Norepinephrine (Nutritional Biochemical Corp.) 
Potassium ferricyanide (AR grade, Mallinckrodt) 
Sodium acetate, anhydrous (AR grade, Mallinckrodt) 
Sodium bisulfite (AR grade, Mallinckrodt) 
Sodium chloride (reagent grade, Baker and Adamson) 
Sodium hydroxide pellets (AR grade, Mallinckrodt) 
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Reagent grade n-butanol and n-heptane were purified by the method 
of Shore and Olin (1958) . Excess water was removed by decanting off 
the butanol after about 24 hours . 
Acetate Buffer, 2M, pH 6 . 0 : One volume of 2M acetic acid is added 
to 22 volumes of 2M sodium acetate. The pH was checked with a Radio-
meter, pH meter 28 1 
Alkaline Ascorbate Solution: This solution was prepared fresh 
daily prior to its use by mixing six ml of lON NaOH (Anton and Sayre, 
1962) with one ml of one percent sodium bisulfite and 0 . 16 ml of ethyl-
enediamine (von Euler and Lishajko , 1960), then adding one ml of a one 
percent ascorbic acid solution . All solutions used in the preparat ion 
of this alkaline ascorbate solution were prepared fresh dai ly . 
Norepinephrine standard : NE . HCl was used for preparing the 
standard solution, the concentration was calculated in terms of the 
base. Because it was observed that a solution of NE (100 ug/ml) in 
O.OlN HCl deteriorated even when refrigerated, the solution was made 
fresh daily and a working standard of suitable concentration (1 ug/ml 
to 5 ug/ml) in 0.0lN HCl were prepared prior to the start of each assay. 
1. Landon Co . , Westlake, Ohio . 
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Glass-distilled water was used in the preparation of all solutions. 
All glassware and polyethylene tubes were washed three times with dis-
tilled water followed by two rinsings with glass-distilled water. 
Method: The method described here was used to determine NE from 
whole rat brain and heart. At the time of the assay, each brain or 
heart was removed from the aluminum foil, weighed and immersed into 
liquid nitrogen as described above . The frozen tissue was then placed 
into a steel tablet die of suitable size and crushed by striking the 
upper punch with a hammer (Cullingham and Cass, 1963). 
A steel tablet die and punch set with an internal diameter of 
15 mm, was placed in a wooden block . One punch (lower) served as the 
base; the other punch (upper) was movable . Prior to placing the tissue 
into the die, the two punches and die were immersed into the liquid 
nitrogen for 15 - 20 seconds to prevent local heating and destruction 
of the NE. 
Each brain was reduced to three pellets by carefully breaking the 
frozen tissue into three approximately equal segments and compressing 
each segment _into a pellet. These pellets of still frozen tissue were 
1 
transferred to a 15 ml homogenizing tube containing five ml of acidi-
fied butanol . Each heart was reduced to two pellets by a similar pro-
cedure and transferred to another homogenizing tube containing acidified 
butanol . The butanol was chilled (Chang, 1964) to o0 prior to its use. 
The brain or heart was homogenized within two minutes in the 
chilled butanol by a motor-driven Teflon homogenizer2 . The homogenizing 
1. Catalogue number s35, TriR Instruments, Inc., Jamaica, New York. 
2. Catalogue number s21, TriR Instruments, Inc., Jamaica, New York. 
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tube was maintained in an ice bath during this procedure. The homogenate 
was transferred to a 50 ml, polyethylene test tube (29 x 105 mm) 1 con-
taining four gm of NaCl. Three successive washings of the homogenizing 
tube with five ml portions of chilled butanol effected quantitative 
transfer of the homogenate. 
One-half or one ml of the NE working standard (1 ug/ml), with 
volume adjusted to five ml with O.OlN HCl was simultaneously carried 
through the assay procedure with the tissue homogenate. Five ml of 
O.OlN HCl was used for the blank. 
The polyethylene tubes were capped and then shaken for 20 minutes 
on a reciprocating shaker. It was observed that the extraction of NE 
was virtually complete after a 10 to 15 minute period and that shaking 
carried on for periods up to one hour had no further effect on the amount 
extracted. Following centrifugation at 10,000 rpm for ten minutes, 13 ml 
of the butanol phase was decanted into a 25 ml polyethylene cylindrical 
graduate and poured into a second set of 50 ml, polyethylene tubes con-
taining 23 ml of n-heptane and two ml of O. OlN HCl. The tubes were 
capped and then shaken for five minutes on a reciprocating shaker and 
then centrifuged at 10 , 000 rpm for five minutes. The organic phase 
(upper) was removed by aspiration. 
One-half ml of the aqueous-acid phase from each sample was then 
carefully transferred to twelve ml polyethylene test tubes (16 x 100 mm) 1 . 
The transfer of any trace of the organic phase was avoided by using 0.5 ml 
1. Ivan Sorvall Inc., Norwalk, Conn . 
2. Lourdes Model AB centrifuge, Lourdes Instruments Corp., Brooklyn, N.Y. 
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Kimax1 volumetric pipettes. Two-tenths ml of water and 0.1 ml of 2M 
acetate buffer (pH 6) were added to each tube . The contents of each 
tube were mixed by manual inversion. To this mixture was added 0.1 ml 
of freshly prepared potassium ferricynide (40 mg%, w/v) and the contents 
were mixed. Two minutes later 0 . 2 ml of freshly prepared alkaline ascor-
bate solution was added and the contents were mixed. The solutions were 
then transferred to quartz cuvettes and their fluorescence intensities 
2 
were read by means of an -Animco-Bowman spectrophotofluorometer at an 
excitation wavelength of 400 mu, and fluorescence wavelength of 520 mu 
(uncorrected) . The source of emission was xenon arc lamp. 
A standard curve for NE was prepared daily prior to the tissue 
assay. Blank, 0.5, 1, 2, 3 and 4 ml portions of the NE working standard 
(1 ug/ml) were prepared and adjusted to five ml with O. OlN HCl. Fiv e 
ml of O.OlN HCl was used for the blank. These samples were extracted 
as were the tissue samples; however, these tissue-free solutions were 
shaken for only a few minutes because prolonged shaking caused partial 
loss of the NE (Shore and Olin, 1958) . Standard curves were also pre-
pared by adding known amounts of NE to separate aliquots of tissue homo-
genate and by carrying these aliquots through the extraction procedure. 
The slope of the line was approximately equal to that of the tissue-
free NE samples. 
Six samples of brain or heart tissue homogenate were extracted at 
one time and assayed fluoreometrically along with an internal or external 
(tissue-free) working standard plus the blank. Periodically, tissue 
1. Owens-Illinois Glass Co., To ledo, Ohio . 
2. American Instrument Co., Silver Springs, Maryland. 
homogenates from control animals were extracted and assayed to check 
the procedure. 
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The spectrophotofluorometer was turned on about 15 minutes before 
the time of taking the readings to obtain a stable zero setting. The 
"zero-adjust" and "dark current" were balanced in the photo multiplier 
as described in the manual . A seniitivity setting of 30 was used for 
all assays. Eight cuvettes were calibrated while containing a known 
amount of a NE (1 ug/ml) and were found to give approximately the same 
relative fluorescence readings. These cuvettes were used for all assays. 
The fluorescence readings for the extracted samples were taken from five 
to ten minutes after the addition of the alkaline ascorbate solution. 
Two to three readings were taken of each sample or were continued until 
the solution stabilized as indicated by consecutive readings which were 
constant. After about 30 - 45 minutes the fluorescence began to fade. 
The samples were then allowed to sit for a period of about 24 hours, 
and the fluorescence was read again . This "tissue-blank" reading, which 
was equal to or very close to the "reagent blank" fluorescence, was then 
subtracted from the corresponding reading obtained for that sample the 
day before, and the difference was taken as the actual fluorescence 
contributed by NE. In actual practice, however, it was not necessary 
to take "tissue-blank" readings for each sanple . Tissue-blank readings, 
taken at random daily during the assays, were not substantially different 
from "reagent-blank" readings. Therefore, "reagent-blank" fluorescence 
reading was subtracted from the fluorescence reading of each tissue sam-
ple, and this difference was considered to be the actual fluorescence 
contributed by NE. 
65 
All the conditions established in this assay were repeated pre-
cisely every time the assay was done, since there are many parameters 
which can alter the ultimate fluorescent readings. Duration of shak-
ing, centrifugation, type of test tubes , etc., were kept constant once 
they were established. Exposure of NE to different reagents for dif-
ferent times may cause a variable rate of destruction of the NE. This 
is particularly important when one is dealing with very dilute solu-
tions. It was also considered necessary to run a set of standards with 
each set of unknowns. 
Distribution of NE between the salt saturated aqueous phase and 
n-butanol was such that, with the volumes used in this procedure, only 
about 65% of the amine was extracted. This partition ratio is inde-
pendent of the CA concentration (Shore and Olin , 1958) and is used 
because lesser amounts of interfer i ng substances are extracted. When 
n-heptane is added to the water-saturated n- butanol , water separates 
out from the solvent and increases the volume of the aqueous-acid phase. 
It was for these reasons that standards were prepared by carrying known 
amounts of NE through the entire extraction procedure. 
NE added to the tissue homogenates (heart and brain) was extracted 
to the extent of 97 to 103% compared with aqueous s o lutions not con-
taining tissue homogenates. 
The hydrochloric acid and sodium hydroxide solutions were stand-
ardized according t o the method in United States Pharmacopea XVII. 
2. Estimation of Serum Corticosterone 
The predominant adrenal cort i costeroid present in the rat plasma 
is corticosterone (Bush , 1953 ) . The method described here utilizes 
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0 . 5 ml of rat serum and is a modification of the method described by 
Guillemin et al. (1959a). Corticosterone was extracted with CHC1 3 and 
the fluorescence was developed using 30N H2so4 . 
Solutions and Reagents : 
Absolute ethyl alcohol (reagent grade, U.S. Industrial 
Chemical Co.) 
Chloroform (spectrophotometric grade, Mallinckrodt) 
Cort i costerone (alcohol free, Nutritional Biochem. Corp.) 
Iso-octane (2,2,4-trimethylpentane, practical grade , 
Matheson, Coleman, and Bell) 
Sodium hydroxide (AR grade, Mallinckrodt) 
Sulfuric acid (AR grade , Mallinckrodt) 
Fluorescence reagent : The 30N H2so4 was prepared as described by 
Guillemin et al . (1959) (420 ml concentrated H2so4 up to 500 ml with 
glass-distilled water). 1~e water was added slowly and with constant 
stirring. The bottle containing the H2S04 was kept at o0 in an ice 
bath. It was observed that this fluorescence reagent was stable for at 
least four weeks under refr i geration . 
Stock standard: A solution containing 1 mg/ml of cor t icosterone 
(free alcohol) was prepared in absolute ethanol . This solution was 
stable for at least two months when refrigerated . Another solution 
containing 10 ug/ml of corticosterone was made in ethyl alcohol and was 
used for preparing the worki ng standard. 
Working standard: A working standard containing 0 . 4 ug/ml of 
corticosterone was made by di lut i ng one ml of an ethanolic solution 
containing 10 ug/ml of cort i cos t erone to 25 ml wi th glass-distilled 
water . The working standard was stored i n a refrigerator and was found 
to be stable for at least a month . However, a worki ng standard was 
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prepared fresh daily. 
Method : At the time of assay, the serum samples were removed from 
the freezer and thawed out, One- half ml of each serum sample was placed 
in an 18 ml glass-stoppered Kimax (Cat. #45100) test tubes. Two-tenths 
and 0.4 ml aliquots of the corticosterone working standard were placed 
in similar tubes. The volume in all tubes was adjusted to two ml with 
glass-distilled water . Two ml of glass-di stilled water was used for 
the reagent blank. Two blanks were used in each assay . A standard 
curve was prepared dai ly, prior to the serum assay. Four ml of iso-
octane were added to all the tubes via a 50 ml buret, and the contents 
were mixed for 15 seconds with a Vortex1 mixer. Following centrifugation2 
at 2500 rpm for three minutes, the iso-octane layer was removed by aspi-
ration . This step removed the neutral steroids. Two ml of glass-dis-
tilled water, followed by five ml of chloroform, were added to each 
tube, and the contents were mixed v i gorously for 30 seconds on a Vortex 
mixer and then centrifuged for f i ve mi nu t es at 3000 rpm . In the case 
of standards and "reagent blanks", the aqueous layer was aspirated off 
by a capillary tube (connected t o a water vacuum pump) unt il the water-
chloroform interface was broken . The t i p of the capi llary was then 
moved around inside the tube above the liquid in order to remove all 
the water in contac t with the sides of the tube. In the serum samples, 
water was removed to just withi n the protei n layer, the film was broken, 
and the rest of the water removed along with the protein precipitate. 
One-half ml of O. lN NaOH was added, and the tubes were shaken 
1. Vortex Model K-500 J, Sc i enti f i c Industries Inc., Queens Village, N.Y. 
2. International Model RN , Internat i onal Equ i pment Co . , Needham Hts.,Mass. 
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for 15 seconds and centrifuged for three minutes at 3000 rpm. This step, 
which removed phenolic estrogens, was carried out rapidly, since pro-
longed exposure to alkali destroys corticosteroids. The aqueous layer 
was removed by aspiration. A four ml aliquot of the chloroform extract 
was then transferred to another set of glass-stoppered test tubes con-
taining 1.5 ml of the fluorescence reagent (30N H2so4). The time was 
noted and the contents were mixed on a Vortex mixer for 30 seconds and 
centrifuged for five minutes, at 3000 rpm. The chloroform layer (upper) 
was removed by aspiration, and one ml of the acid extract was transferred 
to a fluorometer quartz cuvette. Fluorescence was determined in about 
35 - 45 minutes after the last mixing step (excitation 470 mu and flu-
orescence 520 mu - uncorrected) . The values for the unknowns were ob-
tained from the standard curve. 
The exact time for reading the fluorescence was determined to be 
that time (about 40 minutes) at which the reading of the standards was 
stable and at amaximum. Figure 7 shows that stability and maximum flu-
orescence were of relatively long duration; therefore, consistent tim-
ing was not absolutely necessary . The intensity of fluorescence was a 
linear function of the concentration of the corticosterone over a range 
of 0.05 mg to 0.40 mg (Figure 8). The recovery of corticosterone added 
to the serum was about 100% over the range of 0 . 1 mg to 0.4 mg. 
Chloroform (spectrophotometric grade) and iso octane (practical 
grade) were found suitable for the assay . Further purification was not 
necessary . Sulfuric acid obtained from Baker and Adamson gave the 
highest "blank fluorescence" values . Mallinckrodt sulfuric acid gave 
the lowest "blank" values. It was not necessary to redistill the ethyl 
alcohol (analytical grade). 
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The sensitivity of any fluorescence assay is usually limited by 
the fluorescence contributed by the reagents used. It is always nee-
essary to determine the fluorescence of each reagent at the wavelength 
used in the particular assay. Table 1 gives the fluorescence (fluor-
eometer readings) values of each reagent used for corticosterone and 
norepinephrine assays . The readings were taken under experimental 
conditions of the respective assay procedures . It can be easily seen 
that analytical grade reagents made by different manufacturers show a 
wide variation in their fluorescence . 
3. Estimation of Adrenal Ascorbic Acid 
The Sullivan and Clark (1955) method for assaying ascorbic acid 
in urine is based on the reduction of ferric to ferrous ion by ascorbic 
acid and the colorimetric measurement of the ferrous ion through forma-
tion of a red-orange-colored complex with alpha - alpha - dipyridyl. 
Other reducing material was inhibited by the addition of orthophosphoric 
acid and by maintaining a low pH (pH 1. . 0) . Maickel (1960), adapted this 
reaction for the determination of ascorbic acid in the adrenal gland . 
The procedure described here is a modification of this method . 
Solutions and Reagents: 
Trichloroacetic acid (reagent grade, Baker and Adamson) 
Metaphosphoric acid (AR grade, Mallinckrodt, HP03 approxi-
mately 35%, the remainder being sodium metaphosphate) 
Orthophosphoric acid (reagent grade, Baker and Adamson) 
Alpha -Alpha-dipyridyl (Calbiochem.) 
Ascorbic acid (reagent grade, Matheson, Coleman and Bell) 
Ferric chloride (AR grade, Mallinckrodt) 
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5% Trichloroacetic acid+ 2% metaphosphoric acid reagent: Fifty 
grams of trichloroacetic acid (TCA) was dissolved in about 500 ml of 
glass-distilled water. Twenty grams of metaphosphoric acid (MPA) dis-
solved in about 200 ml of glass-distilled water was added to the TCA 
solution, and the resulting solution was diluted to one liter. The 
solution was stored in a refrigerator at o0 . A fresh solution was 
prepared each week . 
1% Ferric chloride solution : One gram of ferric chloride was 
dissolved in glass-distilled water; about 0.1 ml of concentrated HCl 
was added, and the solution was diluted to 100 ml . A fresh solution 
was prepared daily . 
0.5% aqueous alpha -alpha- dipyridyl solution : Five grams of 
crystalline material was dissolved in about 500 ml of hot double-dis-
tilled water and diluted to one liter. A fresh solution was made each 
week. 
Ascorbic acid standards : 
Stock standard : One hundred mg of ascorbic acid were dissolved in 
5% TCA + 2% MPA reagent, and this was diluted to 100 ml with 5% TCA + 
2% MPA. A fresh solution was prepared daily . 
Working standard : A working standard containing 100 ug/ml of 
ascorbic acid was made from the stock solution each day, just prior to 
the assay, by diluting 2.5 ml of the stock standard to 25 ml with 
5% TCA + 2% MPA. 
Method: At the time of assay, the adrenals were removed from the 
test tube, weighed and transferred to a 15 ml homogenizer tube contain-
ing five ml of 5% TCA + 2% MPA reagent. The homogenizing tube was 
placed in an ice bath and the tissue was homogenized in less than a 
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minute by a motor-driven Teflon homogenizer . The contribution of the 
. 
adrenal tissue to the total volume of the homogenate was negligible. 
The homogenate was transferred to a twelve ml polypropylene test tube. 1 
The homogenate was centrifuged2 for ten minutes at 2000 rpm and the 
supernatant liquid was used for the assay. One ml of the supernatant 
(containing 10 - 15 mg of ascorbic acid) was then placed in a 1 . 25 cm 
colorimeter test tube (cat . #33-29-27) 3 . 
Two-tenths, 0 . 3, 0 . 4, 0 . 5, and 0 . 6 ml aliquots of the ascorbic 
acid working standard were placed into 1.25 cm colorimeter test tubes 
and the volume was adjusted to one ml with the 5% TCA + 2% MPA reagent. 
One ml of the 5% TCA + 2% MPA was used for the reagent blank . 
Five ml of 0.5% (w/v) alpha -alpha-dipyridyl solution was added 
to each tube, followed by the addition of 0.2 ml of 85% orthophosphoric 
acid and one ml of one percent ferric chloride solution. The contents 
were thoroughly mixed after each addition . Tubes were kept for 25 min-
utes at 37° - 38° and the absorbance of each sample was determined at 
525 mu on a Bausch and Lomb, Spectronic 203 , colorimeter . If the tubes 
were kept at room temperature, readings were taken after 70 minutes. 
The final readings were the same whether the reaction was run at room 
temperature or at 37-38° . The concentration of unknown was obtained 
from a standard curve prepared daily prior to the assay. Absorbance 
readings of standards were reproducible from day to day. The recovery 
of the ascorbic acid added to the homogenate was about 95%. 
1. Ivan Sorvall Inc . , Norwalk , Conn . 
2. International Model HN, International Equip. Co . , Needham Hts. ,Mass. 
3. Bausch and Lomb, Rochester, N. Y. 
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The color developed was stable for some time . The colorimeter was 
allowed to warm up for about 15 minutes and was adjusted to zero with 
the reagent blank. The optical density followed Beer's law over the 
rang~ of 5.0 to 70.0 mg in a 7.2 ml final volume (Figure 10). 
E) STATISTICAL ANALYSIS 
All values reported herein were analyzed statistically; the signi-
ficant difference between means was calculated using the Student's "t" 
test. The level of significance is reported at the 0.05 level. Stand-
ard error (SE) of the mean was calculated according to the following 
formula: 
SE 
Analysis of variance was ·aone according to the Aardvark program 
used by the University. o·f Rhode Island computer laboratory (Hemmer le, 
1967, p. 177). 
All statistical calculations were done by means of an IBM 360 
computer. 
IV. RESULTS 
Tables and figures are contained in this section . 
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TABLE I 
RELATIVE FLUORESCENCE OF THE REAGENTS USED IN FLUORESCENCE ASSAYS 
OF SERUM CORTICOSTERONE AND BRAIN AND HEART NOREPINEPHRINE 
Reagent Relative Fluorescence 
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Norepinephrine Assay Corticosterone Assay 
A=400 F=520 
Sensitivity=30 
Tap water 
Distilled water 
Glass distilled water 
Heptane (not washed) 
Heptane (washed) 
n-Butanol (not washed) 
n-Butanol (washed) 
n-Butanol (spec. grade) 
O.OlN HCl (AR-Baker Adamson) 
lON NaOH (AR-Mallinckrodt) 
Potassium ferricyanide (AR grade) 
Alkaline ascorbic acid solution 
Chloroform (AR grade) 
Chloroform (spec. grade) 
Iso octane (practical) 
Iso octane (spec. grade) 
Ethyl alcohol (AR) 
Fluorescence reagent 
(AR Baker Adamson) 
Fluorescence reagent 
(AR Mallinckrodt) 
A = activation wavelength 
F = fluorescence wavelength 
0.000 
0.000 
0.000 
0.002 
0.002 
0.010 
0.009 
0.002 
0.000 
0.001 
0.000 
0.004 
A=470 F=520 
Sensitivity=30 
0.000 
0.000 
0.000 
0.000 
0.000 
0.001 
0.000 
0.000 
0.015 
0.009 
_ · TABLE II 
THE EFFECT OF RESTRAINT ON MEAN CUMULATIVE DAILY WEIGHT GAINS 
OF MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE. 
Control Animals 11 Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine Vehicle Guanethidine Reserpine 
2 7 + 6a 4 + 4 2 + 2 -2 + 4 5 + 6 4 + 3 
(10) b (10) (10) Ac (10) A (10) B (10) BD 
3 7 + 5 9 + 4 5 + 4 -2 + 5 3 + 9 0.4 + 4 
(10) (10) (10) (10) A (10) (10) AD 
4 11 + 5 9 + 5 7 + 5 -3 + 5 2 + 7 -2 + 5 
(10) (10) (10) (10) A (10) AC (10) AD 
5 18 + 9 14 + 6 10 + 6 -3 + 6 -1 + 10 -3 + 6 
(10) (10) (10) A (10) A (10) AC (10) AD 
6 19 + 7 15 + 7 8 + 7 -8 + 8 1 + 7 -7 + 9 
(10) (10) (10) A (10) A (10) ABC (10) AD 
7 20 + 8 17 + 8 9 + 9 -7 + 7 0.1 + 9 -10 + 8 
(10) (10) (10) A (10) A (10) AC (10) AD 
8 23 + 8 21 + 6 7 + 10 -8 + 8 0.6 + 8 -14 + 9 
(10) (10) (10) A (10) A (10) AC (10) AD 
9 27 + 7 23 + 8 8 + 11 -5 + 8 0.3 + 8 -11 + 12 
(10) (10) (10) A (10) A (10) AC (9) AD 
10 27 + 7 24 + 10 10 + 12 -5 + 8 2 + 9 -14 + 10 
(10) (10) (10) A (10) A (10) AC (9) ABD -....) Vl 
TABLE II - continued 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine Vehicle Guanethidine Reserpine 
11 32 + 9 29 + 8 13 + 14 -4 + 13 3 + 12 -6 + 9 
(10) (10) (10) A (10) A (10) AC (9) AD 
12 33 + 8 29 + 8 7 + 13 -4 + 10 o. 7 + 9 -13 + 9 
(10) (10) (10) A (10) A (10) AC (9) ABD 
13 33 + 8 28 + 9 9 + 12 -5 + 12 0.2 + 10 -16 + 14 
(lo) (lo) (10) A (10) A (10) AC (9) AD 
14 37 + 9 31 + 8 10 + 13 -5 + 12 0 + 13 -14 + 21 
(9) (10) (10) A (10) A (10) AC (9) AD 
15 37 + 9 33 + 9 11 + 12 -6 + 12 -0.8 + 11 -16 + 25 
(9) (10) (10) A (10) A (10) AC (9) AD 
16 41 + 10 33 + 8 12 + 13 -6 + 13 o. 5 + 11 -10 + 21 
(9) (lo) (10) A (10) A (10) AC (8) AD 
17 39 + 9 35 + 10 11 + 12 -7 + 14 -3 + 10 -14 + 26 
(9) (10) (10) A (10) A (10) AC (8) AD 
18 41 + 11 36 + 10 12 + 16 -7 + 14 -0.8 + 11 -14 + 29 
(9) (10) (10) A (10) A (10) AC (8) AD 
19 43 + 10 35 + 10 12 + 20 -7 + 15 -5 + 11 -6 + 21 
(9) (lo) (10) A (10) A (10) AC (7) A 
-....J 
°' 
TABLE II - continued 
Control Animals II 
Days of 
Treatment Vehicle Guanethidine Reserpine Vehicle 
20 43 + 11 36 + 10 12 + 16 -8 + 14 
(9) (10) (10) A (10) A 
21 45 + 13 40 + 9 13 + 15 -7 + 15 
(9) (10) (10) A (10) A 
22 47 + 12 38 + 7 14 + 23 -4 + 15 
(9) (10) (10) A (10) A 
23 46 + 15 41 + 10 15 + 26 -4 + 14 
(9) (10) (10) A (10) A 
24 49 + 13 44 + 9 17 + 21 -5 + 15 
(9) (10) (10) A (10) A 
a: mean+ S.E., cumulative weight gains (grams) from day one. 
b: number of rats. 
c: statistical comparison at probability, P ( O. 05. 
A - significantly different from vehicle- control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Restrained Animals 
Guanethidine 
-7 + 14 
(10) AC 
-4 + 14 
.(1-0) AC 
-2 + 14 
(9) AC 
-8 + 14 
(9) AC 
-4 + 14 
(9) AC 
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
-14 + 21 
(7) AD 
-8 + 20 
(7) A 
-14 + 26 
(7) AD 
-9 + 27 
(7) A 
2 + 15 
(6) A 
-..J 
-..J 
Figure 1 
THE EFFECT OF RESTRAINT ON MEAN CUMULATIVE DAILY WEIGHT GAINS 
ON MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
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Solid symbols designate significant difference (P< 0. 05) from vehicle-
treated group. Drug doses, (i.p.) daily for 24 days. Guanethidine, 
1.20 mg/kg. Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water, 
1 ml/kg. 
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TABLE III 
THE EFFECT OF RESTRAINT ON MEAN DAILY WATER CONSUMPTION 
OF MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine Vehicle Guanethidine Reserpine 
1 32 + 1. 71 a 34 + 1. 23 36 + 1. 93 31 + 0.95 30 + 3. 01 37 + 1. 52 
c1o)b (10) (lo) (10) (10) (10) 
2 36 + 1. 65 32 + 1. 33 36 + 0.66 35 + 1.42 41 + 5.35 42 + 1.23 
(10) (10) (lo) (10) (10) (10) cc 
3 33 + 1.27 32 + 1.17 32 + o. 73 36 + 1. 84 38 + 1. 08 44 + o. 79 
(10) (10) (10) (10) (10) B (10) c 
4 34 + 1.17 31 + 1. 96 32 + 1. 84 37 + 1.61 36 + o. 95 40 + o. 92 
(10) (10) (10) (10) (10) B (10) c 
5 33 + 0.76 31 + 0.85 32 + 0.98 36 + 1. 39 42 + 3. 73 41 + 1. 99 
(10) (10) (10) (10) A (lo) B (10) c 
6 35 + 1.17 33 + 1.49 34 + 1. 36 39 + 1.68 43 + 1. 99 46 + 2.41 
(10) (10) (10) (10) A (10) B (10) c 
7 35 + 0.85 35 + 1. 74 33 + 1. 17 36 + 1. 93 39 + 1.61 43 + 1.11 
(10) (10) (10) (10) (10) (10) c 
8 31 + 2.15 36 + 2.25 32+1.27 37 + 1.42 40 + o. 76 42 + 1.17 
(10) (10) (10) (10) A (10) (9) c 
9 37 + 1. 39 35 + 1. 80 31 + 1.61 39 + 1. 84 38 + 1. 01 41 + 1.00 
(10) (10) (10) (10) (10) (9) c -...J 
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TABLE III - continued 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine II Vehicle Guanethidine Reserpine 
10 31 + 1. 20 30 + 1.63 31 + 1. 04 35+1.61 38 + o. 54 40 + 0.70 
(10) (10) (10) (10) (10) B (9) c 
11 36 + 1.52 36 + 2.22 32 + 1. 93 38 + 1. 36 37+1.14 39+0.83 
(10) (10) (10) (10) (10) (9) c 
12 34 + o. 66 33 + 1. 90 25 + 1. 52 38 + 2.18 36 + 1.23 36 + 1. 53 
(10) (10) (10) (10) (10) (9) c 
13 36 + 1. 93 34 + 2.47 28 + 1.14 33 + 1. 30 34 + 1.42 31 + 0.90 
(10) (10) (10) (10) (10) (9) c 
14 36 + 1. 80 33+2.97 26 + 1. 65 35 + 1. 39 35 + 1.49 29 + 1.47 
(10) (10) (lo) (10) (10) (9) 
15 35+0.60 32 + 1. 33 21 + 1.49 34 + 1. 61 36 + 1.08 37 + 3.70 
(9) (10) (10) (10) (10) B (9) c 
16 32 + 1. 00 31 + 1. 65 26 + 2.12 33 + 1. 58 35 + 1.42 32 + 2. 08 
(9) (10) (10) (10) (10) B (8) 
17 46 + 1. 87 35 + 2. 06 24 + 1. 90 37 + 2.22 39 + 1. 80 30 + 4. 95 
(9) (10) (10) (10) A (10) (8) 
18 43+ 1.87 34 + 1. 96 33 + 2.97 37 + 1. 80 40 + o. 89 33 + 4.42 
(9) (10) (10) (10) A (10) B (8) 
19 38 + 0.97 32 + 1. 42 28 + 1. 23 38 + 2.69 36 + 1. 39 33 + 2.98 
(9) ( 10) (10) (10) (10) (7) 00 0 
TABLE III - continued 
Control Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine 
20 37 + 0.47 31 + 1.23 27+1.14 
(9) (10) (lo) 
21 37 + 0.80 34 + 1. 01 29 + 1.49 
(9) (10) (10) 
22 40 + 1. 47 33 + 2. 34 27+1.87 
(9) (10) (10) 
23 38+1.57 34 + 1. 87 25 + 2 .12 
(9) (10) (10) 
24 37 + 1. 70 34 + 1. 71 28 + o. 79 
(9) (10) (10) 
a: mean+ S.E., ml of water consumed/rat/day. 
b: number of rats. 
c: statistical comparison at probability, P( 0.05. 
u 
A - significantly different from vehicle-control group. 
B - significantly different from guanethidine-control group. 
C - significantly different from reserpine-control group. 
Vehicle 
33 + 1. 68 
(10) 
39 + 1. 55 
(10) 
36 + 2.18 
(10) 
38 + 1. 84 
(10) 
32 + 1. 55 
(10) 
Restrained Animals 
Guanethidine 
37+1.17 
(10) B 
38 + o. 60 
(10) 
38 + 1.47 
(9) 
41 + 1. 37 
(9) B 
39 + 1.37 
(9) B 
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
37 + 7.77 
(7) 
35 + 2.83 
(7) 
32 + 1.51 
(7) 
29 + 1. 96 
(7) 
25 + 0.87 
(7) c 
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1.20 mg/kg. Reserpine, 0.2 mg/kg. 
l ml/kg. 
difference (P( 0.05) from vehicle-
daily for 24 days: Guanethidine, 
Vehicle, glass-distilled water, 
24 
TABLE IV 
THE EFFECT OF CHRONIC GUANETHIDINE OR RESERPINE TREATMENT 
ON THE MEAN SYSTOLIC BLOOD PRESSURE OF MALE ALBINO RATS 
Days of Control Animals 
Treatment Vehicle Guanethidine 
1 114±3.1~ 115 + 2. 2 
2 117+1.7 118+0.8 
3 119 + o. 8 115 + 1. 7 
4 117 + 3.5 119 + 4.4 
5 114 + 3.1 113 + 1. 7 
6 118 + 1. 7 120 + 2.6 
7 114 + 4.0 116 + 2. 6 
8 117 + 3.1 121 + 0.8 
9 115 + 1. 3 112 + 1. 7 
10 119 + 2.6 122 + 2.6 
11 118 + 3.1 117 + 2.2 
12 116 + 2.6 114 + 2. 2 
14 113 + 2.2 123 + 2. 6 Ac 
16 112+3.5 119 + 3.1 
18 114 + 2. 2 116 + 2.6 
20 111 + 4.4 112 + 4. 9 
22 126 + 3.1 124 + 4.0 
24 124 + 3.5 125 + 2. 6 
a: mean systolic blood pressure (mm Hg) ± S.E. 
b: N = 5 animals/group 
c: statistical comparison at probability; P ( 0.05. 
A - significantly different from vehicle-control group 
Reserpine 
100 + 1. 7 ABC 
91 + 3.5 AB 
95 + 3.1 AB 
108 + 1. 3 AB 
98 + 4.4 AB 
97 + 2. 6 AB 
100 + 2.6 AB 
104 + 4. 9 AB 
96+2.2 AB 
96 + 2.2 AB 
100 + 4.9 AB 
99 + 4.0 AB 
97 + 4.4 AB 
101 + 3.5 B 
96 + 4.9 AB 
94 + 3.5 AB 
93 + 5.3 AB 
88 + 4. 0 AB 
B - significantly different from guanethidine-control group 
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg. 
Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water, 1 ml/kg. 
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Figure 3 
THE EFFECT OF CHRONIC GUANETHIDINE OR RESERPINE TREATMENT 
ON THE MEAN SYSTOLIC BLOOD PRESSURE IN MALE ALBINO RATS 
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Solid symbols designate significant difference (P < O. 05) from vehicle-
treated group. Drug doses, (i.p.) daily for 24 days: Guanethidine, 
1.20 mg/kg. Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water, 
1 ml/kg. 
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TABLE V 
THE EFFECT OF RESTRAINT ON ABSOLUTE ADRENAL WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Days of 
Treatment Vehicle 
1 0.022 + .002 
(lO)b -
3 0.023 + .002 
(10) 
6 0.017 + . 001 
(10) 
12 0.025 + ,001 
(10) 
24 0.028 + .002 
(10) 
a: mean± S.E. (mg). 
b: number of rats 
a 
Control Animals 
Guanethidine Reserpine 
0.020 + .001 0.022 + .001 
(10) (10) 
0.024 + .001 0.025 + .002 
(10) (10) 
0.015 + .002 0.016 + .002 
(10) (10) 
0.025 + .001 0.026 + .002 
(10) (10) 
0.024 + . 002 0.024 + .002 
(10) (10) 
c: statistical comparison at probability, P<0.05. 
A - significantly different from vehicle-control group. 
I 
B - significantly different from vehicle-restrained group. 
Vehicle 
0.021 + .002 
(9) 
0.025 + .002 
(10) 
0.020 + .002 
(10) 
0.030 + .002 
(10) 
0.031 + .002 
(10) 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Restrained Animals 
Guanethidine 
0.022 + .002 
(10) 
0.024 + .002 
(10) 
0.024 + .001 
(10) 
o. 033 + . 003 
(9) AC 
0.031 + .003 
(9) 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
0.021 + .001 
(10) 
0.030 + .002 
(9) ABDC 
0.022 + .001 
(10) AD 
0.027 + .002 
(9) 
0.035 + .004 
(6) D 
Note: Twenty animals selected at random, no treatment, had adrenal weights of 0.029 + 0.002 mg. 
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Figure 4 
THE EFFECT OF RESTRAINT ON ABSOLUTE ADRENAL WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
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Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg . Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Solid symbols designate a significant difference (P(0.05). 
See Table V for statistical comparison. 
TABLE VI 
THE EFFECT OF RESTRAINT ON ABSOLUTE HEART WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
imals II Restrained Animals 
Days of 
Treatment Vehicle 
1 0.62 + .02a 
c1o)b-
3 0.68 + .02 
(10) 
6 0.69 + .02 
(10) 
12 o. 78 + . 03 
(10) 
24 0 . 80 + .03 
(10) 
a: mean + S. E. (grams). 
b: number of rats. 
Guanethidine Reserpine 
0.65 + .01 0.62 + .02 
(10) (10) 
0.66 + .02 0.64 + . 02 
(10) (10) 
o. 71 + .02 0.71 + .01 
(10) (10) 
o. 72 + .02 0.76+ .02 
(10) (10) 
o. 72 + .02 0.76 + . 03 
(10) A (10) 
c: statistical comparison at probability, P ( 0. 05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
Vehicle 
0.63+ .01 
-(9) 
o. 75 + .02 
(10) A 
0.68 + .02 
(10) 
0.69 + .02 
(10) A 
0.66 + .02 
(10) A 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Guanethidine 
0.59 + .02 
(10) -Bee 
0.70 + .02 
(lo) 
0.68 + .03 
(10) 
0.71 + .02 
(9) 
0.67 + .02 
(9) A 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
0.61 + .02 
(10) 
0.69 + .02 
(9) B 
0.67 + .01 
(10) 
0.61 + .02 
(9) ABD 
0.69 + .03 
(6) A 
Note: Ten animals selected at random, no treatment, had heart weight of D.84 + -0.03 grams. 
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Figure 5 
THE EFFECT OF RESTRAINT ON ABSOLUTE HEART WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
3 
o vehicle 
O guanethidine 
A reserpine 
3 6 
6 
CONTROL ANIMALS 
12 
RESTRAINED ANIMALS 
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88 
24 
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Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Solid symbols designate a significant difference (P( 0.05). 
See Table VI for statistical comparison. 
TABLE VII 
THE EFFECT OF RESTRAINT ON ABSOLUTE BRAIN WEIGHT· OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Days of 
Treatment Vehicle 
1 1. 62 + . 02a 
(lO)b-
3 1. 70 + . 04 
(10) 
6 1. 59 + . 03 
(10) 
12 1. 58 + .05 
-(10) 
24 1. 68 + .04 
(10) 
a: mean + S. E. (grams). 
b: number of rats 
Control Animals 
Guanethidine Reserpine 
1. 69 + . 02 1.67 + .02 
- -(10) (10) 
1. 66 + . 02 1.65 + .03 
(10) (10) 
1.63 + .03 1. 64 + . 02 
(10) (10) 
1. 66 + . 03 1. 70 + . 02 
(10) - (10) -Ac 
1.66 + .03 1. 62 + . 04 
(10) (10) 
c: statistical comparison at probability, P(0.05. 
A - significantly different from vehicle-control group. 
II 
B - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Restrained Animals 
Vehicle Guanethidine 
1. 60 + . 02 1.61 + .02 
(9) - (10) -
1. 64 + . 03 1. 64 + . 04 
(10) (10) 
1. 56 + . 03 1.55 + .02 
(10) (10) c 
1. 57 + . 04 1. 52 + . 02 
-(10) (9) c 
1.59 + .03 1. 65 + . 04 
(10) (9) 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-dis~illed water, 1 ml/kg. · 
Reserpine 
1. 66 + . 02 (10) -
1.62 + .03 
(~) 
1. 59 + .03 
(10) 
1.53 + .02 
(9) D 
r. 58 + . 06 
(6) 
Note: Ten animals selected at random, no treatment, had brain weights of 1.64 ± 0.03 grams. 
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Figure 6 
THE EFFECT OF RESTRAINT ON ABSOLUTE BRAIN WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
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Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Solid symbols designate a significant difference (P( 0.05). 
See Table VII for statistical comparison. 
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Figure 8 
TYPICAL STANDARD CURVE FOR CORTICOSTERONE 
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Fluorescence intensity at varying concentrations of corticosterone. 
Fluorescence is given in arbitary units, 
(meter multiplier x % transmission x 100) 
Activating wave length, 470 mu. 
Fluorescence wave length, 510 mu. 
TABLE VIII 
THE EFFECT OF RESTRAINT ON SERUM CORTICOSTERONE OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals Restrained Animals 
Days of 
Treatment Vehicle Guanethidine 
1 22+3.2a 
c1o)b 
3 19 + 2.2 
(10) 
6 19 + 3. 5 
(10) 
12 21 + 2.2 
(10) 
24 23 + 2. 2 
(10) 
a: mean+ S.E. (mg/100 ml) 
b: number of rats 
23 + 2. 5 
(10) 
19 + 2.2 
(lo) 
25 + 1. 6 
(10) 
20 + 2. 8 
(10) 
25 + 2.8 
(10) 
Reserpine 
19 + 2.8 
(10) 
16 + 1. 3 
(10) 
29 + 3.2 
(10) A 
15 + 1. 6 
(10) A 
25 + 2.2 
(lo) 
c: statistical comparison at probability, P< 0. 05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Vehicle 
30 + 1. 7 
(9) Ac 
24 + 2. 2 
(10) 
24 + 2.2 
(lo) 
20 + o. 9 
(10) 
21 + 3. 2 
(10) 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Guanethidine 
33 + 1. 9 
(10) AC 
25 + 1. 9 
(10) 
26 + 2.2 
(10) 
23 + 1. 7 
(9) 
27 + 2.3 
(9) 
Note: Ten animals selected at random, no treatment, had serum corticosterone levels 
of 16 ± 3.0 mg/100 ml. 
Reserpine 
31 + 1. 3 
(10) AD 
25 + 2.0 
(9) D 
25 + 1. 6 
(10) 
28 + 2.5 
(9) ABD 
33 + 3. 7 
(6) B 
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Figure 9 
THE EFFECT OF RESTRAINT ON SERUM CORTICOSTERONE OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
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DAYS OF TREATMENT 
24 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, l ml/kg. 
Solid symbols designate a significant difference (P ( O. 05). 
See Table VIII for statistical comparison, 
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TYPICAL STANDARD CURVE FOR ASCORBIC ACID 
0 
20 30 40 
ug/ml 
50 60 70 
95 
TABLE IX 
THE EFFECT OF RESTRAINT ON ADRENAL ASCORBIC ACID OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals 
Days of 
Treatment Vehicle Guanethidine 
1 570 + 3oa 492 + 23 
(lO)D (10) 
3 551 + 32 462 + 47 
(10) (10) 
6 750 + 59 743 + 77 
(10) (10) 
12 585 + 39 518 + 27 
(10) (10) 
24 560 + 28 572 + 40 
(10) (10) 
a: mean + S.E. (mg{lOOg) 
b: number of rats 
Reserpine 
503 + 29 
(10) 
468 + 42 
(10) 
651 + 50 
(10) 
593 + 44 
(10) 
623 + 50 
(10) 
c: statistical comparison at probability, P<0.05. 
II 
A - significantly different from vehicle-control group. 
Vehicle 
371 + 41 
(9) -Ac 
519 + 31 
(10) 
646 + 48 
(10) 
521 + 39 
(10) 
581 + 53 
(10) 
B - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Restrained Animals 
Guanethidine 
359 + 23 
(10) AC 
490 + 27 
(10) 
555 + 57 
(10) A 
580 + 39 
(9) 
596 + 34 
(9) 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
367 + 29 
-(10) AD 
464 + 35 
(9) 
690 + 47 
(10) 
551 + 27 
(9) 
595 + 58 
(6) 
Note: Twenty animals selected at random, no treatment, had adrenal ascorbic acid levels of 
579 + 35 ug/lOOg. \0 
°' 
Figure 11 
THE EFFECT OF RESTRAINT ON ADRENAL ASCORBIC ACID OF 
MALE ALBINO RATS TREATED 'WITH GUANETHIDINE OR RESERPINE 
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Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Solid symbols designate a significant difference (P < 0. 05). 
See Table IX for statistical comparison 
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Figure 12 
A TYPICAL GRAPH OF THE EFFECTS OF 10 N NaOH AND 5 N NaOH 
ON THE RELATIVE FLUORESCENCE OF NOREPINEPHRINE 
10 N NaOH 
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ML OF NE STANDARD CONTAINING 0.167 ug/ml 
1. After Anton, A.H. and Sayre, D.F.: J. Pharmac. exp. Ther. 
138: 360, 1962. 
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A TYPICAL GRAPH OF THE EFFECT OF ETHYLENEDIAMINE (EDA) 
ON THE RELATIVE FLUORESCENCE OF NOREPINEPHRINE 
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Figure 14 
TYPICAL STANDARD CURVES OF NOREPINEPHRINE (NE) AND EPINEPHRINE (E) 
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Figure 15 
TYPICAL STANDARD CURVE FOR NOREPINEPHRINE 
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Fluorescence intensity at varying concentrations of norepinephrine. 
Fluorescence is given in arbitrary units, 
(meter multiplier x % transmission x 100) 
Activating wavelength, 400 mu. 
Fluorescence wavelength, 520 mu. 
TABLE X 
COMPARISON OF THE CONTROL TISSUE NOREPINEPHRINE (~) ASSAY WITH 
PREVIOUSLY REPORTED VALUES USING THE SHORE AND .OLIN (1958) METHOD 
Tissue NE Cone. (ug/g) Source of Data 
a 
Rat brain 0.237 + 0.008 This report 
b 
0.236 + 0.010 This report 
0.238 + 0.023 (SD) Porter et al. (1961) 
0.243 + 0.011 Green et al. (1962) 
0.255 + 0.026 (SD) Green and Sawyer (1960) 
a 
Rat heart 1.032 + 0.049 This report 
b 
1. 022 + o. 041 This report 
1. 060 + o. 030 Bhagat (196 7) 
1. 020 + o. 040 Bhagat and Gillman (1960) 
102 
0.990 + 0.060 Kuntzman and Jacobson (1964) 
a: 10 rats selected at random, no treatment 
b: 70 rats, vehicle-control, glass-distilled water, 1 ml/kg, i.p. 
All values are expressed as the mean± S.E., except where indicated. 
.... 
103 
TABLE XI 
DOSE-RESPONSE EFFECT OF RESERPINE OR GUANETHIDINE ON BRAIN AND HEART 
NOREPINEPHRINE (NE) OF MALE ALBINO RATS INJECTED (IP) DAILY FOR SIX DAYS 
Treatment Dose BRAIN NEa HEART NEa 
percent percent 
ug/gm deeletion ug/gm depletion 
ml/kg 
Vehicle 1.00 0.224 + 0.005 00.0 1. 017 + 0. 044 00.0 
mg/kg 
23.7b 96.Sb Reserpine 0.05 0. 171 + 0. 008 0.036 + 0.005 
0.10 0.140 + 0.008 37. Sb 0.018 + 0.004 98.2b 
0.25 0.092 + 0.003 58.9b 0. 009 + o. 003 99.lb 
1. 00 0.013 + 0.003 94.2b 0.005 + 0.003 99.sb 
2.50 0.004 + 0.001 98.2b 0.002 + 0.002 99.8b 
ml/kg 
Vehicle 1. 0 0.236 + 0.014 00.0 1. 016 + o. 028 00.0 
mg/kg 
29.7b Guanethidine 0.5 0.274 + 0.007 00.0 0.714 + 0.046 
1. 0 0.238 + 0.016 oo.o 0.358 + 0.037 64.8b 
2.5 0.242 + 0.014 00.0 0.198 + 0.016 80.Sb 
5.0 0.247 + 0.016 00.0 0.096 + 0.008 90.6b 
10.0 0.226 + 0.016 00.0 0.063 + 0.006 93.8b 
a: Concentration of NE expressed as mean± S.E. for 10 animals in 
each group. 
b: significant difference from controls (P<0.01) . 
Figure 16 
CALCULATION OF THE DD1 50 FOR CENTRAL NOREPINEPHRINE 
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A plot of the six day dose-response curve for norepinephrine 
depleting effect of reserpine in the brain tissues of male albino 
rats. (o) are the original points. Line was fitted by the method 
of least squares (Snedecor, 1956). 
1. DD - depleting dose. 
Figure 17 
CALCULATION OF THE DD1 50 FOR PERIPHERAL NOREPINEPHRINE 
DEPLETING ACTION OF GUANETHIDINE 
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A plot of the six day dose-response curve for epinephrine 
depleting effect of guanethidine in the heart tissues of 
male albino rats. (o) are the original points. Line was 
fitted by the method of least squares (Snedecor, 1956). 
1. DD - depleting dose, 
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TABLE XII 
THE EFFECT OF RESTRAINT ON BRAIN NOREPINEPHRINE OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle 
1 0.257+ .007a 
(lO)b -
3 0.227 + .014 
(10) 
6 o. 220 + . 009 
(10) 
12 0.226 + .008 
(10) 
24 0.259 + .014 
(10) 
a: mean+ S.E. (ug/g) 
b: number of rats 
Guanethidine Reserpine 
0.228 + .009 0.252 + .022 
(10) Ac (10) -
0.221 + .007 0.169+ .017 
(10) (10) A 
o. 214 + . 006 0.110+ .012 
(10) (10) A 
0.221 + .015 0.060+ .007 
(10) (10) A 
0.238 + .019 0.025 + .006 
(10) (10) A 
c: statistical comparison at probability, P <.0.05. 
II 
A - significantly different from vehicle-control group. 
Vehicle 
0.229 + .010 
(9) A 
0.209 + .007 
(10) 
0.220 + .009 
(10) 
o. 246 + .014 
(10) 
0.275 + .010 
(10) 
B - significantly different from vehicle-restrained group. 
C - sign~ficantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Guanethidine 
0. 243 + .009 
-(10) 
0.231 + .004 
(10) B 
0.249 + .013 
(10) c 
o. 300 + .013 
(9) ABC 
0.254 + .015 
(9) c 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
0.188 + .008 
(10) ABD 
0.150 + .017 
(9) AB 
0.064 + .008 
(10) ABD 
0.061 + .006 
(9) AB 
0.028 + . 005 
(6) AB 
Note: Ten animals selected at random, no treatment, had brain norepinephrine levels of 
0.237 ±. .008 ug/g, 
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Figure 18 
THE EFFECT OF RESTRAINT ON BRAIN NOREPINEPHRINE OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
o vehicle 
D guanethidine 
6. reserpine 
CONTROL ANIMA;LS 
'·· 
107 
~.15 
:J 
00 
-00 
.10 
.05 
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:J .15 
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.05 
1 3 6 12 24 
DAYS OF TREATMENT 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Solid symbols designate a significant difference (P(0.05). 
See Table XII for statistical comparison. 
TABLE XIII 
THE EFFECT OF RESTRAINT ON HEART NOREPINEPHRINE OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle 
1 1.003 + .033 a 
c1o)b -
3 1.035 + .051 
(10) 
6 0.967 + .032 
(10) 
12 1.091 + .037 
(10) 
24 1. 023 + . 055 
(10) 
a: mean± S.E. (ug/g) 
b: number of rats 
Guanethidine Reserpine 
o. 759 + .040 0.071+ .013 
(10) -Ac (10) A 
0.756 + .089 0.011+ .005 
(10) A (10) A 
0.528 + .025 0.014 + .004 
(10) A (10) A 
0.638 + .041 0.020 + .005 
(10) A (10) A 
0.453 + .042 0.022 + .009 
(10) A (10) A 
c: statistical comparison at probability, P < 0. 05. 
A - significantly different from vehicle-control group. 
Vehicle 
0.942 + .034 
(9) 
o. 702 + .034 
(10) A 
0.635+ .022 
(10) A 
1. 034 + . 046 
(10) 
1.128 + . 046 
(10) 
B - significantly different from guanethidine-control group. 
C - significantly different from reserpine-control group. 
Guanethidine 
0.844 + .038 
(10) A 
0.545 + .047 
(10) AB 
0.698+ .045 
(10) AC 
0.864 + .029 
(9) ABC 
0.845 + .055 
(9) ABC 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reserpine 
0.075 + .018 
-(10) AB 
0.007 + .004 
(9) AB 
0.012 + .004 
(10) AB 
0.018 + .009 
(9) AB 
0.047 + .017 
(6) AB 
Note: Ten animals selected at random, no treatment, had heart norepinephrine levels of 
1.032 + .049 ug/g. '"""' 0 00 
1.0 
0.8 
Figure 19 
THE EFFECT OF RESTRAINT ON HEART NOREPINEPHRINE OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
O vehicle 
D guanethidine 
A reserpine 
CONTROL ANIMALS 
109 
~0.6 
bl) 
;:l 
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0.2 
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DAYS OF TREATMENT 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Solid symbols designate a significant difference (P ( O. 05). 
See Table XIII for statistical comparison. 
TABLE XIV 
THE EFFECTS OF RESTRAINT ON THE FOOD INTAKEa, WATER INTAKE, MEAN WEIGHT 
GAIN AND MORTALITY RATE OF RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Groups 
Vehicle Control 
Guanethidine Control 
Reserpine Control 
Vehicle Restraint 
Guanethidine Restraint 
Reserpine Restraint 
Mean Water Intake 
(ml/rat/day) 
36 + o. 71 
33 + 0.35 
30 + 0.76 
36 + 0.49 
38 + 0.57 
37 + 1. 06 
Mean Weight 
Gain/Day (g) 
2.0 + 0.2 
1.8 + 0.1 
0.7+0.3 
0.2 + 0.2 
0.0+0.2 
0. 1 + o. 3 
All values are expressed as the mean + S.E. for the 24 day study. 
a: food intake; 20 g/day. 
b: accidental death. 
N = 10 animals/group. 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Mortality 
(percent) 
lOb 
0 
0 
0 
10 
40 
,..... 
,..... 
0 
TABLE XV 
THE EFFECT OF RESTRAINT ON ADRENAL WEIGHT OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals I Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine Vehicle Guanethidine 
1 100 + 9a 100 + 5 100 + 5 95 + 10 100 + 9 
(10)0 (10) - (10) (9) - (10) 
3 100 + 9 104 + 4 109 + 8 109 + 8 104 + 8 
(10) - (10) - (10) - (10) (10) -
6 100 + 6 88 + 13 94 + 13 118 + 10 141 + 4 
(10) (10) (10) (10) (10)-AC 
12 100 + 4 100 + 4 104 + 8 120 + 7 132 + 9 
(10) (10) (10) (10) (9) AC 
24 100 + 7 86 + 8 86 + 8 111 + 6 111 + 10 
(10) (10) (10) (10) (9) 
a: values are expressed as the percent of vehicle-control group. (mean+ S.E.) 
b: number of rats -
c: statistical comparison at probability, P<0.05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser ine 
95 + 5 
(10) 
130 + 7 
(9 )-ABDc 
129 + 5 
(10) AD 
108 + 7 
(9) 
125 + 11 
(6)-D 
,,_. 
,,_. 
,,_. 
TABLE XVI 
THE EFFECT OF RESTRAINT ON HEART WEIGHT OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle Guanethidine 
1 100 + 3a 105 + 2 100 + 3 102 + 2 95 + 3 
(lO)o (10)- (10)- (9) - (10)-BC 
3 100 + 3 97 + 3 94 + 3 110 + 3 103 + 3 
(10) (10) (10) (10)-A (10) 
6 100 + 3 103 + 3 103 + 1 99 + 3 99 + 4 
(10) (10) (10) (10) (10) 
12 100 + 4 92 + 3 97 + 3 88 + 3 91 + 3 
(10) - (10) (10) (10)-A (9) 
24 100 + 4 90 + 3 95 + 4 83 + 3 84 + 3 
(10) (10)-AC (10) (10)-A (9) A 
a: values are expressed 
b: number of rats 
as the percent of vehicle-control group (mean± S.E.). 
c: statistical comparison at probability, P<:0.05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Drug doses (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser ine 
98 + 3 
(10) 
101 + 3 
(9) B 
97 + 1 
(lo) 
78 + 3 
-(9) ABD 
86 + 4 
(6) A 
I-' 
I-' 
N 
TABLE XVII 
THE EFFECT OF RESTRAINT ON BRAIN WEIGHT OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle 
1 100 + 1 a 104 + 1 103 + 1 99 + 1 
(10)0 (10) - (10) - (9) -
3 100 + 2 98 + 1 97 + 2 96 + 2 
(10) (10) (10) (10) 
6 100 + 2 103 + 2 103 + 1 98 + 2 
(10) (10) (10) (10) 
12 100 + 3 105 + 2 108 + 1 99 + 3 
(10) (10) (10)-AC (10) 
24 100 + 2 99 + 2 96 + 2 95 + 2 
(10) (10) (10) (10) 
a: values are expressed as percent of vehicle-control group (mean+ S.E.) 
b: number of rats 
c: statistical comparison at probability, P< 0. OS. 
A - significantly different from vehicle-control group. 
B - significantly different from guanethidine-control group. 
C - significantly different from reserpine-control group. 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Guanethidine 
99 + 1 
(lo) 
96 + 2 
(10) 
97 + 1 
(10) c 
96 + 1 
-(9) c 
98 + 2 
(9) 
Reser ine 
102 + 1 
(10) 
95 + 2 
(9) 
100 + 2 
(10) 
97 + 1 
(9) D 
94 + 4 
(6) 
I-' 
I-' 
w 
Figure 20 
A COMPARISON OF THE EFFECTS OF RESTRAINT ON VARIOUS ORGAN WEIGHTS OF NORMAL AND GUANETHIDINIZED 
MALE ALBINO RATS 
RESTRAINT GUANETHIDINE CONTROL GUANETHIDINE RESTRAINED 
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Solid symbols designate significant difference (P<0.05) from vehicle-treated group. 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Vehicle, glass-distilled water, 1 ml/kg. 
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Figure 21 
A COMPARISON OF THE EFFECTS OF RESTRAINT. ON VARIOUS ORGAN WEIGHTS OF NORMAL AND RESERPINIZED 
MALE ALBINO RATS 
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Solid symbols designate significant difference (P(0.05) from vehicle-treated group. 
Drug doses, (i.p.) daily: Reserpine, 0.2 mg/kg. Vehicle, glass-distilled water, 1 ml/kg. 
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TABLE XVIII 
THE EFFECT OF RESTRAINT ON ADRENAL ASCORBIC ACID OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle Guanethidine 
1 100 + 5a 86 + 5 88 + 6 65 + 11 63 + 6 
(lO)b (10) (lo) (9) Ac (10) AC 
3 100 + 6 84 + 10 85 + 9 94 + 6 89 + 6 
(10) (10) (10) (10) (10) 
6 100 + 8 99 + 10 87 + 8 86 + 7 74 + 10 
(10) (10) (10) (10) (lo) A 
12 100 + 7 89 + 5 101 + 7 89 + 7 99 + 7 
(10) (10) (10) (10) (9) 
24 100 + 5 102 + 7 111 + 8 104 + 9 106 + 6 
a: values are expressed as the percent of vehicle-control group. (Mean + S. E.) 
b: number of rats 
c: statistical comparison at probability, P< O. 05. 
A - significantly different from vehicle-control group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser ine 
64 + 8 
(10) AD 
84 + 8 
(9) 
92 + 7 
(lo) 
94 + 5 
(9) 
106 + 10 
...... 
...... 
°' 
TABLE XIX 
THE EFFECT OF RESTRAINT ON SERUM CORTICOSTERONE OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reserpine Vehicle Guanethidine 
1 100 + 14a 105 + 11 86 + 15 136 + 6 150 + 6 
(lo)'D (10) (lo) (9) -AC (10) - AC 
3 100 + 12 100 + 12 84 + 8 126 + 9 132 + 8 
(10) (10) (10) (10) (10) 
6 100 + 18 132 + 6 153 + 11 129 + 9 137 + 8 
(10) (10) (10) A (10) (10) 
12 100 + 10 95 + 14 71 + 10 95 + 5 110 + 7 
(10) (10) (10) A (10) (9) 
24 100 + 10 109 + 11 109 + 9 91 + 15 117 + 9 
(10) (10) (10) (10) (9) 
a: values are expressed as the percent of vehicle-control group (mean+ S.E.). 
b: number of rats. 
c: statistical comparison at probability, P< O. 05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different ~ro~ reserpine-control group. 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser ine 
141 + 4 
(10)-AD 
132 + 8 
(9) D 
132 + 6 
(10) 
133 + 9 
(9) ABD 
144 + 11 
(6) B 
,.... 
,.... 
-..J 
TABLE XX 
THE EFFECT OF RESTRAINT ON HEART NOREPINEPHRINE OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals ii Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle Guanethidine 
1 100 + 3a 76 + 5 7 + 18 94 + 4 
(10)0 (10) AC (10) A (9) -
3 100 + 5 73 + 12 1 + 45 68 + 5 
(10) (10) A (10) A (10) A 
6 100 + 3 55 + 5 1 + 29 66 + 3 
(10) (10) A (10) A (10) A 
12 100 + 3 6 + 6 2 + 25 95 + 4 
(10) (10) A (10) A (10) 
26 100 + 5 44 + 9 2 + 41 110 + 6 
(10) (10) A (10) A (lo) 
a: values are expressed as the percent of vehicle-control group. (mean± S.E.) 
b: number of rats. 
c: statistical comparison at probability, P<0.05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
84 + 5 
(10) A 
53 + 9 
(10) AB 
72 + 6 
(10) AC 
79 + 3 
(9) ABC 
83 + 7 
(9) ABC 
Reser ine 
7 + 28 
(10) AB 
o. 5 + 57 
(9) AB 
1 + 33 
(10) AB 
2 + 50 
(9) AB 
5 + 36 
(6) AB 
I-' 
I-' 
00 
TABLE XX! 
THE EFFECT OF RESTRAINT ON BRAIN NOREPINEPHRINE OF MALE 
ALBINO RATS TREATED WITH GUANE'IHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle Guanethidine 
1 100 + 3a 89 + 4 98 + 9 89 + 4 95 + 4 
(10)0 (10) Ac (10) (9) A (10) 
3 100 + 6 97 + 3 74 + 10 92 + 3 102 + 2 
(10) (10) (10) A (10) (10) B 
6 100 + 4 97 + 3 50 + 11 100 + 4 113 + 5 
(10) (10) (10) A (10) (10) c 
12 100 + 4 98 + 7 27 + 12 109 + 6 133 + 4 
(10) (10) (10) A (10) (9) ABC 
24 100 + 5 92 + 8 10 + 24 106 + 4 98 + 6 
(10) (10) (10) A (10) (9) c 
a: values are expressed as the percent of vehicle-control group (mean± S.E.) 
b: number of rats 
c: statistical comparison at probability, P< O. 05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Drug doses, (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser ine 
73 + 4 
(10) ABD 
66 + 11 
(9) AB 
29 + 13 
(10) ABD 
27 + 10 
(9) AB 
11 + 18 
(6) AB 
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I-' 
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Figure 22 
PITUITARY-ADRENAL RESPONSES AND CHANGES IN BRAIN AND HEART NOREPINEPHRINE AFTER DAILY ADMINISTRATION 
OF SMALL DOSES (1.20 mg/kg, i.p. ) OF GUANETHIDINE. A COMPARISON OF THE EFFECTS OF RESTRAINT ON 
ADRENAL ASCORBIC ACID , SERUM CORTICOSTERONE , BRAIN AND HEART NOREPINEPHRINE LEVELS 
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Solid symbols represent values differing significantly from normal (P(0,05). Each point represents 
the mean of 6 - 10 animals except normal values which represent the mean of 60 animals. 
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Figure 23 
PITUITARY-ADRENAL RESPONSES AND CHANGES IN BRAIN AND HEART NOREPINEPHRINE AFTER DAILY ADMINISTRATION 
OF SMALL DOSES 0.2 mg/kg, i.p.) OF RESERPINE. A COMPARISON OF THE EFFECTS OF RESTRAINT ON 
ADRENAL ASCORBIC ACID, SERUM CORTICOSTERONE, BRAIN AND HEART NOREPINEPHRINE LEVELS 
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Solid symbols represent values differing significantly from normal (P(0,05). Each point represents 
the mean of 6 - 10 animals except normal values which represent the mean of 60 animals. 
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Source of 
variation 
Days 
Drug 
Restraint 
Day vs Drug 
Day vs Restraint 
Drug vs Restraint 
Interaction 
(Day vs Drug vs Restraint) 
a - significant at P<0.01. 
b - significant at P<0.05. 
c - significant at P <0.10. 
d - degrees freedom 
TABLE XXII 
ANALYSIS OF VARIANCE ("F" VALUES) 
Adrenal Serum Brain 
Ascorbic Acid Corticosterone Nore~ine~hrine 
7.8la 1.44 261. 70a 
(4.26)d (4.26) (4.26) 
0.00 0.60 14.17a 
(2.26) (2.26) (2.26) 
10.89a 33. 23a o.oo 
(1. 26) (1. 26) (1. 26) 
10.3la 4.44a 9.92a 
(8.26) (8.26) (8.26) 
1.26 1.25 7.80a 
(4.26) (4.26) (4.26) 
0.68 2.90c 2.84c 
(2.26) (2.26) (2.26) 
2.74a 2.98a 2.84a 
(8.26) (8.26) (8.26) 
Note: took into account unequal number of animals/group due to deaths. 
Drug doses, (i.p.) daily. Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Heart 
NoreRineJi!hrin~ 
686.90a 
(4.26) 
65.30a 
(2.26) 
o.oo 
(1. 26) 
37.79a 
(8.26) 
20.57a 
(4.26) 
0.21 
(2.26) 
11. 69a 
(8.26) 
Weight 
Gains 
13.65a 
(4.26) 
0.91 
(2.26) 
316.54a 
(1. 26) 
14.17a 
(8.26) 
5.6la 
(4.26) 
4.4lb 
(2.26) 
19.50a 
(8.26) 
,..... 
N 
N 
V. DISCUSSION 
A. Circadian Rhythms and Lighting Schedule 
Wurtman (1967) stated that there are two major cycles governing the 
amount of time for which a particular geographic locus is exposed to sun-
light: an on-off, 24-hour cycle of day and night, whose components are 
usually of unequal length but average twelve hours per day in the course 
of a year; and a continuous, annual cycle of change in the length of the 
daily light period. These cycles are accompanied by parallel cycles in 
the intensity of the sunlight. 
Isomorphic with, and frequently dependent upon, these two physical 
cycles are two major endocrine phenomena: diurnal and annual rhythms. 
Many endocrine functions in animals demonstrate a 24-hour periodicity. 
In all cases where these diurnal endocrine rhythms have been studied, 
they have been found to be naturally synchronized with the ambient light-
ing schedule. The adrenal-dependent rhythms tend to respond to experi-
mental lighting regimens, where they rapidly resynchronize to new 
lighting schedules (Wurtman, 1967). 
The studies of Hemmingsen and Krarup (1937) demonstrated that rats 
were able to adapt ,to a complete reversal of the light-dark cycle in 
eight to ten days. Pittendrigh (1960) reported that in some animals a 
repeated light-dark phase shift of a few hours may synchronize the 
physiological rhythms after several days. Pauly and Scheving (1967) 
showed that circadian rhythms are synchronized by the light-dark cycle 
to which the animals are subjected. 
To minimize the annual variations also known to occur in an animal 
(Leduc, 1961), the chronic restraint phase of the study was completed 
123 
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in approximately two months, from October 16th to December 19th. 
B. Stress.ing Procedure 
The safety-pin method, described in the "methods and material" 
section, was used to secure the animals during the stressing period, as 
an alternate to the more usual method (Renaud, 1959) of taking the rats' 
four paws directly to the metal posts of the restraining board. This 
safety-pin modification was employed for two reasons. First, direct 
taping of the rats' four paws to the metal posts each day required ex-
cessive handling of the animals; this extra handling affects behavior 
(Weltman et al., 1961) and also introduced delays into the stress pro-
cedure. Second, the daily removal of the tape from the chronically 
restrained animais caused inflanunation, local edema, and general irri-
tation to the paws. All of these reactions were eliminated by leaving 
the tape intact on the paws throughout the 24 days. Preliminary studies 
showed that most of the animals adapted to the tape and pins in two to 
three days as was evidenced by the fact that they no longer tried to 
remove them. 
C. Weight Gain Studies 
This phase of the investigation was initiated to provide informa-
tion on the effects of restraint on the individual body weight of rats 
treated with guanethidine or reserpine. All animals used in this study 
were routinely weighed to the nearest gram, daily, using an Ohaus 1 small-
animal balance. Individual records were kept of the daily weights. The 
rats were housed, fed and watered as previously described. 
1. Ohaus Seale Corp . , Union, New Jersey. 
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Steinberg and Watson (1959, 1960) showed that a variety of stress-
ful procedures brought about a decrease in growth rate and a reduction 
in the animals' intake of food and water. Scott (1955) and Imms (1965) 
ruled out a connection between the growth rate decrease in rats caused 
by stress, and the reduction of either food or water intake. Imms (1965), 
however, did report some changes in water excretion which varied with 
the types of stress. He concluded that the data could be explained by 
an increase in the rate of oxidative metabolism, since food consumption 
was unchanged during stress while the rate of growth decreased. Similar 
results were noted in this study. 
Jackson (1962) reported that comparing gross weights of the treated 
animals to the gross weights of the untreated, control animals is valid 
only when starting weights of both groups do not . differ. Weight can be 
quantified either in terms of animal weight on the first day of drug 
treatment compared percentage-wise with animal weight at the end of the 
study, (first day weight/final day weight X 100), or by subtracting be-
ginning weight from final weight at the end of the study . Two methods 
of analysis of the body weight data were employed in this study : 
a) Daily weights . For each day of the study, the individual 
daily weights of all animals in each group were compared to the indivi-
dual daily weights of the control groups . 
b) Cumulative daily weight gains . These were determined by sub-
tracting the weight of each animal on day one from its weight on each 
of the remaining days of the study. 
Daily comparisons were made between the control groups and each 
treatment group . Mendillo (1965 ) and Guarino (1966) observed that the 
second method is the most sensit i ve in a study such as this . 
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The total weights of the control (vehicle-treated) group were 
compared to the total weights of each experimental group on each day of 
the study (Table XXIII, appendix). There were no significant differ-
ences on days 1, 2 or 3; however, a significant difference between the 
control group and the stressed (vehicle-treated) group occured on day 4 
and continued until the end of the experiment. This same observation 
was noted with the reserpine-treated, stressed animals. However, the 
guanethidine-treated, stressed animals showed no significant change in 
total weight from the total weight of the control animals until day 5. 
The drug-treated, non-stressed animals showed no difference from the 
control animals on any day of the study. 
When the weights of drug-treated, stressed animals were compared 
to those of the stressed, vehicle-treated animals, there was no signi-
ficant difference . However, when the weights of the control, guanethi-
dine-treated animals were compared to those of the stressed, guanethi-
dine-treated animals, a significant decrease occured on day 5 and conti-
nued throughout the remainder of the study . Further, when the weights 
of the control reserpine-treated group were compared to those of the 
reserpine-treated stressed group, a significant decrease occured on day 
1 and continued throughout the study. 
The cumulative weight gains from day 2 were calculated for each 
animal. The mean+ SE of these values was determined. The cumulative 
weight gains of the control group were compared to the gains of each 
of the experimental groups for each day of the study. This method of 
presenting the data is very sensitive both to small changes in food 
consumption and to altered metabolic rates (Mendillo, 1965) . 
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Data presented in this manner are found in Table II and Figure 1, 
which demonstrate that the reserpine-treated, control animals showed a 
significant decrease in weight gains from day 2 to the end of the study, 
except for days 3 and 4. These values are negligible; however, in view 
of the overall pattern. The weight loss in these animals was completely 
obscured when total weights were considered. Guanethidine-treated, con-
trol animals had weight gains that were as stable as those of the vehicle-
treated control animals. 
All stressed animals showed a decrease in weight gains. Beginning 
on day 2 and continuing throughout the study, weight changes in the 
vehicle-treated, stressed animals were significantly lower than values 
for the control group . These animals exhibited negative weight changes; 
that is, they lost weight. At the end of the treatment these rats were 
-5 + 15 grams lighter than their individual starting weights, while the 
control rats were 49 + 13 grams heavier than their individual starting 
weight. 
Reserpine-stressed rats showed significant weight loss on day 3, 
whereas the guanethidine-stressed rats showed a significant weight loss 
on day 4. These significant changes continued throughout the study. 
When the cumulative daily weight gains of the stressed drug-treated 
animals were compared to the stressed, vehicle-treated animals, a diff-
erent daily pattern was seen; however, there was no significant difference 
in the majority of the daily comparisons . 
When comparing the cumulative daily weight gains of the control, 
guanethidine-treated animals to the stressed, guanethidine-treated ani-
mals, there was a significant difference from day 4 on to the end of the 
study. A similar comparison between the two reserpinized groups revealed 
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a significant difference on day 3 and on to the end of the study. 
D. Food and Water Intake Studies 
This phase of the study involved the observation of daily food and 
water intake of normal and of stressed rats treated with guanethidine 
or reserpine. A similar study done in this laboratory (Rosecrans, 1963) 
showed a 50% mortality in reserpine-treated, restrained rats. He stated 
that reserpinized animals subjected to restraint appeared to die from 
starvation which seemed to stem from their inability to adapt to the 
stress, since normal reserpinized animals had a mortality rate one-fifth 
that of the stressed animals. The decreased water and food balance 
caused by reserpine would attest to this nonadaptation. 
Animals were housed, fed and watered as previously described. 
During the 5-hour period that test animals were being restrained, the 
control animals were kept without food and water. At the end of the 
study the rats were sacrificed as previously described. 
Analysis of the food intake data during the 24-day study showed 
that the rats ate all the food offered to them. Analysis of the water 
intake data during this 24-day period showed that the mean total ml 
intake per control animal per day was 36 + 0.71 . In comparison to the 
vehicle-treated, control animals, the control, guanethidine-treated 
animals drank 8% less water per day and the control, reserpine-treated 
animals drank 17% less water per day. 
The water intake data for the stressed animals showed that there 
were no significant differences in the mean total ml intake per animal 
per day. The vehicle-treated, stressed animals drank 36 + 0.49 ml/day; 
the stressed, guanethidine-treated animals drank 38 ± 0.57 ml/day; and 
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the stressed, reserpine-treated animals drank 37 ± 1.06 ml/day. However, 
when data for the control, guanethidine-treated animals were compared to 
those for the stressed, guanethidine-treated animals, and when the data 
for the control, reserpine-treated animals were compared to those for 
the stressed, reserpine-treated animals, there appeared to be a signi-
ficant difference. A summary of the mean daily intake per rat per day 
for water and for food is found in Table XIV. The daily variations in 
water intake are shown in Table III and Figure 2. The restrained, drug-
treated animals drank more water per day than did the control, drug-
treated animals. 
E. Blood Pressure Studies 
Since both guanethidine and reserpine have the ability to lower 
blood pressure in rats, it was thought that a reduction in blood press-
ure might affect the ability of the rats to adapt to the chronic (24-day) 
restraint procedure. Therefore, the object of this study was to 
determine whether the dose of guanet hidine or of reserpine used in the 
chronic restraint studies had any effect on the blood pressure of the 
test animals. Guanethidine (l . 20 mg/kg) and reserpine (0 . 2 mg/kg) were 
administered i.p., daily for 24 days . Drug vehicle, glass-distilled 
water (1 ml/kg), was administered daily to the control animals. There 
were five animals per group . Housing, handling and daily protocol were 
all as previously described . Blood pressures were recorded daily for 
the first 12 days and then every other day until day 24 . The pressure 
was measured by means of the tail cuff (indirect) method . Blood pres-
sure was not recorded in the rats that were restrained for the 5-hour 
period, because the blood-pressure method requires incubation of the 
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rat at about 40° for 15 to 20 minutes . This incubation would add to 
the daily protocol, another stressor procedure that might obscure the 
results (Mendillo, 1965) . 
The results from this series of experiments showed that the sys-
tolic blood pressure of the guanethidine-treated rats did not signif i-
cantly differ from that of the control rats during the 24 days of 
treatment. The mean systolic pressure in the guanethidine-treated ani-
mals ranged from 112 + 1.7 to 125 + 2 . 6 mm Hg and the mean systolic 
pressures in the control animals ranged from 111 + 4.4 to 126 + 3 . 1 mm 
Hg. However, in rats receiving reserpine, the systolic blood pressure 
was decreased by some 17%, a significant difference from both the con-
trol rats and the guanethidine-treated rats . The systolic pressure 
range was 88 ± 4.0 to 108 ± 1 . 3 mm Hg in the reserpine-treated rats. 
The results are summarized in Table IV and Figure 3 . 
F. General Observation Studies 
Throughout the chronic phase of the study, all the control animals 
appeared to be sedated. The onset of maximal sedation was not observed 
in these animals because of the daily protocol; however, the onset of 
sedation appeared about one to two hours following the administration 
of reserpine and about one hour following guanethidine administration. 
Recovery from sedation was evident after 24 hours in all animals. 
The sedation observed in the vehicle-treated animals was not as 
pronounced as in the drug-treated animals . Reserpine-treated animals 
were less responsive to noise and mild probing than were guanethidine-
treated and vehicle-treated animals . The vehicle-treated animals were 
most responsive . The degree of sedation with reserpine seemed to be 
progressive: less response to noise was observed by the twelfth day, 
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and it decreased even more by day 17. 
All drug-treated animals exhibited some degree of ptosis. Mild 
ptosis was observed daily in the guanethidine-treated animals, but it 
was more pronounced from the fifth:aay t~ the completio~ of the study. 
The daily onset of ptosis in the guanethidine-treated animals was 
earlier than in the reserpine-treated animals; however, ptosis was 
more pronounced in the reserpine-treated animals. 
All control animals were defensive; also, the reserpine- or the 
guanethidine-treated animals were more irritable than the vehicle-
treated animals. Vehicle-treated animals subjected to daily restraint 
demonstrated an extreme degree of excitability during the first six 
days: a behavioral effect that progressively decreased with the dura-
tion of the experiment, indicating some degree of adaptation . Rosecrans 
and DeFeo (1965) reported similar findings . 
The excitability of the vehicle-treated, stressed animals was 
greatest at the onset of the restraining procedure : they struggled 
excessively when being tied down, concentrating their efforts on release 
from the restraining boards . When released, they were exhausted and 
easy to handle. The guanethidine-treated, stressed animals were moder-
ately active when being tied down and during restraint . On release 
from the restraining boards these animals, although they were more 
active than their vehicle-treated counterparts, could nevertheless be 
handled without difficulty . The reserpinized-stressed animals were 
less excitable at the onset of the exper iment; however, they became 
more excitable and difficult to handle as the experiment progressed. 
More specifically, throughout the experiment, the reserpine-treated 
animals were very easily tied down and lay still on the boards; but, 
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as the experiment progressed, they became increasingly vicious upon re-
lease from restraint. These animals appeared to exhibit a type of "sham 
rage", attacking, biting and clawing anything that came within their 
reach. They frequently fought amongst themselves after being placed in 
their cages. These symptoms would indicate a type of non-adaptation. 
Generally, by day 5 all the stressed animals were noisy, but not 
aggressive. The next day all the animals struggled harder on the boards 
and were more difficult to handle when released; particularly, the re-
serpine-treated animals were very aggressive when released. Day 7, all 
the animals became more restless when tied down. By day 10 the animals 
were hard to handle when released from stress; in addition they took on 
the appearance of exhaustion, a condition that increased slowly to day 12. 
On that day the reserpine-treated animals showed decreased activity when 
restrained. Day 13, the vehicle-treated, stressed animals were gasping 
during the restraint procedure and looked lethargic . On day 18 the 
reserpine-treated animals appeared semiconscious and by day 24 there was 
40% mortality in the reserpine-treated, stressed animals . 
All the stressed animals showed increased activity, compared to the 
control animals. All stressed animals defecated and urinated when being 
tied down and also when they were tied down. Diarrhea was noted in the 
stressed animals but not in the control animals . Priapism was noted in 
all stressed animals; however, it did not occur daily in every animal. 
There was 10% mortality in the guanethidine-treated stressed animals. 
When the animals were sacrificed, the hyperreflexia associated with 
decapitation was absent only in the reserpine-treated animals. 
Chromodacryorrhea was noted in all stressed animals at some time 
during the restraining procedure . This varied from 10 to 40% in vehicle-
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treated animals, 30 to 50% in the guanethidine-treated animals and 30 
to 80% in reserpine-treated animals. This response was occasionally 
observed in · some of the drug-treated control animals. 
In summary, the vehicle-treated, stressed animals were excessively 
active and struggled when being tied down but were easy to handle when 
released. The guanethidine-treated stressed animals were moderately 
active and somewhat harder to handle when released from the stress. 
The reserpine-treated stressed animals became progressively excited 
when released from restraint, although the tie-down was initiated with 
greater ease then with the control animals. 
G, Effects of Restraint on the Pituitary-Adrenal Axis and Various 
Organ Weights of Normal, Guanethidine or Reserpine Treated Rats 
1. Organ Weight Studies 
Organ weight relationships, expressed as absolute weights, are 
shown in Tables V, VI, VII and in Figures 4, 5, 6; the relationships, 
expressed as the relative weight (g/lOOg of the body weight), are shown 
in Tables XXIV, XXV, XXVI in the appendix. These values are given in 
both forms to demonstrate the relationship of the organ weights, both 
when compared to each other and when compared to body weight . 
Although the most direct index of ACTH hypersecretion would be the 
elevation of the plasma level of the hormone, a routine method for its 
estimation is not available . Therefore, indirect indices that reflect 
the action of ACTH on the adrenal cortex were sought . However, no 
single test adequately defines the time-course of ACTH release (Maickel 
et~· , 1961). The classical biochemical response evoked by cold stress 
is a decrease in AAA, a rise in plasma corticosterone , an increase in 
liver TP activity, an increase in the weight of adrenal glands, and an 
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excessive metabolization of FFA from body fat depots, (Westermann et al., 
1962). These various responses are also indices of pituitary-adrenal 
stimulation in the rat (Maickel et al., 1961). In the present report, 
three of the preceding responses were used to indicate pituitary-adrenal 
activation: increase in adrenal weight; decrease in AAA; and increase in 
plasma corticosterone. 
The adrenal hypertrophy is a measure of the cumulative effect of 
ACTH, since maximal increases are attained only after several hours of 
pituitary stimulation. This index is particularly useful in describing 
a prolonged pituitary stimulation, because adrenal hypertrophy can per-
sist long after corticosterone have returned to almost normal (Maickel 
et al., 1961). The AAA test indicates the approximate intensity of an 
acute discharge of ACTH; but it is of little value in determining the 
time-course, since ascorbic acid does not return to normal for some hours 
after the pituitary stimulus has stopped (Long, 1947). The plasma corti-
costerone in the rat is an accurate barometer of the intensity of the 
ACTH discharge, and it is also a good indicator of its duration, since 
the adrenal glucocorticoid secretion returns to normal shortly after the 
stimulus is discontinued ( Schonbaum et al . , 1959) . 
The application of these tests in this study indi cate that restraint, 
guanethidine and reserpine elicit similar signs of pituitary-adrenal 
activation: adrenal hypertrophy; decreased AAA; and elevated plasma 
corticosterone. Maickel et al.(1961) reported that similar responses 
in hypophysectomized rats, exposed to cold (4°) and given reserpine, do 
not occur and inferred that they are caused by hypersecretion of ACTH. 
According to Selye's theories regarding chronic stress, animals 
respond differently to individual stressors only in a guantitative way, 
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the responses all being qualitatively the same. Therefore, one of the 
objectives of this experiment was to characterize the effect of CRS in 
normal animals in terms of GAS. Since the brain, heart, and adrenals 
had to be weighed for the analysis of NE and AAA, respectively, it be-
came of interest to see if the stress procedure or drug treatment had 
any effect on the weight of these organs. Selye (1950) stated that, in 
the case of GAS, the AR might be subdivided into two, more or less dis-
tinct phases: 1 . the phase of shock, which might vary from a few min-
utes to about 24 hours, depending upon the intensity of the damage 
inflicted; and 2 . the phase of counter-shock. Here, Selye observed 
an increase in the adrenal weight, indicating adrenal hyperfunction. 
In general, he tnaintained that the reversal of most of the changes seen 
during the shock phase occurred in ·the phase of counter-shock. 
Gray and Munson (1951) reported that the responses of the hypo-
thalamic-pituitary-adrenocortical system to stress are extremely 
rapid. Virnikos-Danelles, (1964) and Stockham, (1964), demonstrated 
an increase in plasma and adrenal corticosteroid in the rat as early 
as 100 seconds after application of a stimulus. Jones and Stockham 
(1966) showed that a second stress maintained the high levels of adreno-
cortical synthesis induced by the first stress for a longer period of 
time, rather than inunediately causing an increase in the plasma levels. 
Because of experimental design and since the pituitary-adrenal 
axis response to stress is rapid, it was not within the scope of these 
studies to characterize the AR completely, or to characterize it in 
terms of different shock-phases . Nevertheless, appearance of the 
shock-phase might be suggested to some degree by the slight decrease 
in the absolute adrenal weight in stressed animals treated with vehicle 
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or with reserpine on day 1 as compared to the non-stressed animals 
(Table V and Figure 4). Guanethidine-treated, stressed rats showed a 
slight increase. Also, appearance of the counter-shock phase might be 
suggested by the enlargement observed in the adrenals in all groups of 
animals on day 3. The maximal increase in relative adrenal weight was 
noted on day 24 for stressed rats treated with vehicle or with reserpine 
and on day 12 for the guanethidine-treated, stressed rats. Control rats 
treated with the vehicle or with the drugs showed similar responses. 
In general, there was an increase in the absolute adrenal weight 
in all the groups studied, but the stressed animals showed a greater 
variation in the adrenal weight than did the control animals. Vehicle-
treated control animals showed an increase of 0,006 mg from day 1 to 
day 24, whereas the vehicle-treated, stressed animals showed an increase 
of 0 . 010 mg over the same period of time. Similar results were obt~ined 
from the drug-treated animals. The reserpine-treated stressed animals 
showed the largest variation in weight, 0.014 mg . Significant differ-
ences, however, appeared only on days 6 and 12 with the guanethidine-
treated animals and on days 3 and 6 with the reserpine-treated group. 
(See Table V for a statistical comparison.) The data in Table V shows 
an increase in the absolute adrenal weight, in the vehicle-treated con-
trol animals suggesting that the injection of water also induced a form 
of stress; however, the data in Table XXIV (appendix) shows that there 
was no change in the relative adrenal weight in these animals over the 
24-day study, except for day 6 . These data also show that, in the 
vehicle-treated, stressed animals, there was an increase in the rela-
tive adrenal weight, reaching a maximum on day 12. In fact, all of the 
stressed animals showed the maximum increase on day 12. Table V, 
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representing the absolute adrenal weight, failed to demonstrate this 
point. The control animals did not show a significant change when the 
adrenal weight was represented in this manner. Comparison of the rela-
tive adrenal weight, Table XXIV, makes clear that the control animals 
treated with vehicle or with drug showed no significant increase in the 
adrenal weight; however, there was an increase in adrenal weight in the 
stressed animals. 
With the possible exception of biological variation, the low 
figures observed on day 6 are impossible of a valid explanation. In 
nearly all parameters tested, day 6 gave an unusual response. 
It is difficult to analyze glandular activity from a weight change 
only, but on the basis of the severity of restraint, the increase in 
weight of the adrenals could be due to ACTH stimulation and associated 
chemical depletion during extreme activation. 
Selye (1950) reported that congestion, edema, and hemorrhage in 
the brain are often particularly conspicuous in men who die from heat-
stroke. Acute swelling, shrinkage, or pyknosis of cells have also been 
reported, but some investigators regard these as postmortem artifacts . 
All these changes are so similar to those produced by other types of 
intense acute stress that they may well be nonspecific manifestations 
of the GAS. Also, experimental evidence has shown that stress and over-
dosage with various hormones which are produced during stress can cause 
characteristic morphologic changes in the heart. Mineralocorticoids can 
elicit a type of myocarditis very similar to that seen in acute rheumatic 
fever. Irritation of animals with an electric current is also effective 
in causing cardiac lesions. Shapiro and Melkado, in 1957, reported an 
increase in heart size in stressed animals. However, these same 
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investigators, in 1958, reported that there was no significant change 
in heart weight due to stress. 
In this study, analysis of heart weights varied according to the 
method of data treatment. The absolute heart weights of the stressed 
animals treated with vehicle or with drug varied from day to day, per-
haps an indication of the effect of stress. The absolute heart weights 
in the control animals treated with vehicle or with drug (Table VI and 
Figure 5) showed an overall increase from day 1 to day 24, perhaps an 
indication of growth. However, when the relative heart weights (Table 
XXV; appendix) were compared, an inverse relationship for these data 
appeared in the control animals (vehicle and drug treated); whereas 
the data for the stressed animals all showed an increase. All groups 
reached I maximum relative heart weight on day 12, and again, there was 
an unusual response on day 6. Because the relative heart weights were 
higher for the stressed animals than for the control animals (See 
Tables VI and XXV for a statistical comparison), there is some indi-
cation that stress had an effect on the total heart weight. 
Absolute brain weights likewise varied from day to day to the 
extent that no correlation could be made in all the groups studied. 
(Table VII and Figure 6). However, when the brain weights were ex-
pressed as the relative weights, Table XXVI (appendix), an inverse 
rel~tionship was noted as with the heart weights. There w.as also a 
change in t:he brain weight on day 12 of all the stres·sed ani'mals, 
except the guanethidine-treated animals, that corresponded to the 
changes seen with adrenal and heart weight, when expressed in this 
manner. (See Tables VII and XXVI for a statistical comparison.) In 
summary, the most significant statement that can be drawn from the 
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brain weight data is that expressing brain weights as percentage of body 
weight seems to be the most sensitive method for analysis. 
The effects of daily restraint on the organ weights of normal rats 
make evident to a degree their ability to adapt. Following the initial 
AR, the tendency of the adrenal weight to return to the original values 
is a good example of animal adaptation to external environment, as is 
perhaps the stabilization of the heart and brain weights on day 12. 
2. Serum Corticosterone Studies 
To establish a reliable method of assay for corticosterone, the 
method described by Guillemin et al., 1959a was used. Two modifica-
tions of the fluorescence reagent were tried and checked for their 
stability and fluorescence ability. A mixture of sulfuric acid and 
50% aqueous ethanol in a ratio of 2.4:1 (Zenker and Bernstein, 1958) 
was tested, as was a mixture of sulfuric acid and absolute ethanol in 
a 65:35 ratio (Peterson, 1957). However, it was found that Guillemin's 
original fluorescence reagent (30N H2so4 ) gave maximal fluorescence, 
sufficient to be measured in a final volume of four ml in an Aminco-
Bowman spectrophotofluorometer. A comparison of the control tissue 
corticosterone values with previously reported values (Maickel et al., 
1967) using the Guillemin et al (1959a) method was also carried out. 
A statistical comparison of the effects of restraint on serum 
corticosterone in the rat treated with guanethidine or reserpine is 
given in Table VIII and Figure 9 . There was an increase on day 1 from 
day 0 in the vehicle-treated, control animals, but it was not as great 
as in the vehicle-treated, stressed animals . There were similar in-
creases in all the other groups, but the stressed group values on day 1 
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were approximately double those on day 0. There was a return to lower 
levels on day 3 in the drug-treated, control animals, followed by an 
even greater increase on day 6. By day 12 and day 24, the cycle appeared 
to repeat itself. 
3. Adrenal Ascorbic Acid Studies 
The reliability of the method for the assay of AAA (Maickel, 1960) 
was determined. It was observed by Dixit (1965) and in this laboratory 
that, when a stock solution of ascorbic acid (10 mg/ml) in 5% TCA was 
prepared in double-glass-distilled water, it oxidized very rapidly, even 
when refrigerated . The rate of oxidation was found to be related to the 
concentration of TCA (Dixit, 1965). Dixit also observed that the addi-
tion of 2% MPA protected the ascorbic acid from oxidation, and that the 
solution was stable for at least five dµys in the refrigerator. However, 
the addition of 2% MPA increased the time required for the development 
of maximal color intensity at room temperature (24-25°), and consequently 
increased the time required to complete the assay . This difficulty was 
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overcome by completing the reaction at 27-38 ; under these conditions, 
maximal color intensity was obtained within 20 minutes . 
Musulin and King (1936) showed that the oxidation of MPA serves to 
protect ascorbic acid in solution against oxidation in the presence of 
TCA. They suggested that the high aci_dity could protect the ascorbic 
acid from oxidation; and in this respect, MPA (5.0 to 8.0%) was rated 
highest. In the present study, it was found that the pH of 5% TCA and 
of 5% TCA + 2% MPA were practically the same, pH 1.0 and 0.95 respec-
tively, an indication that high acidity, as such, is of little impor-
tance in preventing the oxidation of ascorbic acid. A comparison of 
the control AAA values with previously reported values (Dixit, 1965), 
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both using the Maickel (1960) method, was carried out. 
The AAA values are presented in Table IX and Figure 11. Values 
for vehicle-treated, control rats were fairly stable throughout the 
study, except for day 6, which showed an unusual response. Control ani-
mals treated with guanethidine or reserpine showed similar responses 
throughout the study; however, on day 6, the response with the reserpine-
treated animals was less than that with the guanethidine-treated animals. 
Both these groups showed higher values on day 24 than those for the 
vehicle-treated, control animals. 
The restrained animals, vehicle and drug treated, showed initially 
the same response; a decrease on day 1, followed by increases on days 
3 and 6. Guanethidine-treated animals showed less of a gain on day 6 
than did either the vehicle- or reserpine-treated animals . The values 
from day 12 to day 24 were not significantly different from controls. 
These tables and figures show that there was a fall in AAA and a 
rise in serum corticosterone on day 1 in the vehicle-treated, stressed 
animals: an indication of an AR and an activation of the pituitary-
adrenal system. These responses were reversed by day 3 : an indication 
of physiological adaptation. By day 6 the responses were fairly constant, 
a confirmation of the animals' adaptation to the external environmental 
changes. 
Control animals, treated with guanethidine or reserpine, exhibited 
variations in AAA and serum corticosterone that were similar to the stress 
reaction seen with the vehicle-treated, stressed animals; reserpine-
treated rats were less reactive to the stress than were the other ani-
mals. The response varied somewhat in each group of animals, but the 
guanethidine-treated, control animals appeared to adapt by day 12, 
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whereas the reserpine-treated, control animals never seemed to adapt. 
This was not unexpected; Maickel ~ al. (1961) had shown that reserpine 
produces a biochemical picture similar to that produced by cold stress. 
Nor was the response seen with the guanethidine-treated, control ani-
mals unexpected; however, it has not been reported in the literature. 
The vehicle-treated, control rats also exhibited a slight AR . Day 6 
ag~in showed the unusual response in the control animals. 
In general, the drug-treated, stressed animals exhibited a 
greater AR as compared with the vehicle-treated, stressed animals. 
The respons~s reversed themselves by day 3 in both groups of animals; 
however, the reserpinized animals did not appea~ to adapt until about 
day 12, another indication that reserpine tends to prevent adaptation. 
The pituitary-adrenal system was apparently active throughout the 
period of chronic stress even though serum corticosterone returned to 
normal by day 12. The fact that the adrenal weight did not return to 
control values, but showed a general trend of returning toward normal, 
may indicate an increase in adrenal efficiency or responsiveness. Simi-
lar observations were noted by Rosecrans and DeFeo (1965). This effect 
may be the result of a progressive response of the adrenals to ACTH as 
demonstrated by Stark et al . (1963). AAA, however, returned to normal 
by day 24 . 
Although an apparent decrease in pituitary and adrenal function 
prevailed during adaptation to stress, the serum corticosterone exhib-
ited relative adaptation and appeared to be maintained at high levels 
throughout the experiment, especially in the guanethidine- and reserpine-
treated animals . If the adrenal weights can be considered an indication 
of corticosteroid synthesis and release, then the concurrent maintenance 
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of both serum corticosterone and increased adrenal weight would indicate 
an increased adrenal efficiency during adaptation to stress. These 
indices are also good indications of the duration of ACTH discharge and 
prolonged pituitary stimulation respectively. 
Reserpine appears to have produced a definite effect of its own on 
the pituitary-adrenal axis. At the beginning, the effects of reserpine 
on organ weights of normal animals were almost identical to the effects 
of restraint in the vehicle-treated animals. However, on day 3, the 
heart weights in the vehicle-treated, stressed animals showed an increase, 
while the reserpine-treated, non-stressed animals showed a decrease in 
weight. Organ weight changes, Figures 20 and 21, were divergent, in con-
contrast to untreated animals under stress; however, there were some 
signs of adaptation in the organ weight values. 
The serum corticosterone values would indicate that reserpine does 
not prevent animals from achieving adrenal adaptation, since these values 
are approximately the same .as those of untreated stressed animals. 
Reserpine evoked adrenocortical responses similar to those seen in the 
restrained animals (Figure 23), but it apparently did not inhibit CRS 
to any degree. In fact, it seemed to act as an acute stimulator of the 
pituitary-adrenal axis and prevented the animal from adapting to the 
stress. How reserpine prevented adaptation has not been determined. 
Guanethidine also produced a definite effect on the pituitary-
adrenal axis. Guanethidine-treated, control animals showed responses 
in organ weights almost identical to those for the reserpine-treated, 
control animals. Similar responses were also noted in the stressed 
drug-treated animals with regard to organ weights. Guanethidine also 
appeared to prevent adaptation to stress, as indicated by its dissimilar 
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effects on the various organ weight changes. However, by day 24, the 
adrenal weights were returning toward normal, an indication of a type 
of adaptation. 
Serum corticosterone and AAA in guanethidine-treated, nonstressed 
rats were identical to those of the reserpine-treated, nonstressed rats. 
Similar responses were also noted in the vehicle-treated, nonstressed 
animals . These responses lead to the suggestions, first, that the in-
jection per ~ had some effect on the pituitary-adr-enal axis, second, 
that a drug having a systemic response stimulates the ~i.tuit.µ-y-adrenal 
f ,' I 
axis to a greater degree, and, third, that the response observed may 
be identical in most if not all drug studies . While these suggestions 
are admittedly based on mere speculation at this point, it is fact 
with the two drugs used in this study and may not apply to other drugs. 
It can also be seen in Figure 22 that the guanethidine-treated, stressed 
rats appeared to adapt to the stress, as indicated by the tendency of 
serum corticosterone and AAA to return to normal . Reserpine-treated, 
stressed rats showed quite a different picture, Figure 23. 
H. Effect of Restraint on the Brain and Heart Norepinephrine Levels 
in Normal, Guanethidine or Reserpine Treated Male Rats 
1. Norepinephrine Assay Studies 
The method used was designed to permit a rapid evaluation of the 
ability of certain compounds to deplete both brain and heart of NE; it 
is a modification of existing procedures, principally the Shore and 
Olin (1958) organic extraction method. According to Anton and Sayre 
(1962), this method is probably the most convenient one to determine 
CA in tissue; however, it can be used only for tissue, and it may be 
further restricted to certain tissue, such as the brain and heart. 
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They could not completely recover added CA from rat and guinea pig liver, 
and occasionally recoveries from brain decreased from about 60% to about 
25% for no apparent reason. This variability was also noted by other 
investigators (Green and Erickson 1960). 
Shore and Olin (1958) reported that the partition coefficient of 
NE between the butanol and the aqueous-acid phase (10:1) was 0.65. In 
this investigation about 65% of NE added to tissue homogenates was re-
covered. These recoveries were not consistant; however, replicate 
determinations carried out on homogenates without adding NE gave values 
for the endogenous CA that were reproducible within 10% (±3 SEM). 
Since the present investigation was concerned with the effect of 
drugs on tissue levels of NE, the absolute amount of NE in the tissue 
was of consequence, only if, under rigidly controlled analytical condi-
tions, the replicate determinations of NE were constant. Hence, all 
the results reported are in terms of micrograms of endogenous NE per 
gram of tissue, without correction for the partition coefficient of 
added amine, between the organic phase and the aqueous-acid phase. 
It was observed in this laboratory that the alkaline ascorbic 
acid solution prepared by the method of Maynert and Klingman (1962) 
tends to age rapidly, turning pink in less than an hour. Anton and 
Sayre (1962) observed that the use of lON NaOH made the ascorbate 
solution more stable and less subject to discoloration. They also 
found that in their oxidation procedure, as the volumes of a standard 
CA solution increased, an almost linear response was obtained with 
alkaline ascorbate made with lON, but not with SN NaOH. A similar 
response was noted in the present investigation (Figure 12). However, 
it was observed that the mixture of ascorbic acid and the lON Na(ji was 
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also somewhat unstable, discoloring after a few hours. This change was 
usually accompanied by increased relative fluorescence values in the 
blank sample and sometimes by a decrease of the net fluorescence. These 
effects were minimized by the addition of 0.16 ml of ethylenediamine to 
the alkaline ascorbate solution, which stabilized the solution by delay-
ing the development of the pink color in the alkaline ascorbate solution 
for 3 - 4 hours (von Euler and Lishajko, 1961). These workers also 
observed that the net fluorescence values for NE were markedly higher 
if transformation of lutines was made with alkaline ascorbate solution 
to which ethylenediamine had been added. Similar results were obtained 
in this study (Figure 13) . The increased fluorescence action of this 
reagent is attributed to condensation of the CA with ethylenediamine 
(Weil-Malherbe and Bone, 1952). 
Since other CA can be extracted and may therefore interfere with 
this method, standards were prepared using E, NE and dopamine. Dopamine 
did not fluoresce at the particular wavelength used, but there was some 
interference from E as is seen in Figure 14. According to Udenfriend 
(1962), however, there is little or no measurable E in the brain or 
heart tissue of the rat. 
The relative fluorescence at varying concentrations of NE is shown 
in Figure 15. 
The reliability of the modified Shore and Olin (1958) NE assay 
method was established by performing numerous assays on untreated ani-
mals selected at random from those present in the laboratory. The 
results were then compared with accepted literature values and appear 
in Table X. The data for brain and heart NE fall within an accepted 
range and are consistent throughout the study. 
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Udenfriend (1962) reported an average of 0.44 ug/g of NE in wet 
brain tissue of rats. Other investigators, including Maynert and 
Klingman, 1961; Merrills, 1962; Anton and Sayre, 1964 and Grabarits and 
Harvey, 1966, reported similar values. In this study, the modified 
Shore and Olin (1958) NE assay method gave values that were approximately 
half those reported by the other workers. Nevertheless, other authors, 
those listed in Table X, all using the Shore and Olin (1958) method or 
a modification of it, reported values similar to those seen in this 
report. The heart NE values were similar to those reported by Udenfriend 
(1962) and others. 
2. Dose-Response Studies 
The purpose of this experiment was to determine what dose of re-
serpine would effect a 50% depletion of brain NE and what dose of guan-
ethidine would effect a 50% depletion of heart NE. These two doses, as 
determined here, were then used in the chronic restraint studies. 
The results obtained from these experiments show that reserpine 
(Figure 16) exhibited a typical dose-response relation to the NE con-
centration in the rat brain, when given over a suitable range, and that 
guanethidine (Figure 17) has a similar effect on the NE concentration 
in rat heart. The results are summarized in Table XI. 
Reserpine had a gradual, depleting effect on brain NE and exerted 
a maximal or near-maximal effect when given at a dose of 1.0 mg/kg. 
However, the effect of reserpine on heart NE showed near-maximal deple-
tion following the administration of 0.05 mg/kg and larger doses exhib-
ited no significantly greater effect. 
Since this phase of the study was done to determine which dose of 
reserpine gave a 50% depletion of brain NE, and since 1.0 mg/kg showed 
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a near-maximal effect, only the data from rats given the first three 
doses of reserpine, and from rats given the vehici~ were used to plot 
the dose-response curve. Figure 16 shows that the dose of reserpine 
causing a 50% depletion of brain NE was calculated to be 0.19 mg/kg; 
therefore, a reserpine dose of 0.2 mg/kg was used throughout the 
chronic restraint phase of the study. 
The results in Table XI show that increasing amounts of guanethidine, 
up to 5 mg/kg, led to progressively greater decrease in heart NE. How-
ever, when 10 mg/kg of guanethidine were administered, the decrease 
obtained was about the same as that from only 5 mg/kg. 
Guanethidine showed no depletion of brain NE at any dose tested. 
At the 0.5 mg/kg dose level, however, guanethidine effected a slight 
increase in brain NE and this value was significantly different from 
the control values (P< 0.05), whereas none of the other doses altered 
brain NE. It is difficult to draw any significance from this finding 
and it may well be an artifact. Inasmuch as the action of guanethidine 
on cardiac NE was the principal aim of the study, and since the increase 
in brain NE was not related to the investigation, the finding was not 
followed up at this time. 
As with reserpine, the data from rats given the first three doses 
of guanethidine, and from rats given the vehicle, were used to plot the 
dose-response curve. The dose of guanethidine effecting a 50% depletion 
of cardiac NE was 1.20 mg/kg (Figure 17). This dose was used throughout 
the chronic restraint phase of the study. 
The method of least squares was used to plot the dose-response 
curve for both drugs (Snedecor, p. 124, 1956), with the aid of an IBM 
360 computer. 
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3. Chronic Restraint Studies 
Brain and heart NE was calculated and fluctuations were noted. NE 
is released from neurons at accelerated rates by stimuli (Glowinski and 
Baldessarini, 1957) and its decline after pharmacological inhibition of 
its biosynthesis is dependent on the presence of adequate stimuli 
(Hillarp et al., 1966b). In some instances its concentration in brain 
(Maynert and Levi, 1963) and in heart (Chang and Su, 1967) has been 
reported to be lowered by stress. 
Comparative determinations for brain NE are presented in Table XII 
and Figure 18. There does not appear to be a significant change in 
brain NE in vehicle and guanethidine control rats. Reserpine control 
animals showed a progressive decline in brain NE from day 1 to day 24. 
Vehicle-treated, stressed animals showed a decline in brain NE on day 3, 
followed by a gradual increase. The guanethidine-treated, stressed ani-
mals also showed an increase in brain NE on day 1 and then a significant 
decrease on day 3, followed by a gradual increase on days 6 and 12 and 
then a decline again on day 24 . The reserpine-treated, stressed animals 
showed a significant decrease in brain NE on day l; it decreased even 
further on the consecutive days of study. 
Usually brain NE is resistant to decline, even under conditions of 
a highly intensified stimulus (Paulsen and Hess, 1963); in some circum-
stances, a stressor, which under certain circumstances or in different 
degrees might have reduced NE, may actually raise it (Welch and Welch, 
1968) . This resistance to reduction of brain NE was noted in these 
studies, especially in the vehicle- and guanethidine-treated, stressed 
animals. 
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The exact mechanism whereby stress causes the release of brain NE 
is unknown (Maynert and Levi, 1964); however, Welch and Welch (1968) 
postulated a mechanism to explain the rapid elevation of brain NE that 
may be induced by stress. They suggested that a mechanism is activated 
which conserves NE by inhibiting its normal intraneuronal catabolism 
concurrent with the increased requirement for it to maintain neurotrans-
mission. 
A statistical comparison of the heart NE values is presented in 
Table XIII and Figure 19. Heart NE was lower on day 6, as compared to 
the other animals in the vehicle-treated, control group. Guanethidine-
treated, control animals showed a significant decrease on day 1, and a 
further significant decline on the following days. Reserpi ne-treated, 
control animals showed almost no cardiac NE from day 1, and it fell 
even lower as the experiment progressed. Vehicle-treated, stressed 
animals showed a low level of NE on day 1, compared either with the 
vehicle-treated, control animals or to day 0. This level fell even 
further by day 6; however, the values on day 12 compared favorably to 
those of vehicle-treated, control animals and to those of non-treated 
animals on day O. By day 24, the heart NE rose even higher in these 
animals. The guanethidine-treated, stressed animals showed a signifi-
cant decrease in heart NE on day l; it fell even lower by day 3, but 
by day 12, it returned to values comparable to those on day 1 . Reser-
pine-treated, stressed animals had values comparable to those of the 
reserpine-treated, control animals. Control brain and heart NE was 
fairly stable throughout the experiment. 
Chang and Su (1967) demonstrated that increased sympathetic activ-
ities in the rat heart, induced by exposure to cold, primarily release 
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NE. Others (Leduc, 1961; Feller and Hales, 1964) postulated that the 
increased excretion of CA during exposure of animals to cold stress 
might indicate a gre~t~f~ activity of the sympathoadrenal system. 
4. Adaptation Studies 
Along with behavioral adaptation, there also appeared to be a 
neurohumoral adaptation. The problem in analyzing these results was 
the fact that the brain NE of stressed rats was not significantly 
different from control rats, except for day 1.. Some correlation can 
be seen among the differences between these two groups of animals and 
their heart NE. The decrease in brain NE, shown in Figure 22 corre-
sponds fairly well to the general activity of the stressed animals 
during the first week of the study. The significant decrease in heart 
NE during this period is perhaps an indication of increased sympathetic 
activity and non-adaptation at this stage of the study. Graham (1966) 
obtained increased E and NE excretion rates in restrained rats and 
suggested that the stress of physical restraint caused marked increases 
in both adrenomedullary and neurogenic sympathetic activity. 
The importance of a possible correlation between behavioral 
adaptation and brain and heart NE is not to be denied, although it is 
difficult to quantify the behavioral parameters studied here. The fact 
that stress brought about a decrease in brain NE at first and then an 
increase on day 12 appeared to associate this amine with the behavioral 
activity associated with this group of animals. Guanethidine-treated, 
stressed animals demonstrated an intermediate behavioral effect as com-
pared with vehicle-treated, stressed animals (exhausted) and reserpine-
treated, stressed animals (hyperactive), upon their release from re-
straint. In the guanethidine-treated, stressed animals, the heart NE 
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was identical with the vehicle-treated, stressed animals but not to the 
guanethidine-treated, control animals. There appeared to be no deple-
tion of the heart NE due to the action of guanethidine. This effect 
may be due to the ability of the stress situation to stimulate the 
drug's metabolism by mediating a rapid induction of the liver microsomal 
enzymes responsible for its metabolism (Driever and Bousquet, 1965). 
Reserpine treatment led to dissimilar response effects on heart NE. The 
deviation may be due to the fact that reserpine action is seen long 
after there are no traces of the drug. This evidence also suggests that 
these two drugs do not deplete heart NE by the same mechanism. 
J. General Discussion 
There were no deaths attributable to the experimental design in any 
of the control groups (vehicle or drug-treated). That no deaths were 
noted in the vehicle-treated, stressed rats in the 24-day study indi-
cated that the animals adapted to this procedure. Similarly, the one 
death in the guanethidine-treated, stressed group also indicated adapta-
tion in this group of animals. The mortality of the reserpine-treated, 
stressed rats was very high; 40% in 24 days clearly indicated the inabil-
ity of reserpinized animals to adapt to the chronic, forced restraint 
stress (Table XIV). 
Other investigators, using other forms of stress, reported a high 
mortality in reserpinized animals. Rosecrans and DeFeo (1965), using 
restraint for three hours, reported 50% mortality in reserpinized rats. 
They stated that the high mortality may have resulted in part from star-
vation (they noted a decreased food and water intake); but starvation 
does not appear to be the answer, since in this study and in others 
(See page 124) the animals ate all the food offered to them. Buckley 
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et al. (1964), using flashing lights, autogenic stimulation, and cage 
oscillation stressors, showed that reserpine not only failed to protect 
the rats from chronic stress but potentiated the lethal effect of the 
stressors . The mortality of reserpine-treated animals under stress was 
over 200% at the end of 27 weeks . They concluded that under prolonged 
chronic stress the reserpine produced a potentiating or an additive 
effect on the pituitary-adrenal response to stress, thus producing 
adrenal insuff i ciency that l ed to t he death of t he animals . Westermann 
et al . (1962) stated that failure of rats to respond to stressful stim-
uli after large doses of reserpine m·i .ght be attributed partly to a 
pituitary-adrenal system which is already under maximal stimulation and 
partly due to exhaustion of the pi tuitary ACTH. If the animals were 
then exposed to cold, the plasma corticosterone did not rise further 
(Maickel et al . , 1961) and the inability of the animal to respond to 
cold-exposure was reflected in a higher death rate, resulting from the 
stress . Other investigators (Leduc, 1961; Johnson, 1963) suggested 
that failing NE excretion in animals exposed to cold could be due to 
the inhibition of NE synthesis by reserpine despite the report by 
McDonald and Weise (1961), who demonstrated that reserpine does not 
alter the biosynthesis of CA. Johnson (1966) reported that survival 
of cold-exposed animals appeared to be related to the liberation of 
NE, with E release serving as an important secondary mechanism of 
defense against cold . 
Pouliot (1966) stated that a drug should be free of central effects 
if the correlation between NE secretion from peripheral tissue stores 
of CA and resistance to cold stress is to be considered. He employed 
guanethidine, whose act i on is largely peripheral and without effect on 
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brain NE, in adrenodemedullated rats, all of which died when exposed to 
cold stress. The failure of the guanethidine-treated rats to increase 
their NE excretion led him to conclude that guanethidine prevents either 
the increase in release or the biosynthesis of NE, or both, normally 
induced by cold exposure. He also concluded that the sympathetic block-
ade by guanethidine could be partly responsible for the lack of accel-
eration of CA liberation. His results corroborated those of previous 
investigators who showed that cold resistance is dependent upon the 
liberation and action of NE. 
Since non-adaptation may be associated with the inhibition of some 
physiological mechanism, it would be interesting to speculate on the 
relationship between apparent exhaustion of central and peripheral NE 
with non-adaptation. Many data are available in the literature to 
suggest that NE plays an important role in enabling animals to respond 
to pituitary-adrenal stimulation induced by environmental stress. Ani-
mals without a functioning peripheral sympathetic nervous system would 
not be able to adapt to a chronic stress, even though the pituitary-
adrenal system might be functioning normally (Rosecrans and DeFeo, 
1965). 
It is not possible to correlate completely non-adaptation in 
reserpinized, stressed animals and CA depletion. In Figure 23, the 
heart NE patterns are similar to those in the brain; hence, the deple-
tion of peripheral NE alone does not explain the toxicity in the stressed, 
reserpinized rats. Further, the heart NE is virtually the same in the 
stressed, reserpinized rats as in the nonstressed, reserpinized rats. 
Guanethidine and its principal action on peripheral NE also offers no 
clue to the cause of death in reserpinized, stressed rats because here 
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the heart picture and mortality are different and no correlation can be 
seen. However, when speculations on the increased toxicity in reserpin-
ized, stressed rats are set forth, it should be kept in mind that reser-
pine affects both peripheral and central CA and indolamines and that it 
produces marked sedation, whereas, guanethidine affects only peripheral 
CA and at the low dose used here it probably does not affect the CA in 
the adrenal medulla. Pouliot (1966) suggested the dependency of sur-
vival of cold-stressed adrenodemedullated animals upon a peripheral 
secretion of NE, Bygdeman ~ al. (1960) reported an acceleration of CA 
synthesis in the adrenal medulla following an increased nervous stimu-
lation and Pouliot (1966) assumed that the same mechanism occurs in 
noradrenergic fibers. The work of Leduc (1961) also suggests increased 
synthesis of NE occurs as a result of increased nervous activity. 
The rats in the present study were not demedullated; hence, the 
guanethidine-treated animals were able to respond to the stress and 
adapt perhaps by increased NE synthesis . The stress seemed to override 
the NE-depleting action of guanethidine (Figure 22). Since reserpine 
affects total CA content in the rat, then, in a sense, they were chemi-
cally demedullated and could not adapt to the stress by increasing their 
NE content. However, it is not certain that the increased toxicity in 
reserpinized, stressed rats was due solely to CA depletion per se, either 
central or peripheral. That CA play an important role in adaptation can 
be seen from the work of Necinu and Kregei (1961), who observed that the 
usual peptic ulcer produced by reserpine and cold stress could be com-
pletely inhibited by the administration of DOPA, a NE precursor, and that 
the usual 50% mortality produced by cold stress was prevented by DOPA in 
reserpinized rats . 
\ 
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The decrease in central sympathetic outflow in reserpine-treated 
animals (McCubbin and Page, 1958) may also be an important fac~or in 
non-adaptation with these animals. However, numerous other parameters 
(mentioned both by other investigators and throughout this report) may 
also come into play, and CA depletion is but one factor in the total 
picture of adaptation and reserpine toxicity. 
The work of Welch and Welch (1968) should also be kept in mind, 
when attempts are made to correlate stress and CA depletion, They state 
that during stress, mice , which differ in behavioral reactivity because 
of differences in their previous environmental conditions, metabolize 
brain biogenic amines at different rates and also activate to different 
degrees temporal mechanisms which control the availability of the amine 
during stress , 
Neurochemical adaptation which appears to parallel behavioral 
adaptation for the most part has been characterized in normal drug-
treated rats , The increased behavioral activity associated with the 
initiation of restraint followed the changes in brain NE and it tended 
to return to normal when behavioral adaptation occurred , Serum corti-
costerone also appeared to be a good index of behavioral adaptation, 
The results from previous investigations support the validity of these 
observations. Pfeifer and Galarnbos (1967) suggested that NE has a 
more important role in the change of susceptibility to seiz4res than 
serotonin or dopamine, ·smith (1963) showed that enhancement of the 
activity-increasing effect of d-amphetamine after alpha-methyl dopa 
followed changes in brain NE more closely than changes in either brain 
serotonin or dopamine. Mayner t and Klingman (1962) discussed the possi-
bility that brain NE functions as part of the sympathetic nervous system 
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and that its release is accompanied by arousal or excitement, 
Grundfest (1957), summarizing research from previous years, conclu-
ded that central nervous transmission is accomplished via neurochemicals. 
He was unable to demonstrate electrically excitable central dendrites. 
Rothboller (1959) and Brodie and Shore (1957) contended that changes in 
brain NE represent fluctuations of excitatory activity initiated by an 
adrenergic system. Rosecrans (1963) and Guarino et al. (1967) also 
showed that NE was associated with increased CNS excitation . 
It should be pointed out again that reserpinized, stressed animals 
demonstrated abnormal behavior after release from restraint, although 
they were quiet while under restraint, an important observation because 
it cannot be concluded that stress inhibited the reserpine-induced seda-
tion. At the same time, reserpine produces chemical sympathectomy 
(Trendelenburg, 196la), a fact that may account for the decreased activ-
ity in these rats under restraint. Reserpine may be stimulating the 
excitatory brain mechanisms that are controlled by NE, since restraint 
caused variations in NE and overt activity was noted when brain NE was 
decreased . Reserpine also, by producing its exhaustive depletion of 
the central sites of NE, may have produced a central hypersensitivity 
similar to nerve postsynaptic hypersensitivity following denervation. 
Such an apparent hypersensitivity may be responsible for the behavioral 
excitation observed in reserpinized, stressed rats (Rosecrans, 1963). 
The ability of reserpine to prevent adaptation was again demonstrated 
beyond doubt. The means by which it was accomplished, however, are de-
batable, for it should be remembered that reserpine has important deple-
ting effects on both brain CA and indolamines (Sheppard and Zimmerman, 
1960a). The guanethidine-treated, stressed animals appeared to adapt 
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to the stress, and their behavioral pattern, similar to the vehicle-
treated, stressed animals, also indicates that perhaps NE plays a role 
in behavior patterns. 
VI. SUMMARY AND CONCLUSIONS 
A. A modification of the Shore and Olin (1958) method for the extraction 
of tissue NE has been described, which was applied to the routine esti-
mation of brain and heart amines of rats subjected to restraint and 
treated with guanethidine or reserpine. 
B. Serum corticosterone was estimated by the method of Guillemin et ~· 
(1959a) and AAA was estimated by the method of Maickel (1960). 
C. Dose-response studies were carried out over a period of six days, 
to establish what dose of reserpine would effect a 50% depletion of 
central CA and what dose of guanethidine would effect a 50% depletion 
of peripheral CA. 
D. The dose of reserpine (0.2 mg/kg, i.p.) and of guanethidine 
(l.20 mg/kg, i.p.), established in the dose-response studies were used 
throughout the chronic (24 day) phase of the study. 
1. Reserpinized, control animals gave adrenalcortical responses 
similar to those of the stressed animals. That reserpinized, stressed 
rats failed to adapt to the stress was indicated by the high mortality, 
40% in 24 days. Starvation was eliminated as a causative factor in the 
increased mortality, since all animals ate all of the food offered to 
them. The high mortality could not be attributed either to the peri-
pheral depletion or to the central depletion of CA per se, since 
reserpine depletes both areas of their CA. There was some evidence to 
indicate that depletion of both central and petipheral CA may account 
in some degree for the increased mortality. A mechanism is postulated 
to explain why reserpine prevented adaptation. Some correlation was 
noted between the brain NE levels and behavior. The abnormal behavior 
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noted in the reserpinized, stressed rats may have been due to the 
depletion of brain NE. 
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2. Guanethidine also produced adrenalcortical responses similar 
to those evoked by restraint; however, the responses were not as great. 
All values tended to return to normal by day 6, except heart NE which 
showed a continuous depletion until day 12 and then a gradual return 
toward normal. The guanethidine-treated, stressed rats showed the 
characteristic adrenalcortical responses: increased adrenal weight; 
increased serum corticosterone; and decreased AAA. The stress appeared 
to overcome the peripheral NE depletion caused by guanethidine and 
values started to return to normal by day 12. This may have been the 
result of increased syntheses of CA, particularly from the adrenal 
medulla, since it has been reported that low doses of guanethidine do 
not affect adrenal E and NE. This may also account for the adaptation 
of these animals to restraint, since there was only 10% mortality. 
These animals displayed behavioral patterns similar to those of the 
vehicle-treated, stressed animals; their brain NE patterns were also 
similar. 
E. Evidence is presented indicating that reserpine and guanethidine 
affect CA by different mechanisms. 
F. Adaptation to CRS was demonstrated by organ weight changes and by 
the analyses of the interrelationship among serum corticosterone, AAA, 
brain and heart NE. After an initial AR, all of the parameters measured 
tended to return to control levels: an indication of physiological 
adaptation. The pituitary-adrenal system was apparently active through-
out the period of chronic stress. Control animals, subjected to stress, 
exhibited some degree of behavioral adaptation, passing from an extreme 
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degree of excitability at the initiation of the stress to a moderate 
degree of docility when released from it . Brain NE showed an initial 
decrease, followed by an increase on day 12. Heart NE tended to return 
to normal also by day 12. The vehicle-treated, control animals showed 
some indication of pituitary-adrenal stimulation which was due probably 
to the handling and to the injection procedure . 
Non-adaptation of rats subjected to chronic ' res~raint may be due 
at least in part to exhaustion of both central and peripheral NE since 
the reserpine-treated, stressed animals showed an increased mortality 
(40%) in 24 days and the guanethidine-treated, stressed animals had 10% 
mortality over the same time period . The results from this study sug-
gest the possible significance of the sympathetic division of the ANS 
and adrenal CA in adaptation of the animals to chronic stress . 
VIII. APPENDIX 
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TABLE XXIII 
THE EFFECT OF RESTRAINT ON MEAN DAILY BODY WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals 11 Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle Guanethidine Reser ine 
1 215 + l 7a 218 + 25 230 + 24 209 + 22 212 + 14 208 + 17 
(10)0 (10) (10) (10) - (10) - (10)-C 
2 222 + 20 222 + 25 231 + 24 207 + 23 217 + 14 212 + 16 
(10) (10) (10) (10) (10) (10)-C 
3 222 + 21 227 + 23 235 + 23 207 + 21 214 + 15 209 + 17 
(10) (10) (10) (10) (10) (10)-C 
4 226 + 20 227 + 24 237 + 21 206 + 21 214 + 14 207 + 17 
(10) (10) (10) (10)-AC (10) (10)-AC 
5 233 + 23 232 + 25 240 + 23 206 + 22 211 + 16 206 + 17 
(10) (10) (10) (10)-A (10)-AB (10)-AC 
6 235 + 22 233 + 23 238 + 23 201 + 21 213 + 14 202 + 18 
(10) (10) (10) (10)-A (10)-AB (10)-AC 
7 235 + 22 235 + 23 238 + 22 203 + 23 212 + 14 198 + 17 
(10) (10) (10) (10)-A (10)-AB (10)-AC 
8 238 + 20 239 + 23 237 + 23 201 + 20 211 + 17 196 + 19 
(10) (10) (10) (10)-A (10)-AB (9) AC 
9 242 + 21 241 + 22 238 + 23 204 + 22 211 + 18 198 + 24 
(10) (10) (10) (10)-A (10)-AB (9) AC 
,..... 
°' w 
TABLE XX.III - continued 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle Guanethidine Reser ine 
10 242 + 20 242 + 23 240 + 25 205 + 23 213 + 16 196 + 23 
(10) (10) (10) (10)-A (10)-AB (9) AC 
11 247 + 22 247 + 24 243 + 26 205 + 20 215 + 20 203 + 21 
(10)~ (10) (10) (10)-A (10)-AB (9) AC 
12 248 + 20 247 + 23 237 + 26 206 + 20 213 + 17 196 + 22 
(10) (10) - (10) (10)-A (10)-AB (9) AC 
13 248 + 18 246 + 27 239 + 24 204 + 19 212 + 18 193 + 23 
(10) (10) - (10) (10)-A (10)-AB (9) AC 
14 255 + 20 249 + 23 240 + 26 204 + 22 212 + 21 195 + 30 
(9) (10) (10) (10)-A (10)-AB (9) AC 
15 256 + 20 251 + 23 241 + 26 203 + 20 211 + 19 193 + 32 
(9) (10) (10) (lO)A (10) AB (9) AC 
16 260 + 20 251 + 24 242 + 25 203 + 16 212 + 19 201 + 28 
(9) (10) (10) (10)-A (10)-AB (8) AC 
17 258 + 20 253 + 23 241 + 20 202 + 17 209 + 18 197 + 32 
(9) (10) (10) (10)-A (10)-AB (8) AC 
18 260 + 22 254 + 24 242 + 22 202 + 18 210 + 20 197 + 32 
(9) (10) (10) (10)-A (10)-AB (8) AC 
19 262 + 21 254 + 24 243 + 25 202 + 18 207 + 20 202 + 33 
(9) (10) (10) (10)-A (10)-AB (7) AC 
t-' 
°' ~
TABLE XX.III - continued 
Control Animals 
Days of 
Treatment Vehicle Guanethidine 
20 262 + 22 254 + 23 
(9) (10) 
21 264 + 24 258 + 25 
-(9) (10) 
22 266 + 23 256 + 25 
(9) (10) 
23 265 + 26 259 + 26 
(9) (10) 
24 268 + 25 262 + 26 
(9) (10) 
a : mean± S.E., daily weights (grams). 
b: number of rats. 
Reser ine 
242 + 24 
(10) 
243 + 26 
-(10) 
244 + 34 
(10) 
245 + 38 
(10) 
247 + 31 
(10) 
c: statistical comparison at probability, P< O. 05. 
A - significantly different from vehicle-control group. 
II 
B - significantly different from guanethidine-control group. 
C - significantly different from reserpine-control group. 
Vehicle 
201 + 20 
(10)-A 
202 + 17 
(10)-A 
205 + 20 
(10)-A 
205 + 18 
(10)-A 
204 + 18 
(10)-A 
Restrained Animals 
Guanethidine 
205 + 22 
(10)-AB 
208 + 23 
(10)-AB 
213 + 18 
-(9) AB 
213 + 19 
(9) AB 
215 + 19 
(9) AB 
Drug doses, (i.p.) daily for 24 days: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser i e 
194 + 32 
(7) AC 
201 + 33 
(7) AC 
194 + 39 
(7) AC 
200 + 39 
(7) AC 
215 + 21 
(6) AC 
I-' 
0\ 
\J1 
TABLE XXIV 
THE EFFECT OF RESTRAINT ON RELATIVE ADRENAL WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine 
1 0.011 + o.001a o. 011 + o. 001 
(lO)b (10) 
3 0.011 + 0.001 o. 011 + o. 000 
(10) (10) 
6 0.008 + 0.001 0.007 + 0.001 
(10) (10) 
12 0.010 + 0.001 o. 011 + o. 000 
(10) (10) 
24 o. 011 + o. 001 0.009 + 0.001 
(10) (10) 
a: mean± S.E. (g/100 g of body weight) 
b: number of rats 
Reser ine 
0.011+0.001 
(10) 
0.012 + 0.001 
(10) 
0.008 + 0.001 
(10) 
0.011 + 0.001 
(10) 
0.010 + 0.001 
(10) 
c: statistical comparison at probability, P<0.05. 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
Vehicle 
0.011 + 0.001 
(9) 
0.012 + 0.001 
(10) 
o. 010 + o. 001 
(10) A 
0.016 + 0.001 
(10) A 
0.015 + 0.001 
(10) A 
C - significantly different from guanethidine-control group, 
D - significantly different from reserpine-control group. 
Drug doses (i.p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Guanethidine Reser ine 
0.011 + 0,001 0.011 + 0.001 
(10) (10) 
0.012 + 0.001 0.014 + 0.001 
(10) (9) ABDc 
0.012 + 0.001 0.011 + 0.001 
(10) AC (10) AD 
0.017 + 0.001 0.016 + 0.001 
(9) AC (9) AD 
0.015 + 0.002 0.016 + 0.002 
(9) c (6) A 
t-' 
°' 
°' 
TABLE XXV 
THE EFFECT OF RESTRAINT ON RELATIVE HEART WEIGHT OF 
MALE ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Ani mals II Restrained Animals 
Days of 
Treatment Vehicle Guanethidine Reser ine Vehicle 
1 0.322 + .008a 0.316 + .006 0.308 + .009 o. 324 + . 004 
(lO)b - (10) - (10) - -(9) 
3 0 . 325 + . 006 0.316 + ,002 0.309 + .005 0.357 + .011 
(10) (10) (10) (10) A 
6 0.319 + .004 0.324 + .005 0.343 + . 006 0.358 + .007 
(10) (10) (10) A (10) A 
12 0.329 + . 014 0.301 + .005 0 . 335 + .005 0.374 + .011 
(10) (10) (10) (10) A 
24 0 . 305 + .010 0.276 + .003 0 . 309 + . 007 0 . 323 + .006 
(10) (10) A (10) (10) 
a : mean + S.E. (g/100 g of body weight) 
b : number of rats 
c: statistical comparison at probability, P < 0. 05 
A - significantly different from vehicle-control group. 
B - significantly different from vehicle-restrained group. 
C - significantly different from guanethidine-control group. 
D - significantly different from reserpine-control group. 
Guanethidine 
0 . 314 + . 007 
-(10) 
0.339 + .007 
(10) c 
0.351 + .011 
(10) AC 
0.372 + .010 
(9) AC 
0.314 + .005 
(9) c 
Drug doses; (i.p.) daily : Guanethi dine, 1.20 mg/kg. Reserpine, 0 . 2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. 
Reser ine 
0.306 + .007 
(10) BC 
0.334 + .005 
(9) D 
0 . 347 + .006 
(10) A 
0. 350 + . 006 
(9) 
o. 3-20 + . 006 
(6) 
I-' 
°' ........ 
TABLE XXVI 
THE EFFECT OF RESTRAINT ON RELATIVE BRAIN WEIGHT OF MALE 
ALBINO RATS TREATED WITH GUANETHIDINE OR RESERPINE 
Control Animals II Restrained Animals 
Days of 
Treatment Vehicle Guanethid i ne Reserpine Vehicle 
1 0 . 838 + .025 a 0.822 + . 016 0 . 831 + .012 0.820 + .019 
(1o)b - (10) (10) (9) -
3 0.813 + .027 0.806 + .026 0.802 + .028 0. 784 + . 023 
(10) (10) (10) (10) 
6 0 . 740 + .018 o. 744 + .017 0 . 799 + .020 0.824 + . 015 
(10) - (10) (10) -Ac (10) - A 
12 0 . 672 + .022 0.698 + .015 0 . 757 + .024 0 . 847 + .029 
(10) (10) (10) A (10) A 
24 0.643 + .025 0.641 + .022 0.663 + .016 0. 783 + . 018 
(10) (10) (10) (10) A 
a : mean + S.E. (g/100 g of body weight) 
b: number of rats 
c : statistical comparison at probability, P <o . 05. 
A - significantly different from vehicle-control group. 
C - significantly different from guanethidine-control group . 
D - significantly different from reserpine-control group. 
Guanethidine 
0.839 + .024 
-(10) 
0 . 793 + .019 
(10) 
0.801 + . 027 
-(10) 
o. 802 + . 022 
(9) AC 
0.771 + .025 
(9) AC 
Drug doses, (i . p.) daily: Guanethidine, 1.20 mg/kg. Reserpine, 0.2 mg/kg. 
Vehicle, glass-distilled water, 1 ml/kg. / 
Reserpine 
0.834 + .028 
(10) 
o. 792 + .024 
(9) 
0.827 + .015 
(10) A 
0.883 + .028 
(9) AD 
0.743 + . 048 
(6) 
1--' 
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